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 The malignant cells of chronic lymphocytic leukemia (CLL) over-express PKCβII, 
a feature pathogenically important because the TCL1 mouse model of CLL fails to 
develop disease when PKCβ expression is disrupted. The purpose of this project was to 
generate transgenic mice in which PKCβII is over-expressed only in B cells. The central 
hypothesis of this thesis was that over-expression of PKCII in developing B cells will 
shift development to favour the generation of the B-1 and MZ B cell populations and 
eventually lead to the development of a CLL-like disease in the mouse. To construct the 
expression plasmid, an Eµ promoter was used to direct B cell-specific expression of 
PKCβII in transgenic mice (Eµ-PKCβII tg mice). PKCβII was tagged with 
haemagglutination antigen (HA) for identification in Western blots and 
immunohistochemistry (IHC). Also, mCherry was integrated within the expression 
plasmid construct in order to visualize transgenic B cells. Over-expressed PKCβII and 
mCherry fluorescence were detected when this plasmid was tested in A20 cells, a 
mouse B lymphoma cell line. The construct was then injected into pro-nuclei of fertilized 
ova isolated from pregnant mice. The injected ova were then transferred to recipient 
mice to generate potential founder mice. Sequential crossings of transgenic litters born 
from a single founder mouse led to the generation of homozygous Eµ-PKCβII tg mice. In 
the spleen of Eµ-PKCβII tg mice, the expression of the transgenic PKCIIHA was 
detected and quantification of PKCβII, using Western blotting, showed that PKCβII was 
over-expressed in Eµ-PKCβII tg mice compared with wild type mice. However, the 
mCherry could not be detected; this might be due to the fact that expression of the 
secondary gene(in this case mCherry) was not always efficient because of variable 
transcription from the IRES sequence. IHC analysis of the spleen of Eµ-PKCβII tg mice 
confirmed the expression of PKCIIHA in B cell-rich tissues where the staining for either 
HA or for PKCII showed the high expression of these proteins in the white pulp of the 
spleen specifically to the follicular region. There was no notable development of disease, 
CLL-like or otherwise in aged Eµ-PKCβII tg mice, but Flow cytometry analysis pointed 
out that the over-expression of PKCII resulted in a reduction in the proportion of 
 iv 
follicular B cells and an increase in the proportion of MZ B cells in the spleen, and in B-1 
cells in peritoneum and periphery of Eµ-PKCβII tg mice. This expansion of MZ B cells in 
the spleen was confirmed by H&E stains showing an enlarged marginal zone within the 
structure of the spleen, and IgM stains showed that this expanded MZ consists mainly of 
IgM+ cells. Thus, the generation of a mouse that over-expresses PKCII specifically 
within the B cell compartment led to an expansion in the populations of IgM+ B cells (MZ 
and B-1 B cells) and a reduction of follicular (mature) B cells. This mouse may be useful 
for the study of human CLL because of the potential to accelerate disease progression, 
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1.1 Importance of CLL 
 
Chronic lymphocytic leukaemia (CLL) is considered to be the most common adult 
leukaemia (Zwiebel and Cheson 1998); it is defined as the proliferation of malignant B 
lymphocytes with mature appearance in blood and lymphoid organs (Zenz, et al 2010). 
CLL cells are clonal in nature, and fail to undergo terminal differentiation into antibody-
secreting cells. Nevertheless, CLL is a heterogeneous disease with respect to disease 
progression; where some patients have progressive disease while others have indolent 
disease (Rodriguez-Vicente, et al 2013). Many factors are involved in disease 
pathogenesis of CLL such as genomic aberrations, epigenetic modifications, gene 
mutations, and deregulated micro-RNA (Zenz, et al 2010). In addition, there is defective 
function in T, NK (natural killer) and dendritic cells in CLL patients, and this leads to the 
development of hypo-gammaglobulinemia and progressive immunodeficiency. 
All CLL cells carry the surface membrane phenotype of antigen experienced 
(CD27+) and activated (CD23+, CD25+, CD69+, CD71+) B cells. However, CLL cells 
express much lower levels of surface membrane immunoglobulin and CD19 than do 
normal B cells. Gene expression analysis shows that CLL cells are more closely related 
to memory than to naive B cells (Damle, et al 2002), and these cells also express CD5 
which is an antigen typically expressed by T cells (Seifert and Kuppers 2009). More 
recently, further gene analysis has revealed that CLL cells originate from a post-
germinal centre B cell subset that was previously unrecognized and bore CD5 and 
CD27 (Seifert, et al 2012). 
CLL can be subdivided into progressive versus indolent disease (Damle, et al 
1999). Although there are many methods that can be used to predict disease outcome in 
CLL, possibly the most powerful and reliable means remains determination of the 
degree of somatic hyper mutation within the variable regions of the immunoglobulin (Ig) 
heavy chain (IGHV) genes expressed in the malignant cells. Thus, patients where the 
IGHV genes retain the germ line sequence, or less than 2% mutational deviation from 
germ line sequence (so-called un-mutated CLL or U-CLL) generally have a poorer 
outcome than those patients having IGHV genes containing greater than 2% mutational 
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deviation (so-called mutated CLL or M-CLL)(Hamblin, et al 1999). This relationship 
between antigen-receptor structure and disease outcome in CLL has an important 
consequence. Studies have shown that the antigen-binding region of the B cell receptor 
(BCR) on CLL cells from U-CLL patients has a broader specificity than that of the BCR 
on CLL cells from M-CLL patients. Thus, interaction with antigen is thought to have a 
major role in clonal survival and expansion of the malignant clone in U-CLL, and this has 
become a paradigm of CLL pathogenesis (Stevenson and Caligaris-Cappio 2004). 
 An additional consideration comes from studies investigating the differences in 
signals mediated by BCR engagement between M- and U-CLL clones. The signals in M-
CLL clones are much weaker than those observed in U-CLL clones. This may be due to 
the presence of proteins that enhance the BCR signal. For example, expression of 
tyrosine kinase zeta-associated protein 70 (ZAP-70) is mainly associated with U-CLL 
clones, and is therefore considered to be a surrogate marker of Ig mutational status  
(Wiestner, et al 2003). More importantly, the presence of this protein within CLL cells 
has been shown to enhance BCR signaling through a mechanism that is independent of 
its kinase activity. Thus, the association of ZAP70 expression and poor disease 
prognosis supports the role of BCR signals in CLL pathogenesis. The initiation of BCR 
downstream signaling in CLL leads to up-regulation of the anti-apoptotic protein Mcl-1 
which has crucial role in survival of CLL cells (Chen, et al 2005).  
Whether CLL is progressive or indolent, the disease is presently incurable using 
conventional chemotherapeutic therapies (Binet, et al 1977). When the disease is 
indolent a “watch and wait” approach is taken because the application of therapy here 
can be worse than the disease itself (Chiorazzi, et al 2005). The median life expectancy 
of CLL patients with indolent disease ranges from 8 to 12 years, and in patients with 
progressive disease the median life expectancy is much shorter. Therapeutic strategy in 
CLL mainly focuses on controlling the disease symptoms (Rozman and Montserrat 
1995), and current therapy for this disease is based on the use of cytotoxic 
chemotherapy with agents such as Chlorambucil (alkylating agent) and Fludarabine 
(purine analogue). These drugs cause apoptosis by inducing DNA damage, but CLL 
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cells become resistant to these drugs and more aggressive treatment must be used 
during disease relapse (Rai, et al 2000).  
 
1.2 B cell differentiation 
 
In order to understand CLL pathogenesis, an understanding of B cell 
development is crucial. Figure 1-1 summarizes B cell lineage development. 
 
 
Figure 1-1. The differentiation of hematopoietic progenitor cell into the B-lymphoid 
lineage; Adapted  from (Janeway. 2001). Commitment to B cell differentiation is an irreversible 
process characterized by activation of the genes regulating expression of the B cell antigen 
receptor (BCR). These genes include those encoding the µH chain and surrogate L chain of the 
pre-BCR as well as genes responsible for the rearrangement of the antigen-binding portion of 
the Ig genes (i.e., RAG-1 and RAG-2). 
 
The development of intra-embryonic from mesenteric cells leads to production of 
the first haematopoietic progenitor cells called the Hemangioblast. These cells are the 
common precursor of endothelial and haematopoietic stem cells (HSC) (Munoz-Chapuli, 
et al 1999). HSCs can divide and maintain their stem-cell state of differentiation(Paul 
2003). During embryogenesis, HSCs migrate from the Aorta Gonad Mesonephros 
(AGM) to the foetal liver, thymus, omentum and bone marrow to undergo further 
differentiation. This localization is based on a specialized program of erythroid, myeloid 
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or lymphoid differentiation. Haemic cell production continues in these areas until after 
birth. Within the first four weeks post-partum, the bone marrow becomes the major site 
of haematopoiesis including B-cell development (Munoz-Chapuli, et al 1999). However, 
recent evidence suggests that B cell development can also take place in the gut lamina 
propria, and is influenced by microbial colonization(Wesemann, et al 2013). 
HSCs are responsible for the generation of all haemic cells, the first step of 
differentiation occurs when these cells form the common lymphoid (CLP) and common 
myeloid (CMP) progenitor cells. CMP cells then go on to differentiate into the myeloid-
derived cells such as megakaryocytic / platelets, neutrophils, monocytes and red blood 
cells. CLP cells differentiate into lymphoid cells such as natural killer cells, T cells and B 
cells. The rest of this section is devoted to B cell development (Kondo, et al 1997). 
In B cell development, each stage of early differentiation represents a change in 
the immunoglobulin (Ig) genes coding for antibody production (Figure 1-1). CLP cells 
that express B220 and CD43, but lack expressi3on of HSA and BP-1 are considered to 
be the earliest B-cell progenitor (Paul 2003). In the presence of Interleukin 7(IL-7), these 
early B cells give rise to pro-B cells where rearrangement of the variable (v), diversity (d) 
and joining (j) region genes within the Ig heavy chain initiates (Lee, et al 1989). This 
involves expression of the genes controlling this Ig rearrangement, RAG-1 and RAG-2.  
When this rearrangement is productive and results in generation of Ig heavy chain 
protein in combination with surrogate light chains (which serve as templates for Ig light 
chains and stabilize the Ig heavy chain), pro-B cells then become pre-B cells. At the pre-
B cell stage, Ig light chain genes undergo rearrangement to ultimately produce protein 
that can appropriately combine with Ig heavy chains to construct “good BCRs”. Cells 
that are able to express good BCRs survive and clonally expand, whereas the cells that 
are unable to do this undergo apoptosis. In the next step, BCR assemble with the Ig 
accessory proteins: Igα and Igβ then express on the cell surface as IgM. At this point, 
pre-B cells become immature B cells. Auto-antigens located in bone marrow interact 
with surface IgM positive B cells and this plays a crucial role in further differentiation of 
these cells. Those immature B cells that experience strong stimulation through antigen 
receptor signaling undergo apoptosis (a process called clonal deletion), those cells that 
6 
 
experience weaker or no interaction with these auto-antigens develop into transitional 
type-1 B cells (T-1 B cells) that exit the bone marrow and migrate to the spleen where 
they undergo further development (Hardy and Hayakawa 2001, Paul 2003). 
Transitional B cells that enter the spleen localize to the follicle part of the white 
pulp where they become more responsive to supportive T cell signaling and differentiate 
to T2 B cells. Here the cells gain surface IgD and CD23. At this point the B cell can 
experience one of three fates: in the first instance cells that do not experience any 
stimulation through the BCR undergo apoptosis due to neglect. In the second instance 
cells that experience strong signals through the BCR, and in conjunction with T cell help 
within germinal centre further differentiate into antibody-producing plasma cells, or 
mature memory B cells. Passage through the germinal centre can also stimulate 
somatic hyper-mutation of Ig gene variable regions through a process called affinity 
maturation in which antibody affinity to antigen is increased. Also, within germinal 
centre, the constant region of the Ig heavy chain can undergo a process called class 
switching from IgM/IgD to IgG, IgA or IgE. The final fate of T2 B cells are marginal zone 
B cells (MZ B cells). These cells experience low level signals through the BCR, but do 
not have T cell help. Once MZ B cells become mature they migrate and are retained in 
the marginal zone of the spleen, and participate in the defence against systemic blood-
borne antigens trapped in the spleen. The T2 B cells that experience these fates are 
known as conventional, or B2 cells. Conventional B cells are considered to be the main 
B-cell compartment in the adult and mediate adaptive immunity in collaboration with T 
cells (Carsetti, et al 1995, Pillai and Cariappa 2009). 
There is another distinct population of B cells known as B-1 cells. These cells can 
be discriminated from conventional B cells by expression of CD5, which is primarily 
expressed on T cells, on their surface. B-1 cells locate in pleural cavities and 
peritoneum, and are responsible for natural antibody secretion (Bos, et al 1989, Hardy 
2006). Unlike B-2 cells, which have an extremely diverse BCR repertoire that reflects 
broad usage of v d j gene rearrangement, the BCR on B-1 cells is more restricted and 
this is reflected in the usage of v d j genes which are typically associated with this B cell 
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subtype (Hardy 2006). The origin of B1 cells is controversial; in the lineage model, B1 
cells arise from the transitional B cells I have so far described and are the result of 
normal haematopoiesis (Witt, et al 2003) (Figure 1-2). In contrast, in the induced 
differentiation model, B-cell commitment to B1 or B2 occurs during embryogenesis at 
the point where pro-B cells are generated from the fetal liver progenitor. 
Subsequent differentiation of B cells destined to become mature B1 cells is then 
similar to that of conventional B cells, and the total population is supported by an ability 
of these cells to self-renew (Hardy and Hayakawa 1991, Lam and Rajewsky 1999). It is 
important to note that in this model production of B1 cells never switches to the bone 
marrow. Because the B1 population cannot be easily reconstituted in adult mice, the 
induced differentiation model of B1 ontogeny is favoured. However, it was recently 
proposed that the lineage and induced differentiation models of B1 cell development are 
not mutually exclusive, and that both pathways exist in order to ensure that the B1 
population is preserved. The reason why B1 cell production is inhibited within the 
lineage model is because B1 cells of foetal origin act within adult mice to severely 







Figure 1-2. Lineage model of differentiation for B-1 and B-2 B cells. The lineage model 
suggests that B-1 B cells originate from foetal liver progenitor cells during embryogenesis 
whereas B-2 B cells originate from progenitor cells located in the bone marrow. 
 
B1 cells function in a T cell-independent manner and because of this they bypass 
the GC reaction in the follicular part of the spleen. B1 cells can be induced to proliferate 
and differentiate into plasma cells outside the GC microenvironment. This B cell subset 
is thought to act as a bridge between innate and adaptive immunity, and dysfunction of 
B-1 cells is associated with auto-immunity and leukaemia (Martin, et al 2001). 
 
1.3 CLL origin 
 
The normal B cell that transforms to become a CLL cell has not been 
characterized. Gene expression analysis of CLL cells show that they have a distinct 
pattern of gene expression that distinguishes them from the cells of other B cell 
malignancies. When this pattern is compared with that of normal B cells, it is suggested 
that CLL cells are more closely related to memory (cells that are antigen-experienced) 
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than to naive B cells (Klein, et al 2001), and to a subset of previously uncharacterized 
CD5+CD27+ B cells (Seifert, et al 2012). This observation leads to a principal question: 
How do CLL cells arise from their normal counterpart? 
Do CLL cells arise from single or from multiple cell clones? In the case of CLL 
originating from a single clone, all genetic events causing the transformation into CLL 
cells would happen in a distinct subset of B cells at a specific stage of differentiation. If 
this is the case, genetic changes would occur in a distinct sequence, and would likely 
follow a standard model of carcinogenesis. If CLL cells arise from multiple clones, 
genetic lesions can happen in B cells at different stages of development, but the final 
nature and structure of CLL is determined by a combination of these lesions with 
exposure to particular factors at particular times to give the transformed cell a growth 
and survival advantage over other cells. Evidence for this latter model of CLL 
development has recently come to light. The development and number of CLL-like cells 
increases with age in adults; such cells are the likely source of the malignant clone. 
Furthermore, in some patients the presence of multiple CLL-cell clones, each bearing 
different usage of Ig genes, has been noted. Finally, whole genome analysis of CLL-cell 
clones indicates that mutations within NOTCH1 and XPO1 are associated with U-CLL 
whereas mutations in MYD88 and KLHL6 are associated with M-CLL. This could mean 
that U-CLL and M-CLL are dependent on different signaling pathways for survival 
(Balatti, et al 2012) (Chen, et al 2005).   
With regard to the normal counterpart of CLL cells, there is much controversy that 
is likely to arise from our lack of understanding of whether CLL develops from single or 
multiple clones. Two B cell subtypes have been put forward as likely normal 
counterparts of CLL; MZ and B1 cells. MZ B cells are antigen experienced and behave 
in a T cell independent manner (Weill, et al 2009). More importantly, the BCR of MZ B 
cells is known to undergo somatic hyper-mutation the outside germinal centre, and this 
might explain the genesis of U- and M-CLL (Chiorazzi and Ferrarini 2003). However, MZ 
B cells do not have quite the same phenotype as CLL cells, particularly with respect to 
the expression of CD5. With B1 B cells, these cells are phenotypically more similar to 
CLL than are MZ B cells. These cells express CD5, and the BCR of B1 B cells uses V, D 
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and J segments and possess complementary-determining regions (CDR3) that are 
highly similar to those used by CLL cells, particularly U-CLL cells(Messmer, et al 2004). 
However, only 30% of CLL cases carry this stereotypical structure of the BCR (Rossi, et 
al 2013). Furthermore, B1 B cells have only been well characterized in the mouse, and 
only recently has evidence been generated that potentially establishes a human 
counterpart (Seifert, et al 2012). CD5 positive B cells are known to be present in 
humans, but the function and nature of these cells needs further characterization (Zenz, 
et al 2010). That CLL cells bear a gene expression profile relating them to human B-1-
like B cells provides further evidence for their existence in health and disease. Whether 
B1 B cells of either human or mouse origin can undergo somatic hyper-mutation of the 
Ig genes is not known (Fischer, et al 1997). Nevertheless, further evidence for a B1 B 
cell of origin for CLL comes from mouse studies. All of the existing mouse models for 
CLL-like disease derive from B1 B cells (Oppezzo 2012). Figure 1-3 summarizes the 






Figure 1-3. Origin of M- and U-CLL cells. (Adapted from (Zenz, et al 2010)).  Based on current 
paradigms CLL cells can arise from CD5+ B cells (B-1a) and marginal zone (MZ)-like B cells or 
the mature B cells experience the germinal centre.(TD: T cell dependent, TI: T cell independent, 
IGHV: Immunoglobulin heavy chain, MZ: marginal zone).      
 
1.4 Current mouse models for CLL 
 
The main reason for studying a mouse model of CLL is to gain insight into the 
factors that are important for disease pathogenesis and progression. Such insight can 
lead to the development of better systems to test therapeutic treatments for the disease. 
The first mouse model for CLL was described in a New Zealand black mouse that 
spontaneously developed a CLL-like disorder. Here, the malignant cells of this condition 
resemble those of human CLL (Phillips, et al 1992). Importantly, this model provides key 
evidence to explain a genetic component within human disease (Oppezzo 2012). 
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However, the CLL-like disease suffered by the mice is indolent in nature, and does not 
give insight into progressive disease. 
A second important model of CLL was derived by transgenic expression of TCL1. 
Here, expression of the TCL1 oncogene is placed under the control of the 
immunoglobulin gene promoter (IgH-Eµ enhancer) so that over expression appears only 
in B cells. Thus, the TCL1 transgenic mouse develops a CLL-like disease where the 
malignant cells result from polyclonal proliferation of IgM+CD5+ B cells (Bichi, et al 
2002). TCL1 expression is important to human disease pathogenesis because high 
expression levels of this oncogene are correlated to progressive disease(Narducci, et al 
2000). Indeed, the CLL-like disease associated with the TCL1 transgenic mouse has 
many features that are associated with the aggressive form of human CLL (Herling, et al 
2009). For example, the CLL-like cells from the TCL1-transgenic mouse bear un-
mutated IgHV genes, and are stereotypic in terms of the HCDR3 gene sequences used  
(Yan, et al 2006). This implicates BCR signaling as an important contributor to the 
pathogenesis of the CLL-like disease in the TCL1-transgenic mice. Furthermore, 
constitutive activation of Akt is an important factor in the patho-physiology of aggressive 
disease in human CLL, and TCL1 may play a role in this activation by interacting with 
the phosphatidylinositol 3-kinase–Akt pathway leading to enhanced cell survival (Longo, 
et al 2007, Pekarsky, et al 2000). However, the argument against this model is that it 
does not truly represent CLL because the TCL1 transgenic mouse develops other B 
lympho-proliferative disorders with high frequency. 
  A second transgenic model of aggressive CLL has been developed by 
transgenic co-expression of Bcl-2 with a RING and zinc finger mutant of TNF receptor 
associated factor-2 (TRAF-2) (Zapata, et al 2004). TRAFs are adaptor proteins that 
connect tumour necrosis factor (TNF)-family receptors (TNFRs) to intracellular signal 
transduction (Zapata, et al 2007). Up regulation of TRAF family proteins, particularly 
TRAF1 has been observed in CLL cells, and TRAF1 expression is associated with 
chemo-refractory disease in CLL (Michie, et al 2007, Munzert, et al 2002). TRAF2 which 
lacks the RING and zinc finger domains located within its N terminus (TRAF2DN) is 
structurally similar to TRAF1, and targeted over expression of TRAF2DN in mouse B 
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cells leads to the development of low-grade B cell malignancies. The same is true for 
Bcl-2, targeted over expression of this protein in B cells leads to the development of low-
grade malignancy of this cell type in mice. This is relevant for human CLL because the 
malignant cells of this disease typically over express Bcl2. When TRAF2DN and Bcl2 
transgenic mice are crossed together a CLL-like disease develops, and the malignant 
cells are phenotypically similar to human CLL cells. Significantly, double transgenic mice 
died much earlier than did either TRAF2DN or Bcl2 single transgenic mice. Furthermore, 
the extent of splenomegaly and lymphadenopathy was much more severe in the 
TRAF2DN/Bcl2 double transgenic mouse. Studies of cell proliferation and apoptosis 
showed that the malignant cells derived from the TRAF2DN/Bcl2 double transgenic mice 
were largely resistant to apoptosis and proliferated only very slowly. This model is 
thought to explain the role of over expressed TRAF1 and Bcl-2 in human CLL cells, 
particularly with respect to the resistance of these cells to apoptosis (Zapata, et al 2004).  
A third transgenic model of CLL was generated by over expressing the TNF-
related factor A ProlifeRation-Inducing Ligand (APRIL, TNFSF13) under the control of 
the T cell specific Lck promoter. Over expression of APRIL under these conditions acts 
to stimulate expansion of the CD5+ B1 cell population, and eventually results in 
development of a CLL-like disease later in the life of the mouse (Planelles, et al 2004). 
The phenotype of this mouse is much milder than that of either the Tcl1 transgenic or 
the TRAF2DN/Bcl2 double transgenic mouse (Oppezzo 2012). In the APRIL transgenic 
mouse model the NF-κB signaling pathway is constitutively active, possibly resembling 
the constitutive activation of this pathway in human CLL cells (Endo, et al 2007). It is 
believed that the APRIL transgenic model sets up the conditions whereby B cell 
oncogenic transformation is prompted, but whether this event happens likely requires a 
“second hit “such as over expression of Bcl-2 or Tcl1 (Michie, et al 2007). 
Another CLL transgenic mouse model that will be mentioned in this section is the 
miR-29 transgenic mouse. The rationale for creating this transgenic mouse is based on 
findings that over-expression of miR-29a is associated with indolent CLL in humans   
(Calin, et al 2004). In this mouse miR-29 is transgenically highly expressed in B cells, 
and the resulting phenotype is an expansion of the CD5+ B cell population and eventual 
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development of an indolent “CLL-like” leukaemia later on. An important target gene of 
miR-29 is TCL1, a gene that is crucial in the pathogenesis of aggressive CLL. This 
suggests that miR-29 is associated with the pathogenesis of indolent CLL in humans  
(Santanam, et al 2010). 
The final mouse model of CLL that I will speak about here results from deletion of 
a gene cluster on chromosome 13 at position q14. This gene cluster, known as the 
minimal deleted region (MDR), consists of the genes coding DLEU-2 and miR-15a/16-1 
(Calin, et al 2008, Klein and Dalla-Favera 2010). This deletion causes the expansion of 
CD5+ CLL like B cells leading to an indolent form of CLL. That this model represents 
indolent CLL is consistent with human disease because patients with only 13q14 
deletions have better prognosis than patients with other chromosomal abnormalities. 
Also, low levels of miR15a/16-1 are observed in human CLL cells. The reduction in miR-
15a/16-1 levels resulting from the gene deletion seems to stimulate B cell proliferation 
by regulating the expression of Bcl-2. Thus, Bcl-2 becomes more highly expressed in 
these cells, leading to increased survival of potentially malignant cells (Klein, et al 2010). 
However, the increase in Bcl-2 expression observed in the B cells of MDR mice does 
not explain why B-1 cells are selected for expansion. In Bcl2-transgenic mice the 
development of lymphoid malignancies occurs in all B cell populations, not just B-1 cells. 
This argues that other genes are also important in B-1 cell differentiation regulated by 
miR15a/16. Further work needed to identify these genes and their potential impact on 
CLL pathogenesis (Klein, et al 2010, Lichter 2010).  
Different CLL mouse models have brought new insight into CLL pathogenesis by 
emphasizing a particular mechanism that is important in this process. Although the 
current CLL mouse models do not genuinely represent human disease, combining the 
different models has given a wider and more comprehensive picture of CLL. One 
important observation from these mouse models of CLL is that the disease is the result 
of an expansion of CD5+ B cells. This observation suggests that malignant cells in 




1.5 PKC structure and function  
 
PKCs are a family of serine/threonine kinases that have extensive structural 
homology between the different isoforms. In spite of having similar structures, PKC 
isoforms mediate different cellular functions such as proliferation, differentiation, 
apoptosis and cell survival in a wide range of cell types (Dempsey, et al 2000, Saito, et 
al 2002). PKCs are divided into three subfamilies based on the structure of their 
regulatory domains; a structure which determines what co-factors induce activation of 
PKC. Classical PKCs (PKCα, βI, βII, and ) require the presence of diacyl-glycerol 
(DAG) and calcium for activation, while novel PKCs (PKC, ε, θ and η) require only the 
presence of DAG. In contrast, atypical PKCs (PKC, /) are both calcium and DAG 
independent. The basic structure of all members of the PKC family proteins is illustrated 
in Figure 1-4 (Tan and Parker 2003). 
 
 
Figure 1-4. Schematic representation of PKC isoforms structure. Pseudo-substrate (PS) 
sequence is located at PKC’ N-terminus and binds to the substrate-binding site within the 
catalytic domain to hold PKC in an inactive state. C1A and C1B are the regions responsible for 
DAG binding. C2 is the calcium-binding domain. C3 is the ATP-binding domain. C4 is the 





The regulatory domain of PKC has sites for membrane association and activation 
of the kinase. Within the C1 domain, there are motifs for binding DAG/Phorbol esters 
and a pseudo-substrate (PS) sequence at its N-terminus. The latter binds to the 
substrate-binding site within the catalytic domain to hold PKC in an inactive state. 
Atypical PKCs have a unique C1 region (C1 AT) as well as a Phox and Bem1 (PB1) 
region which are likely responsible for protein interaction resulting in kinase activation. 
The C2 domain is responsible for regulation of Ca2+-mediated phospholipid binding to 
the classical PKC isoforms. Novel PKCs have a C2-like domain that does not bind Ca2+ 
(C2 N). The catalytic domain of all PKCs is conserved and contains the regions 
necessary for ATP-binding (the C3 domain) and for binding to substrate (the C4 
domain). The motif called PDZ exists in some PKC isoforms and mediates protein-
protein interactions following kinase activation. 
All PKC isoforms have a homologous kinase domain located at the C-terminus of 
the protein. The structure of the kinase domain is highly conserved and bears homology 
with the AGC super family of serine/threonine protein kinases (Bononi, et al 2011). 
Within the kinase domain there are the ATP- and substrate-binding sites, as well as a 
phosphorylation-dependent docking site for regulatory molecules that interact with PKC 
(Newton 2010). 
The kinase domain of PKC is connected by a flexible hinge segment to the N-
terminal regulatory domain. This flexible hinge region is crucial for PKC function as it 
allows the close apposition of the regulatory and catalytic domains when PKC is 
inactive. Once PKC becomes activated, the hinge region allows the protein to unfold and 
allow interaction of the catalytic domain with substrates and regulatory proteins(Newton 
2010).  
 
1.6 PKC regulation 
 
The maturation of PKC isoforms requires a series of ordered, consecutive 
phosphorylations on serine and/or threonine residues within the catalytic domain 
(Newton 2003). These phosphorylations are summarized in Figure 1-5. The presence of 
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these phosphorylations is needed for the stability and catalytic capability of PKCs. The 
first step of maturation begins when newly synthesized PKC binds the chaperone 
protein heat shock protein 90 (HSP90) (Gould, et al 2009). This occurs via a molecular 
clamp within the kinase domain of PKC, and is followed by three ordered 
phosphorylation events within this region. These phosphorylation sites are located in: 1) 
the activation loop, 2) the turn motif, and 3) the hydrophobic motif (Keranen, et al 1995).  
Initial phosphorylation of the activation loop within newly synthesized PKC is 
catalyzed by 3-phosphoinositide-dependent kinase-1(PDK-1) (Chou, et al 1998). This is 
an important site of phosphorylation in conventional and novel PKC isoforms because 
mutation of this site or disturbance of PDK-1 function disallows maturation of PKC and 
leads to its degradation (Chou, et al 1998, Newton 2010). Phosphorylation within the 
turn motif of the kinase domain is catalyzed by the mTORC2 complex (Ikenoue, et al 
2008), and leads to further stabilization of the structure of PKC (Guertin, et al 2006). The 
final phosphorylation within the hydrophobic motif leads to the generation of a fully-
mature and catalytically competent PKC enzyme. However, it is not clear whether this 
phosphorylation is the result of auto-phosphorylation, or whether this site is a second 
phosphorylation site for the mTORC2 complex (Newton 2010).  
Mature PKC enzyme localizes to the cytosol of the cell where it interacts with 
regulatory proteins. This interaction facilitates binding of the N-terminal PS domain to 
the substrate-binding site within the catalytic domain, thereby holding PKC in an inactive 
conformation (Schechtman and Mochly-Rosen 2001). PKC activation occurs when its N-
terminus is no longer in close proximity to its C-terminus. In general, classical isoforms 
of PKC are activated following the induction of PIP2 hydrolysis within certain pathways 
of intracellular signaling. This produces free Ca2+ and DAG, two second messengers 
that are important for the activation of classical PKCs. Ca2+ binds to the C2 domain of 
classical PKC, and facilitates interaction with phospholipids such as 6-
pyruvoyltetrahydropterin synthase (PtS), and Phosphatidylinositol 4,5-bisphosphate 
(PIP2)  that are located in the plasma membrane. DAG is also membrane-bound, and 
interacts with PKC via the C1 domain (Giorgione, et al 2006). In classical PKC isoforms 
the engagement of both C1 and C2 domains leads to the release of the PS from the 
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substrate-binding site of the catalytic domain, and frees membrane-bound PKC to 
catalyze the phosphorylation of downstream substrates. The nature of these substrates 
and resultant cellular response is largely dependent upon the inciting stimulus and cell 
type (Gallegos, et al 2006, Newton 2010).  
 
1.6.1 Down regulation and degradation 
 
Classical PKC isoform activity is principally down regulated by the removal of 
Ca2+, through sequestration, and DAG, by diacylglycerol kinases (Hansra, Garcia-
Paramio et al. 1999) (Figure 1-5). In this way classical PKC isoforms can shuttle 
between the cytosol (inactive state) and membrane (active state), thereby PKCs have a 
long half-life. However, under conditions of long-term stimulation, such as that 
generated by the presence of Phorbol esters PKCs can be rapidly degraded. This is 
possibly because when PKC is active for a long period of time, its open conformation 
makes it more prone to de-phosphorylation, and then protein degradation (Dutil, et al 
1994, Hansra, et al 1999). PH domain leucine-rich repeat protein phosphatases 
(PHLPP) 1 and 2 are phosphatases that dephosphorylate the hydrophobic motif of novel 
and classical PKC isoforms that are in open membrane-bound conformation (Brognard 
and Newton 2008). One model has shown that PHLPP  binds and dephosphorylates the 
hydrophobic motif of activated PKCβII, and this re-localises this PKC isoform into a 
detergent-insoluble fraction of the cell where it can be further de-phosphorylated at the 
turn motif by an okadaic acid-sensitive phosphatase such as PP2A. Once PKC is fully 
dephosphorylated, it is then degraded by the proteasome (Gao, et al 2008). However, 
HSP90 can rescue dephosphorylated PKC from destruction; as in the case with de-novo 
synthesis of PKCs, HSP90 in this context allows re-phosphorylation of the PKC to take 
place and generate a catalytically competent enzyme (Gould, et al 2009).  
The importance of PHLPP in initiating PKC degradation is underlined by studies 
showing that these phosphatases have crucial role in colon cancer. In this study, 
reduced PHLPP expression in colon cancer cell lines leads to a threefold increase in the 
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expression of PKCβII, an isoform of PKC that is highly expressed by primary colon 




Figure 1-5. Regulation of PKC activation and degradation. (Adapted from Newton, et al.,2010) 
Active PKC is generated by ordered consecutive phosphorylations of serine and threonine residues 
located in the catalytic domain. However, PKC is not able to phosphorylate its substrates because the 
regulatory domain holds PKC in a closed state. Interaction with the plasma membrane results in unfolding 
of PKC allowing interaction with substrates. Deactivation can either be achieved by removal of Ca
2+
/DAG, 
or by dephosphorylation by PHLPP. In the latter case PKC can be either recycled or is further 
dephosphorylated and destroyed in the proteosome.   
 
1.7 PKC in CLL  
 
It is well known that DAG analogues such as bryostatin and phorbol esters induce 
differentiation of B cells. Therapeutically this property could be useful in the treatment of 
CLL because the malignant cells of this disease are characteristically resistant to 
20 
 
differentiation. Indeed, one study has demonstrated that bryostatin induces 
differentiation of CLL cells when it is administered to patients (al-Katib, et al 1993, 
Totterman, et al 1980). However, these studies have not been well followed up, possibly 
because of subsequent studies showing that treatment of CLL cells with bryostatin 
provided these cells with protection to the cytotoxic effects of glucocorticoids and 
Fludarabine through up-regulation of XIAP and Mcl-1 expression (Bellosillo, et al 1997, 
Kitada, et al 1999, Thomas, et al 2004). PKC inhibitors have also been used to 
understand the role of PKC in CLL cell survival. Compounds such as UCN01 (Byrd, et al 
2001), PKC412 (Ganeshaguru, et al 2002), LY379196 (Abrams, et al 2007) and 
Bisindolymaleimide (Barragan, et al 2002) induce apoptosis of CLL cells in vitro. 
Interestingly, the expression of Induced myeloid leukemia cell differentiation protein 
(Mcl-1) and X-linked inhibitor of apoptosis protein (XIAP) decreases when CLL cells are 
treated with UCN01 or Bisindolymaleimide, making these cells more susceptible to 
apoptosis (Kitada, et al 2000, Snowden, et al 2003). All these observations suggest that 
activation of PKC is an important mediator of CLL cell survival signals (Oppezzo 2012).  
 
1.7.1 Expression profile 
 
Work in this Department showed that CLL cells express PKCβI, βII, α, , ε, , and 
PKC / (Abrams, et al 2007, Alkan, et al 2005). Furthermore, a comparison of the 
expression levels of these isoforms to those in normal B cells shows that CLL cells 
express less PKCβI and PKCα, and more PKC. However, what clearly distinguishes 
CLL cells from normal B cells and other B-lymphoid malignancies is an over expression 
of PKCβII; equating to 0.53 ± 0.25% of total cellular protein(Abrams, et al 2007). The 
focus of this thesis is PKCβII, however, to gain a full understanding of PKC functioning 
in CLL cells I will first relate the established roles of PKCα,  and other important PKC 




PKCα has been shown to have both tumour promoting and tumour suppressing 
roles. Up-regulation of PKCα is observed in breast, prostate, gastric and brain cancers  
(Griner and Kazanietz 2007, Michie and Nakagawa 2005). In contrast, down regulated 
expression of PKCα is found in epithelium, pancreas and colon cancer cells, as well as 
in CLL cells (Abrams, et al 2007, Alvaro, et al 1997, Detjen, et al 2000, Neill, et al 2003). 
It is thought that over expressed PKCα promotes cancerous cell survival through an 
ability to phosphorylate Bcl-2 at the mitochondrial membrane. This leads to an increase 
in the ability of Bcl-2 to sequester the apoptosis-inducing protein Bim, which also acts at 
the mitochondrial membrane to promote depolarisation (Jiffar, et al 2004). With respect 
to the tumour suppressor effects of PKCα, it has been demonstrated that PKCα 
knockout mice spontaneously develop intestinal lesions with greater frequency than do 
wild type mice. Moreover, the mitotic index of malignant cells from PKCα knockout mice 
is greater than that of malignant cells from wild type mice (Oster and Leitges 2006). 
In CLL cells PKCα may also have tumour suppressive effects. Nakagawa et al 
have shown that expression of a kinase-dead mutant of PKCα (PKCα-KR) within foetal 
liver-derived hematopoietic progenitor cells (HPCs) that have been stimulated to 
undergo B cell differentiation induces the development of malignant cells carrying a CLL 
cell phenotype (CD19hi, CD23+, CD5+, sIgMlo). It is not clear how PKCα-KR produces 
this phenotype. However, this particular model of malignant cell development in CLL is 
appealing because it allows for genetic manipulation to take place (Nakagawa, et al 
2006, Oppezzo 2012).  
 
PKC 
Although PKC is implicated in CLL cell pathophysiology, its exact role is unclear  
(Mecklenbrauker, et al 2004). PKC plays an important role in the BAFF signaling 
pathway as demonstrated by work showing that BAFF binding to B cells prevents 
nuclear localization of this PKC isoform. When B-cell activating factor (BAFF) is absent, 
PKC localizes to the cell nucleus where it contributes to phosphorylation of histone H2B 
at serine 14. This, in turn, promotes apoptosis by allowing chromosomal de-
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condensation and cleavage. In CLL, BAFF plays a key pro-survival role, possibly by 
promoting PKC localisation to the cytosol of the malignant cells. Here, PKC may have 
some additional pro-survival effects that have not yet been characterised  
(Mecklenbrauker, et al 2004, Oppezzo 2012). Ringshausen et al have shown that 
inhibition of PKC leads to the induction of CLL cell apoptosis through down regulation 
of XIAP and Mcl-1 expression (Ringshausen, et al 2006, Ringshausen, et al 2002). 
Subsequent work in this Department agrees with these observations and has shown that 
PKC can have important pro-survival effects in CLL cells by phosphorylating STAT3 on 
serine 727. Such phosphorylation allows for an increase in Mcl-1 gene expression. This 
may have therapeutic importance as high expression of Mcl1 is associated with 
aggressive disease in CLL by protecting the malignant cells against chemotherapy 
(Allen, et al 2011, Pepper, et al 2008).  
 
Other PKC isoforms in CLL 
With the exception of PKCβII, the roles of other PKC isoforms expressed in CLL 
cells are less understood. PKCε may play an anti-apoptotic role. This PKC isozyme has 
been shown to phosphorylate Akt and Signal transducer and activator of transcription 3 
(STAT3) in other cell types, and this may be important in CLL because of the 
established role these proteins play in the pathophysiology of the malignant cells (Aziz, 
et al 2010, Matsumoto, et al 2001). Knockout mouse models have shown that atypical 
PKC regulates B-cell survival and proliferation through an ability to participate in 
Extracellular signal-regulated kinases (ERK) and nuclear factor kappa-light-chain-
enhancer of activated B cells signaling pathways (NF-κB). Signaling through these 
pathways is also patho-physiologically important in maintaining the survival and 
proliferation of CLL cells (Martin, et al 2002). Future studies, not related to this thesis, 
are needed to pave the way for better understanding of the roles of this group of kinases 





PKCβII is the most highly expressed PKC isoform in CLL cells. High expression 
of PKCβII in these cells distinguishes this malignancy from other B cell malignancies 
such as mantle cell lymphoma, diffuse large B cell lymphoma and follicular lymphoma. 
High PKCβII protein expression is the result of high expression of the gene coding for 
this protein, PRKCB. This gene is located on chromosome 16 at position p11.2. Two 
polypeptides, PKCβI and PKCβII, are encoded by this gene, and result from alternative 
splicing of the transcribed mRNA within the C-terminal exons of the gene. Thus, PKCβI 
and PKCβII proteins differ within the C-terminal 50 and 52 amino acids, respectively 
(Ono, et al 1986); The mechanism controlling PKCβ mRNA splicing has been partially 
worked out and it has been shown that insulin facilitates splicing in favour of PKCβII 
mRNA in cardiac myocytes through a mechanism that involves Akt2. The resulting 
increased protein level of PKCβII in these cells significantly affects the ability of insulin to 
induce glucose transport (Blobe, et al 1993, Patel, et al 2005). In CLL cells 
approximately 90% of the total PKCβ mRNA that can be extracted codes for PKCβII, 
and this is reflected in the protein over-expression of PKCβII and under-expression of 
PKCβI (Abrams, et al 2007). The importance of PKCβI versus PKCβII in B lymphocyte 
development is unclear because gene knockout studies have only considered the 
function of the entire gene (Leitges, et al 1996). 
A crucial role for PKCβ in CLL pathogenesis was recently shown in an in-vivo 
study using a CLL mouse model where the TCL1 oncogene is specifically over 
expressed by B cells. This mouse model, termed the TCL-1 mouse, develops a disease 
phenotype that is similar to the aggressive form of CLL in humans, and the malignant 
cells in this model bear many of the hallmarks of the malignant cells in human CLL (Yan, 
et al 2006). Interestingly, when TCL-1 mice were crossed with mice having disrupted 
expression of PKCβ, development of the CLL-like disease is inhibited (Figure 1-6). Thus, 
TCL-1 mice homozygous for disruption of PKCβ gene expression did not develop a CLL 
like disease over the course of the study. In same study, TCL1-mice heterozygous for 
disruption of PKCβ gene expression did develop a CLL-like disease, but did so with a 
much slower kinetic than did TCL-1 mice which were in a wild type configuration for 
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PKCβ gene expression. These data strongly suggest that the level of expression of 
PKCβ is a key factor in CLL pathogenesis. An explanation for this observation is that the 
PKCβ-knockout mouse is deficient in B-1 cells, the population of B cells that expands 
within TCL-1 mice to eventually develop into a CLL-like disease (Holler, et al 2009). 
Another explanation was recently provided in a paper published by Lutzny et al. Here it 
was demonstrated that CLL cells induce PKCII expression in stromal cells, and that 
expression and activation of PKCII in these stromal cells supported CLL cell survival. 
Thus, CLL-like disease would not develop in TCL-1 mice where PKC gene expression 
has been disrupted because the stromal environment would not be able to support 
disease development (Lutzny G 2013). Taken together, these notions suggest that 
targeted over-expression of PKCβ in B cells will lead to expansion of the B-1 cell 
population, and, when crossed with the TCL1 mouse, will result in accelerated 
development of the CLL-like disease. 
 
 
Figure 1-6. PKCβ is essential for the development of TCL1 transgenic mouse model of 
CLL.  
 
What is the patho-genetic role of PKCβ in the generation of CLL? PKCβ does not 
have a direct role in the maintenance of CLL cell survival, because inhibition of this 
enzyme with specific inhibitors only results in the death of a minor proportion of the 
Accumulation of CD5+
B-cell population





Slower  CLL development 
25 
 
malignant cells in CLL (Abrams, et al 2007). However, PKCβII known to function within 
the context of BCR signaling, and BCR signaling is known to contribute to CLL 
pathogenesis (Kang, et al 2001, Stevenson and Caligaris-Cappio 2004). 
 
Role of PKCβ in B cell signalling Pathways 
PKCβ functions to activate the NF-κB pathway during BCR engagement, but also 
functions to down regulate BCR signals. With respect to the former, PKCβ transmits 
BCR signals to the NF-κB pathway by phosphorylating CARD-containing MAGUK 
protein 1 (CARMA1), which, together with MALT1 (Mucosa-associated lymphoid tissue 
lymphoma translocation protein 1), B-cell lymphoma/leukemia 10 (Bcl10) and TAK1 
(TGF-beta activated kinase 1) act to stimulate IκB-kinase activity (IKK), which then 
phosphorylates IκBα to stimulate its dissociation from RelA (v-rel avian 
reticuloendotheliosis viral oncogene homolog A). Phosphorylated IκBα is then degraded 
within the proteasome, and RelA translocates to the nucleus where it activates gene 
transcription (Shinohara, et al 2007, Shinohara, et al 2005). This pathway of NF-κB 
activation is illustrated in Figure 1-7A. This may by pathologically important in CLL as 
constitutive activation of the NF-κB pathway is a characteristic of the malignant cells in 
this disease (Hewamana, et al 2008). The evidence supporting this idea comes from the 
studies of diffuse large B cell lymphoma (DLBL). Those patients bearing the activated B 
cell phenotype also have high levels of NF-κB pathway activation caused by over-
expressed active PKCβ-mediated phosphorylation of the CARMA1/MALT1/Bcl10 
complex. Interestingly, some patients with activated B cell type DLBL benefit from 
treatment with PKCβ inhibitors (Naylor, et al 2011). 
With respect to PKCβ-mediated down regulation of BCR signalling, this occurs 
through an ability of PKCβ to phosphorylate Bruton’s tyrosine kinase (Btk) on serine 
180. Such phosphorylation of Btk promotes its dissociation from the plasma membrane, 
and impedes its function by limiting its ability to phosphorylate and activate PLC-2 
(Phospholipase C-γ2) (Figure 1-7B). Regarding CLL, there is inverse correlation 
between PKCβII activation and CLL cell response to BCR engagement. Thus, BCR 
signalling is less efficient in CLL cells bearing highly active PKCβII. It is proposed that 
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high expression and high activity of PKCβ in CLL cells is patho-genetically important 
because it suppresses pro-apoptotic BCR signalling (Abrams, et al 2010, Abrams, et al 
2007). 
Further work by zum Büschenfeld et al have advanced the role of PKCβII in anti-
apoptotic BCR signaling. They have shown that ZAP-70 in CLL cells acts as a platform 
to recruit downstream signaling proteins, including PKCβII, into lipid rafts. This 
stimulates the translocation of PKCβII to mitochondrial membranes, where it is able to 
phosphorylate anti-apoptotic Bcl-2 and pro-apoptotic BimEL. Phosphorylated Bcl2 is 
able to sequester BimEL and promote cell survival, whereas phosphorylation of BimEL 
results in its proteasomal degradation (Barragan, et al 2006, zum Buschenfelde, et al 
2010) (Figure 1-7C). 
Finally, PKCβII may act to mediate signaling by the receptor for B cell-activating 
factor (BAFF). In this context BAFF stimulation of B cells results in PKCβ-mediated 
phosphorylation of Akt on S473, to promote its activation. Active Akt is an important 
regulator of anti-apoptotic and pro-survival signals in cells (Patke, et al 2006)(Figure 1-
7D). Therefore, over-expressed PKCβII in CLL cells may additionally protect against 









Figure 1-7. Role of PKCβ in B cell signaling pathways. PKCβ is shown to have role in B cell 
signaling downstream of the BCR by activating the NF-κB pathway (A) or down-regulating BCR 
signaling  by phosphorylating Btk on serine 180 and impeding its function of regulating PLC2 
activation (B). PKC also mediates phosphorylation of anti-apoptotic Bcl-2 and pro-apoptotic 
BimEL, promoting cell survival (C) or interacting with BAFF and consequently phosphorylating 
Akt on S
473
. Active Akt can then phosphorylate GSK3 to deactivate its kinase activity, and this 





In a wider context PKCβII over-expression is important in other cancers. A 
PKCβII transgenic mouse has been generated to study the role of this protein in 
oncogenesis of colon cancer. In this model, high expression of PKCβII in intestinal 
epithelial cells leads to an increased proliferation of these cells, and an increased 
susceptibility to pre-neoplastic lesions. Also, this work demonstrated that PKCβII 
mediates the inactivation of glycogen synthase kinase 3β (GSK3β) in these cells. This 
leads to the activation of the Wnt/adenomatous coli (APC)/β-catenin pathway and 
increased cell survival (Murray, et al 1999). Interestingly, in CLL cells Wnt signals also 
contribute to cell survival (Lu, et al 2004). 
In conclusion, the above studies strongly suggest that PKCβII plays a crucial role in 
maintaining CLL cell survival. 
 




Although there is controversy about the origin of CLL, in-vivo studies strongly 
suggest that CLL cells are derived from CD5+ B-1 cells (Hamano, et al 1998, Holler, et al 
2009, Oppezzo 2012). There is a lot of similarity between B-1 and CLL cells: both cell 
types express CD5, both require antigen binding for further development, and the 
antigen-binding region of expressed Ig chains use a restricted set of variable region 
genes (Joshi 2010). B-1 cell development is unclear. If the lineage model of B cell 
development is used, both B-1 and B-2 cells originate from the same progenitor in the 
bone marrow. Differentiation into B-1 or B-2 cells is determined at the transitional stage 
when these cells enter the spleen. This process relies on antigen engagement; B-2 cells 
develop from cells where BCR is strongly engaged, whereas differentiation into MZ and 
potentially B-1 cells results from weaker challenge of the BCR (Hardy 2006). Expression 
of PKCβ is known to play a role in this differentiation process; the absence of PKCβ 
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results in inhibition of B-1 cell development. This may be because PKCβ controls the 
strength of antigen receptor signaling. In the TCL1 mouse model of CLL, the absence of 
PKCβ expression inhibits development of disease (Holler, et al 2009). This may be 
because the B-1 cell population, from which the CLL-like disease develops in this model, 
is no longer present, and/or because PKCβ plays a central role in CLL pathogenesis.  
The main purpose of this project is to generate transgenic mice that over-express 
PKCβII within their B cells. We hypothesize that such over-expression of PKCβ in B cells 
will lead to a lymphocytosis of transitional B cells and expand IgM+ B cells ( the B-1 and 
MZ B cell populations). Furthermore, we also hypothesize that this expansion of the B-1 
and MZ B cell population will lead to the development of a CLL-like disease in the 
transgenic animals (Figure1-8). This study will add further insight into the role of PKCβII 
in B cell differentiation and in human CLL pathogenesis. Potentially, if this animal is 
mated with another CLL mouse model (such as the TCL-1 or MDR-KD transgenic 











This project principally consists of creation and characterisation of a transgenic 
mouse that highly expresses PKCβII within their B cells. This transgenic mouse will be 
referred to as a Eµ-PKCβII tg mouse for reasons that will become apparent in Chapter 5. 
Subsequent to this introduction, this thesis consists of 5 additional chapters containing 
the following information: 
 
Chapter 2 
o Material and methods 
Chapter 3 
- Construction of a plasmid to highly express PKCβII specifically in B cells 
o Place PKCβ coding sequence into a plasmid where expression is under the control 
of the promoter for immunoglobulin (Eµ plasmid). This will direct PKCII expression 
to B cells within the transgenic mouse. 
o Tag PKCβ coding sequence with HA so that transgenic enzyme can be 
distinguished from endogenous enzyme. The tag also gives the possibility of 
immuno-precipitating transgenic PKCII from mouse B cells. 
o Add a mCherry gene for tracking transgenic B cells using imaging. 
o Ensure plasmid integrity by expression analysis (Western Blotting and confocal 
microscopy) in a mouse B cell line (A20 cells). 
Chapter 4 
-Generation of Eµ-PKCβII tg mice  
o Create transgenic mouse (injection into fertilised eggs and transfer into recipient 
mouse to generate founder mice) 
o Identification of founder mice by genetic screening for the insertion of the gene. 
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o Creation of Eµ-PKCβII tg mice by backcrossing founder mice with wt animals, and 
by inter-crossing identified heterozygous Eµ-PKCβII tg mice. This includes 
screening for identification. 
o Confirmation of creation of homozygous Eµ-PKCβII tg mice by crossing with wt 
mice. 
Chapter 5 
-Characterization of Eµ-PKCβII transgenic mice  
o Confirmation of protein expression driven by genes encoded by the plasmid in 
Eµ-PKCβII tg mice. 
o Analysis of CLL-like disease development in Eµ-PKCβII tg mice. 
o Characterisation of phenotype of Eµ-PKCβII tg  mice, examining specifically the B 
cell populations in periphery, spleen, peritoneum and bone marrow 
o Immunohistochemistry(IHC) and histopathological analysis of the spleen of Eµ-
PKCβII tg mice 
o Perform functional assay to assess PKCβII activity in Eµ-PKCβII tg  mice 
o Compare PKCβ expression between malignant cells derived from MDR mice and 
Eµ-PKCβII tg  and wild-type mice 
Chapter 6  
















































2.1 Techniques involved in generation of the E-PKCIItg 
mice  
2.1.1 Bacteria 
2.1.1.1 Strains used and basic maintenance 
In general, two different kinds of competent bacterial cells were used in this 
project: Shot® TOP10 Competent Cells (Invitrogen) and dam-/dcm- Competent E. coli 
(C2925I)(NEB). TOP10 bacteria were used for general cloning, whereas the dam-/dcm- 
E. coli were used when unmethylated DNA was required for digestion by a dam-
sensitive restriction enzyme such as Cla-1(see Section 3.2.4). 
All bacterial procedures were performed under aseptic conditions. Competent 
cells were grown in sterile Luria Broth (Sigma-Aldrich) liquid media, consisting of 25g/L 
of Luria Broth (Formulation 10g/L tryptone, 5g/L yeast extract and 10g/L NaCl2) 
dissolved in deionised distilled water, followed by autoclaving at 122ºC. Once the 
solution was cooled, a relevant antibiotic was added to its recommended working 
concentration (Table 2-1). To prepare solid media, I followed the same recipe but added 
15g/L of agar (derived from seaweed). 
 
 
Table 2-1.Antibiotics used for DNA cloning. (*:30µg/µl in C2925 strain) 
 
 
To expand E.coli populations carrying a plasmid of interest, cells were initially 
grown in a starter culture. For this purpose, an individual bacterial colony carrying the 
plasmid of interest was picked from an LB-agar plate and inoculated into a 14 ml sterile 
Falcon 2059 tubes containing 5ml LB liquid media (with appropriate antibiotic). This was 
then incubated overnight at 37ºC with vigorous shaking (~ 230 rpm). For larger scale 
E.coli propagation, a conical flask was used, in which the volume of the flask should be 





Ampicillin Sigma Aldrich H
2
O X 1000 100µg/µl 





at least five times the size of the culture volume in order to have enough aeration. The 
flask containing the media was grown overnight at 37ºC in a shaking incubator with an 
approximate speed of 230 rpm. 
Preparation of transformed E.coli for long term storage was done by growing the 
bacteria overnight so that they reached saturation. The cells were then mixed with 50% 
glycerol at a ratio of 1:1 and subsequently frozen and maintained at -80ºC. Viability was 
validated a few weeks later by scraping frozen E.coli from the top of frozen glycerol 
stocks with an inoculation loop (this should be performed promptly to avoid thawing the 
glycerol stock), and then inoculating an LB-agar plate. The plate was then incubated 
over night at 37ºC, and if visible clones appeared on the plate the following day, the 
glycerol stock was accepted. 
 
2.1.1.2 Transformation of plasmid DNA into competent bacteria 
The aim of transformation is to introduce foreign DNA (in this case plasmid) into 
bacteria. For this purpose, heat shock-based chemical transformation was used. Thus, 
50 µl of competent bacteria (Top10) were slowly thawed in the 2ml screw cap tube in 
which they are provided. In the next step, 1 pg-100 ng of plasmid DNA is added,  mixed 
gently and placed on ice for 30 minutes. This was followed by heat shock at 42ºC for 30 
seconds (without shaking) and immediate incubation on ice for 5 minutes. 250 µl of 
Super Optimal broth with Catabolite repression (SOC) medium (Invitrogen) pre-warmed 
to room temperature was added. The transformation reaction was then incubated at 
37ºC for an hour for recovery in shaking incubator with a speed of 250 rpm. Following 
this the transformation reaction was spread on to pre-warmed LB-agar plates containing 
the relevant antibiotics, and this was incubated overnight at 37ºC to allow the 
transformants to grow. In general, for each tube, a 10% and 90% aliquot of the total 
volume of the transformation reaction was spread on to the LB-agar plates. 
Transformation efficiency was assessed using 10 pg of control plasmid such as pUC19 




2.1.2 DNA extraction methods 
 
2.1.2.1 Basic small scale isolation of plasmid DNA employing alkaline lysis and 
phenol/chloroform/isoamyl alcohol (PCI) 
This technique was used for purifying DNA from recombinant bacterial clones 
because this allowed a large number of colonies to be screened in a short period of 
time. Table 2-2 shows the list of the reagents used for this technique. Initially, 
recombinant bacterial clones were chosen from culture plates and inoculated in 4 ml LB 
broth containing an appropriate antibiotic. These cultures were grown overnight and 
then 2ml was transferred into a 2 ml micro-centrifuge tube. This was centrifuged in an 
Eppendorf centrifuge 5415 at 6800 x g for 5 minutes at RT. The pellet was re-
suspended in 200µl of GTE solution (see Table 2-2) by vortexing, and then 200µl of 
NaOH/SDS lysis solution was added and mixed by gentle pipetting. This was followed 
by successive adding, and gentle mixing by inversion, of 200l of K+Ac- solution to 
neutralize NaOH from the previous lysis step, and then 500µl PCI to extract proteins 
from DNA. The tubes were then centrifuged at maximum speed (12K – 14K xg) for 10 
minutes precipitate protein. The supernatant was immediately transferred into a fresh 
1.5 ml tube containing 500µl of isopropanol (VWR), mixed and incubated at RT for 5 
minutes. To pellet precipitated DNA, the sample was centrifuged at maximum speed for 
10 minutes, and the DNA pellet was washed by adding 1 ml of 70% ethanol. The 
samples were centrifuged briefly (14000xg) and the supernatant was gently decanted, 
and the residual ethanol allowed to evaporate. The now dry pellet was re-suspended 
and dissolved in 20µl of 0.1% TE buffer with RNAase (10 µg/ml), then incubated in a 
37ºC water-bath for 30-60 minutes. In the end, 2 µl of a 1:10 diluted DNA solution in 




Table 2-2.  The recipes for the buffers/regents used for small scale isolation of plasmid 
DNA employing alkaline lysis and PCI. 
 
2.1.2.2 Small scale preparation of high quality plasmid DNA 
This technique also relies on alkaline lysis of bacteria, but DNA is purified by 
binding to a silica membrane under high salt conditions and produces small quantities (5 
to 20 µg) of high quality DNA that can be used for downstream applications such as 
DNA ligation and DNA sequencing. For this purpose, the QIAprep spin Mini-prep kit 
(QIAGEN) was used. Table 2-3 shows a list of the reagents/buffers provided by all 
QIAGEN plasmid DNA preparation kits used in this project. 
Solution Components Source
GTE(re-suspension buffer) 50mM Glucose
25mM TRIS(pH 7.4)




















TE buffer+RNase A 10Mm Tris.Cl(pH 8.0), 1mM EDTA
10µg/ml RNAase A
Qiagen




Table 2-3. The recipes of the buffers used in QIAGEN Plasmid DNA preparation kits. 
 
 
Briefly, the overnight bacteria culture was transferred into 2ml micro-centrifuge 
tubes and bacteria were pelleted by centrifugation at 6800 x g for 5 minutes at RT. The 
bacterial pellet was then re-suspended in 250µl of buffer P1, followed by adding 250l 
buffer P2 and mixing thoroughly by inverting the tube several times to lyse the bacterial 
cells. To neutralise the reaction, 350µl of buffer N3 was added, and each sample was 
centrifuged for 10 minutes at 14000xg at RT. The supernatant was then transferred into 
a QIAprep spin column and centrifuged for 30-60 seconds at high speed. The flow-
through was discarded, and 500µl of buffer PB was added to the column to wash it from 
endonuclease activity following centrifugation for 30-60 seconds. This flow-through was 
again discarded and the column further washed by adding 750µl of buffer PE (to remove 
the salts) following centrifugation for 30-60 seconds. The flow-through was discarded, 
and the column was centrifuged again for 1 minute to ensure that there was no residual 
wash buffer left. The QIAprep spin column was then placed into a fresh 1.5 ml micro-
centrifuge tube and DNA was eluted by adding 30-50 µl of milliQ H2O, or X 0.1 TE buffer 
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(DNA eluted because of the creation of low-salt conditions). The column was allowed to 
stand on the bench for 1-5 minutes, and then centrifuged for 1 minute. The flow-through 
was saved, and the DNA concentration was determined using a spectrophotometer 
equipped with a UV lamp (see section 2.1.3.1). 
 
2.1.2.3 Medium scale preparation of high quality plasmid DNA 
A Midi-plasmid prep kit (Qiagen) was used to purify larger quantities (75-100 µg) 
of high quality DNA. The buffers/ regents used in this technique are listed in table 2-3. 
Thus, bacteria were grown in 25 ml culture overnight, and then harvested by 
centrifugation at 4500xg for 60 minutes at 4°C. The bacterial pellet was re-suspended in 
4 ml of buffer P1, and then lysed by the addition of 4 ml of buffer P2 and mixing by 
inverting the reaction tube 4-6 times. The lysis reaction was allowed to sit at room 
temperature for 5 minutes, and then it was neutralised with 4 ml of chilled buffer P3 and 
mixed promptly by inverting the sealed tube 4-6 times. This was further incubated on ice 
for 15 minutes. The lysate suspension was then centrifuged at 20,000xg for 30 minutes 
at 4°C, the supernatant was removed and transferred into a fresh centrifuge tube and 
the centrifugation step was repeated. 
A QIAGEN-tip 100 anion-exchange resin column was prepared by equilibrating it 
with 4ml of buffer QBT, and to this column the bacterial extract supernatant was then 
transferred, allowing it to go through the resin by gravity flow. The resin column was 
washed twice with 10 ml of buffer QC. After the wash steps, the DNA was eluted with 5 
ml of buffer QF, and then precipitated by adding 3.5 ml of RT isopropanol. The sample 
was centrifuged at 14,000 x g for 30 minutes at 4°C and the DNA pellet was washed 
with 70% ethanol. Then sample was centrifuged at 14,000 x g for 10 minutes at 4°C and 
the ethanol was carefully removed from the DNA pellet. In the final stage, the DNA pellet 
was air dried for 5-10 minutes and then re-suspended in 50-75 µl of TE buffer. DNA 




2.1.2.4 Isolation of genomic DNA from animal tissues 
The method for isolation of genomic DNA from mouse tails was adapted from the 
protocol described in “Molecular Cloning: laboratory Manual” by Sambrook (Sambrook 
2000). Typically, each mouse tail (~ 0.5 cm) was chopped into smaller pieces with a 
scalpel and transferred into a 2ml screw-cap tube. Then, 500 µl of lysis buffer (50 mM 
Tris (pH 8.0), 100 Mm EDTA and 0.5% SDS (w/v)) with 250 µg proteinase K (final 
concentration 5µg/µl) (Sigma-Aldrich) was added to the tube and incubated overnight at 
55°C in a water bath. The following day, 500 µl of phenol was added to each sample 
and incubated for 1 hour at RT with gentle shaking using nutator. Then, the sample was 
centrifuged at 14,000xg for 5 minutes and the supernatant was transferred into a fresh 
tube. 500 µl of PCI was added and the tube, mixed for 5 minutes by inversion (no 
vortexing), followed by centrifugation at 14,000xg for 5 min. The supernatant was 
transferred into a fresh tube and the 50µl 3M sodium acetate (pH 6.0) and 500µl of 
100% ethanol were added to precipitate DNA. The tube was well mixed by inversion for 
1 minute, and then centrifuged for 10 minutes at 14,000xg to pellet the DNA. The 
pelleted DNA was washed with 70% ethanol and re-suspended in TE buffer + RNase A.  
 
2.1.2.5 Extraction of DNA from agarose gels 
DNA extraction from agarose gels was performed using a GENECLEAN Turbo Kit 
(Q.Biogene) according to the manufacturer’s guidelines. Typically, the DNA band of 
interest was excised from the agarose gel using a scalpel blade. The gel slice was 
placed into a 1.5 ml eppendorf tube, and weighted. To each 100µg of gel slice 100µl of 
Gene clean turbo salt solution was added, and the sample was incubated in a water 
bath set to 55°C for approximately 10 minutes, or until the agarose gel was melted 
completely. Each sample was applied on to a cartridge with glass milk membrane 
placed inside a second carrier tube which was used to collect the flow-though (called a 
catch-tube). The DNA/gel/salt solution was then centrifuged for 10 seconds, the liquid in 
the catch tube was discarded and the membrane was washed twice by adding 500 µl of 
GENECLEAN turbo wash solution over the column and then centrifuged for 10 seconds. 
After the second wash, the Gene clean turbo cartridge was spun into an empty tube for 
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2 minutes at 14,000xg to ensure that the membrane was completely dried and no trace 
of ethanol was left (ethanol has an inhibitory effect on downstream applications (Loffert 
1997)). In the last step, the column was placed into a fresh 1.5 ml micro-centrifuge tube 
with a detachable lid (provided in the kit) and the DNA was eluted by adding 30 µl of 
GENE clean turbo elution solution directly on to the cartridge. Each cartridge was 
incubated for 5 minutes at RT, and then centrifuged for 1 minute at 14000xg to transfer 
the eluted DNA into the freshly provided tube. To estimate DNA yield, 10% of the eluted 
sample was run on an agarose gel (see Section 3.2.3).  
Also, this technique was particularly used when a segment of DNA needed to be 
digested by two restriction endonucleases that had incompatible buffers. In this case, a 
liquid version of the GENECLEAN reaction was used, which is very similar to the GENE 
CLEAN protocol described above. The only difference is that X5 (v/v) GENECLEAN 
turbo salt solution was added into the tube containing DNA that was cut by the first 
restriction enzyme. This was followed by loading the mixture on to a GENECLEAN 
column and purifying as described. The resulting purified DNA could then be digested 
with the second restriction enzyme. 
 
2.1.3 DNA analysis 
 
2.1.3.1 Determination of the purity and concentration of DNA by UV spectroscopy 
The purity and concentration of DNA were determined using a UV 
spectrophotometer (BioPhotometer, Eppendorf). 1 µl of extracted DNA was diluted 
1:100 with a relevant re-suspension buffer (usually water or TE buffer), mixed well and 
transferred into an UV cuvette (Eppendorf). The re-suspension buffer without any DNA 
was used as a blank control. The samples were measured in the BioPhotometer and the 
concentration of DNA was calculated using the equation described below: 
Concentration (µg/ml) = (A260 reading - A320 reading) x dilution factor x 50µg/ml   
Based on this equation, absorbance measured at a wavelength of 260nm (A260) 
indicates concentration of DNA and this is corrected for the turbidity by subtracting light 
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absorbance measured at 320nm (A320). The adjusted A260 was then multiplied by the 
dilution factor and 50 (this latter comes from using a relationship in which a 50 µg/ml 
concentration of DNA has an absorbance of 1 at A260). Total yield of purified DNA was 
calculated as DNA yield (µg) x total volume (µl). The DNA purity was assessed based 
the A260/ A280 ratio in which pure DNA has value of 1.8, however values between 1.7 and 
2 are considered as high quality DNA. A value of less than 1.8 is an indication of protein 
contamination, whereas a value greater than 2.0 is an indication of RNA contamination. 
 
2.1.3.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate a mixed population of DNA 
fragments, and also used for estimation of DNA yield after extraction from the agarose 
gel. In general, Gensieve LE agarose (Flowgen) was used for gel electrophoresis. 
However, when a DNA fragment was to be used for molecular cloning procedures 
SeaKem®GTG® agarose (Lonza) was preferred. The agarose solution was melted in a 
standard microwave oven on full power for 2-4 minutes, and then cooled to 
approximately 50°C. Then, ethidium bromide (Roche) (0.5 µg/ml) was added to the 
solution, and this was followed by pouring the solution into a sealed gel cast with comb 
(to form wells) and allowing the gel to set. Once the gel set comb and sealing tape were 
carefully removed, and the cast containing the gel was placed in the gel tank containing 
1 x TAE buffer (40mM Tris-Base, 1mM EDTA (pH 8.0), and 1.142% glacial acetic acid). 
There should be a minimum of 1mm of TAE buffer covering the surface of the gel. 
Samples were prepared by the addition of 10% (v/v) of orange G loading buffer (50% 
glycerol with adequate amount of orange G dye (BDH) to give clearly visible orange 
colour), and they were loaded in the wells. At least one well of the gel was loaded with a 
DNA marker (either the 100bp DNA ladder (NEB) or the 1kb DNA ladder (Invitrogen)) in 
order to estimate the size of DNA within the loaded samples.  
Gels were made up using different percentages of agarose (typically 0.5, 0.7, 1.0, 
1.3 and 2% (w/v) agarose) in order to obtain best resolution depending on the size of the 
DNA. The gel (Scie-Plas) unit was run in horizontal fashion by applying a voltage of 1-10 
V/cm. The gel was run until the DNA bands were satisfactorily separated. As a result of 
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intercalation of ethidium bromide present in the agarose gel into the DNA structure, DNA 
could be visualised using a High Performance UV trans-illuminator (UVP). A Kodak 
EDAS 290 digital camera was used to obtain images of the gel, Adobe Photoshop was 
used to edit pictures into a desirable format. DNA yield was estimated from the agarose 
gel and is described in Section3.2.3.  
 
2.1.3.3 Southern blotting 
In this project Southern blotting was used for detecting the transgene in genomic 
DNA extracted from the tail of potential Eµ-PKCβII tg mice. The protocol used in this 
project was adapted from the book, Molecular Cloning: A Laboratory Manual (Sambrook 
2000). Thus, 10µg of genomic DNA extracted from the tail of the mice was digested with 
a relevant restriction enzyme (See section 4.6.1), and then the fragments were 
separated by electrophoresis on a 0.7% agarose gel. Alongside these samples a 1kb 
DNA ladder, DNA extracted and similarly prepared from wild-type control and transgene 
plasmid added at equivalent amounts corresponding to 0.1, 1, 10 and 20 copy numbers 
of the transgene (used as a positive control (see Section 4.6.1)). Following sufficient 
electrophoresis the gel was placed on UV trans-illuminator and a ruler was placed 
beside the gel. A digital photograph was taken to record the ethidium bromide staining 
pattern, and this was a very important indicator of complete digestion of the genomic 
DNA samples (see Section 4.6.1).  
In the next stage the agarose gel was washed several times in denaturation, 
depurination and neutralisation solutions (Table 2-4). Initially, the gel was subjected to 3 
x 15 min washes in denaturing buffer and using agitation. This was followed by a 5 
minute wash in 0.2 N HCL, again with agitation and a quick rinse in ultrapure 
(˃18Mohm) water. Preparation of the gel for transfer was completed by 3 x 15 min 
washes in neutralisation buffer using agitation. In the meantime, an appropriately sized 
piece of nitrocellulose membrane (HyClone), Whatman filter papers and paper towels 
were prepared. The nitrocellulose membrane was soaked in water for 20 minutes, 
followed by soaking in 10 X Saline-sodium citrate (SSC). Before transfer, the gel was 
placed into 10 X SSC, and the transfer apparatus was assembled; the layout of the 
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apparatus is described in Figure 2-1. When the apparatus was set up it was wrapped in 
cling-film to avoid excessive evaporation. The transfer was performed for 16-24 hours. 
Table 2.4 shows a list of buffers used for the Southern blotting. 
 
 












20 x SSC (pH 7.0) 3 M NaCl
0.3 M Sodium citrate
VWR
Sigma-Aldrich









Figure 2-1.Southern blotting transfer apparatus. 
 
 
After completion of the transfer, the apparatus was disassembled and the back of 
the nitrocellulose membrane was labelled to identify the position of the first well. To 
check the transfer efficiency the post-transfer agarose gel was re-stained with a 0.5 
µg/ml solution of ethidium bromide for 30 minutes with agitation, followed by 
visualisation when exposed to UV light. The nitrocellulose membrane was placed on a 
clean sheet of Whatman paper and air-dried for 10-15 minutes. The bound DNA was 
immobilised on to the nitrocellulose membrane by exposure to UV irradiation using a UV 
cross-linker using a set programme for this purpose. The membrane was then soaked in 
1 M NaCl for approximately 30 minutes, ensuring that the membrane was thoroughly 
wet. Meanwhile, the pre-hybridisation mixture (pre-hybe mix) and hybridisation bottles 
were heated at 65°C in hybridisation oven. In the next step, 25 ml of pre-heated pre-
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hybe mix was transferred into the hybridisation bottle. In the case where more than one 
membrane was used, two membranes could be placed into one hybridisation bottle with 
a special mesh screen between them. The membrane was then incubated in pre-hybe 
mix at 65°C with circular moving for approximately 3 hours. If there is no time limitation, 
the incubation can be performed overnight. 
 The construction of the probe is described in section 4.6.1. In order to 
radioactively label the probe, an Amersham Megaprime DNA Labelling System 
(RPN1604) was employed. Based on this system, 50 ng of probe DNA was added to 5 
µl of primer mix in a 0.2 ml PCR tube. A final volume of 26 µl was achieved by adding 
H2O. This was followed by heating the mixture in a PCR machine set to 98C for 5 
minutes, and allowing it to cool to RT. A brief centrifugation concentrated the liquid in the 
bottom of the tube. In the next step, 4µl of dATP (Deoxyadenosine triphosphate), 4µL of 
dTTP (Thymidine triphosphate), 4µl of dGTP (Guanosine triphosphate) and 5 µl of 
reaction buffer were added. Then, 5µl of 32P labeled dCTP (Cytidine triphosphate )(Easy 
Tides Deoxycytidine 5’-triohosphate, [α-32P] 250µCi (9.25 mBq) in 25µl from Perkin 
Elmer) was added into the mixture (this was done behind a Perspex radiation screen in 
order to reduce personal exposure to radioactivity), following by addition of 2µl of 
Klenow DNA polymerase. The reaction was mixed by pipetting and incubated at 37°C 
for 45 minutes. Meanwhile, a G-50 sephadex separation column was prepared 
consisting of a glass Pasteur pipette blocked with a small quantity of siliconised glass 
wool (Sigma-Aldrich) and filled with swollen G-50 sephadex beads (50% G-50 sephadex 
w/v in water). Once the incubation of the radioactively labelled probe was completed, it 
was placed on ice for approximately 2 minutes before running it through the column.  
To prepare the probe to run through the column, it was first mixed with 20µl of 
Orange G and 20µl of dextran blue. Then, the mixture was loaded on to the column in a 
drop-wise fashion, and eluted fractions liquid were collected in a 1.5 ml micro-centrifuge 
tube. Once all the reaction was loaded, water was added in a drop-wise fashion. Within 
the column the blue dextran co-migrates with DNA whereas Orange G co-migrates with 
unincorporated nucleotides. Therefore, the blue droplets are expected to contain the 
probe (approximately 400µl) and were collected in an allocated screw cap top tube. 
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For measuring radioactivity, a 2µl aliquot of the probe measured in a scintillation 
counter (PACKARD, 1500 TRI-CARB). The radioactivity of the probe was represented 
as dpm/µg, and used to calculate the volume needed to achieve a desired 1 x 106 
dpm/ml within 25ml of the hybridization buffer. To reduce non-specific binding of the 
hybridization probe to the surface of the membrane Salmon sperm DNA (Sigma-Aldrich) 
was used as a blocking regent at a final concentration of 100 µg/ml. This was added into 
the probe and the mixture was then boiled for 10 minutes and then immediately 
incubated on ice for 5 minutes before adding it to the pre-heated pre-hybe mix. The 
hybridisation reaction was performed in a hybridisation bottle at 65°C overnight in the 
hybridisation oven where the bottle was gently rotated.  
The following morning, the membrane was taken out from the hybridisation bottle, 
briefly washed twice in 2 X SSC buffer on a rocker at RT, and then twice more for 15 
min. This was followed by 2 x 15 min  washes in 2 X SSC + 0.1 % SDS buffer preheated 
to 65°C, and this was performed using a sealed Tupperware box in a shaking (60 rpm) 
water-bath at 65°C. The last wash was in 0.1 X SSC at RT for 5 minutes on the rocker. 
To visualise the signal the membrane was wrapped in cling-film, placed on to X-ray film 
(Kodak Biomax MS Film, sourced from Sigma-Aldrich) in a cassette containing an 
intensifying screen. This was incubated at -80°C for 1-3 days, after which the film was 
developed. It should be added that all the reagents used for radio-labelling the probe 
were from Amersham, unless stated otherwise.   
 
2.1.4 Enzyme based DNA manipulation  
 
2.1.4.1 Digestion with restriction endonucleases 
Most of the restriction endonucleases used in this project were purchased from 
New England Biolabs (NEB), and were used for digesting plasmid DNA during the 
cloning process (i.e. for ligation reactions). Typically, in this process 0.5-1 µg of plasmid 
DNA, 5-10 units of restriction enzyme, relevant buffer and BSA (final concentration of 
100µg/ml if necessary) were mixed in a total volume of 20 l (Table 2-5). The digestion 
reaction was incubated for approximately 2 hours at 37°C. The total volume was 
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determined based on the fact that the enzyme content is not allowed to exceed 10% of 
the total volume of the digestion reaction (v/v) in order to prevent non-specific cutting, 
which is called star activity. To ensure that the DNA was completely digested a 10X 
excess of enzyme (10 U/µg) is used to cut the DNA. The digested DNA fragments can 
then be separated by electrophoresis on a GTG® (genetic technology grade) agarose 
gel. In the case that DNA needed to be digested with two restriction endonuclease 
enzymes, a compatible buffer was chosen that ensured a minimal activity of 75% for 
both enzymes and this was done following NEB (New England Biolabs)’s guidelines. If 
the two chosen enzymes did not have a compatible buffer, a sequential digestion was 
performed by purifying the DNA using the liquid GENECLEAN protocol following the first 




Table 2-5.Components of a typical digestion reaction. 
 
2.1.4.2 De-phosphorylation of Vector DNA (Antarctic phosphatase reaction) 
To prevent vector self-ligation, Antarctic phosphatase (NEB) was used to remove 
the 5’ phosphate group. Thus, following restriction enzyme digestion of backbone vector 
DNA (1-5 µg) further enzymatic activity was inactivated by incubation at 65°C. In the 
next step the reaction was mixed with a 1/10th volume of provided 10X Antarctic 
phosphatase buffer and 1µl of Antarctic phosphatase (5 units). This was mixed by 
vortexing for 2-3 seconds, and the reaction was briefly centrifuged and then incubated at 
37°C for 15 minutes for 5’ extensions or 60 minutes for 3’ extensions. The reaction was 
Digestion reaction Concentration
Plasmid DNA Approx. 0.5-10 µg
NEBuffer 10 X
BSA (100 µg/ml)
Restriction endonulease Approx. 10 U/µg
Water Up to final volume
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then stopped by heating to 65°C for 5 minutes, or alternatively by adding 1/10 volume of 
orange G dye.   
 
2.1.4.3 Blunting DNA ends using DNA polymerase I, large (Klenow) fragment 
During DNA cloning, DNA blunting is used when no compatible end restriction 
sites are available, or if the sticky end created by a restriction enzyme is required to be 
removed for a particular downstream cloning purpose (see Section 3.4). DNA 
polymerase I, known as the large (klenow) fragment (NEB) is used to create blunt ends 
on digested DNA fragments by either filling in 5’ overhangs or by removing 3’ 
overhangs. To do this plasmid digests where the restriction enzyme reaction (Total 
volume of 100µl) was heat inactivated at 65°C for 15 minutes were mixed with 1 unit of 
Klenow/1µg of DNA and 33 µM of each dNTP (Deoxyribonucleotide triphosphate 
)according to the manufacturer’s protocol. This reaction was then incubated at 25°C for 
15 minutes. The reaction was stopped by heat inactivation at 75°C for 10 minutes, and 
then let to cool down slowly. To ensure that the blunting reaction was stopped, EDTA 
(Ethylenediaminetetraacetic acid)was added to the final concentration of 10mM before 
adding x 10 orange-G loading buffer and running the samples on a GTG® agarose gel. 
 
2.1.4.4 Ligation of DNA fragments 
T4 DNA ligase (Fermentus) was used for DNA ligation, and the procedure was 
performed according to the manufacturer’s instructions; the components of the ligation 
reaction were mixed together in a 0.2 ml PCR tube (table 2-6) to a final volume of 10µl, 
well mixed by vortexing for 2-3 seconds, centrifuged briefly and incubated at 14°C for a 
minimum of 18 hours. Then, 1-5 µl of the reaction was added to competent cells within 
the transformation reaction (see Section 2.1.1.2). Two control reactions were also 
routinely used, consisting of the vector DNA with and without DNA ligase in the 
appropriate buffer. The presence of bacterial clones on the control plate with ligase 
would suggest that the de-phosphorylation reaction has not been successful, whereas 
the presence of the clones in the control without ligase means that the digestion of the 
49 
 
DNA was incomplete and the ligation reaction might have been contaminated with uncut 
plasmid DNA. 
 
Table 2-6.Components of a typical ligation reaction. 
 
2.1.4.5 Using intermediate vector (TA-cloning) 
The details of the TA cloning strategy I employed in this project are described in 
section 3.2.3. Firstly, I had to ensure that there was no trace of Phusion DNA 
polymerase because this enzyme has 3’ to 5’ exonuclease activity which could result in 
the removal of the desired poly A-tail. Inactivation of Phusion DNA polymerase was 
achieved by heat-treating the reaction at 98°C for 20 minutes promptly after completion 
of the PCR. Then, the reaction was allowed to cool slowly, and once cool 1µl of 10mM 
dATPs and 1 µl of Taq DNA polymerase (10 units) were added into the old PCR reaction 
(50 µl), mixed well ,and centrifuged briefly. This was followed by incubation at 72°C for 
20 minutes. Finally, the reaction was run on a GTG® agarose gel and DNA was 
extracted for downstream cloning. 
 
2.1.5 Amplification of DNA by polymerase chain reaction (PCR) 
 
2.1.5.1 Standard Procedures and optimization 
Polymerase chain reaction (PCR) was used to amplify the DNA of interest using 
appropriate forward/reverse primers, and was mediated by a thermo-stable DNA 
polymerase such as Taq or Phusion. In general, the total volume of the PCR reaction 
Compounds Amount
Vector   50 ng
Insert (DNA ) At least 1:1 molar ratio of vector: insert,
but aimed for much higher insert
concentration up to 1:10
10 x T4 buffer                   1 µl                                                                       
T4 DNA ligase (1 
unit) 
1 µl
Water Make up volume 10 µl                      
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was 20-25 µl and contained a polymerase enzyme supplemented with its buffer, 800 µM 
dNTPs (GE Healthcare), 0.05 µg of each primer and an adequate amount of the 
template DNA which required PCR optimisation and was typically 10 ng of DNA (see 
Section 3.2.2) (see table 2-7). The reaction was then topped-up with distilled water to 
achieve a total volume of 25µl. Finally, the PCR tube containing the reaction mixture 
was placed in a thermal cycler (P X2 Thermal Cycler, Thermo.Electron Corporation). 
The appropriate number of cycles as determined by PCR optimisation was applied for 
the specific DNA of interest (see Section 3.2.2). Amplified DNA was separated on an 
agarose gel by electrophoresis and then visualized by UV light after staining with 
ethidium bromide.  
Taq DNA polymerase (NEB) was used to amplify DNA fragments destined for 
DNA cloning, and for screening of bacterial colonies. Phusion (Hot Start) High-Fidelity 
DNA polymerase (Finnzymes) and JumpStart Taq DNA polymerase (Sigma-Aldrich) 
were used for screening of genomic DNA extracted from mouse tails. The PCR 
conditions for these DNA polymerases are listed in table 2-8. 
To design primers for PCR, Primer3 (http://simgene.com/Primer3) and primer 
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast) programmes were used. The 
length of primers was typically 18-25 nucleotides with a 40-70% GC content and a 
melting temperature (Tm) of approximately 60°C. The designed oligonucleotides were 
synthesised by Eurofin (http://www.eurofinsgenomics.eu/) MWG Operon and 









Table 2-8. Standard cycle condition for the DNA polymerases used in this project. 
 
2.1.5.2 Specialized PCR methods 
 
2.1.5.2.1 DNA Sequencing (Eurofins MWG Operon/GATC) 
In order to sequence the DNA, high quality DNA was prepared using a QIAGEN 
mini-prep kit (see Section 2.1.2.2). In this project, the DNA samples were sent to either 
Eurofins MWG Operon or GATC Biotech for sequencing. The DNA samples were 
Compounds 25µl




DNA polymerase 0.4-1 units
DNA template 250 ng-1µg of genomic 
DNA
5-10 ng  of plasmid DNA






























68°C 5 m 1
4°C
JumpStart Taq DNA 
polymerase
Temp. Time cycles












prepared for sequencing according to manufacturer's instructions, which are 
summarized in table 2-9.  
 
 
Table 2-9. Standard high quality DNA preparation for sequencing at Eurofins MWG 
Operon and GATC Biotech. 
 
2.1.5.3 Phire Animal Tissue Direct PCR kit 
Phire® Animal Tissue Direct PCR Kit (Finnzyme) was used to DNA isolated 
directly from tissues without the need for high quality purification. This method was used 
for the propagation of the MDR-KO mice used in Chapter 5 of this thesis. Tissue 
samples from these mice were typically ear-notches of 2-3 mm in diameter, and these 
had been stored at -20°C until used. To extract DNA, the tissue was placed into 20µl of 
Dilution Buffer and 0.5µl of DNA Release Additive was added. The solution was mixed 
by vortexing, centrifuged briefly and then incubated for 2-5 minutes at RT. The reaction 
was then placed into pre-heated block (98°C) for 2 minutes, supernatant transferred into 
a fresh tube and stored at -20°C if not used immediately. The PCR was performed using 
Phire ® Hot Start II DNA Polymerase, provided with the kit. This polymerase has a high 
resistance to many PCR inhibitors residing in animal tissues. PCR was performed on 1-2 
µl of isolated DNA using conditions shown in table 2-10. 
Eurofins MWG Operon GATC Biotech
High quality
plasmid DNA





Primers 15 pmol, sent pre-mixed
with template DNA
10 pmol/µl in 20





Table 2-10.Standard cycle condition(A) and reaction (B) for PCR using Real time PCR 
Phire ® Animal Tissue Direct PCR Kit. 
 
2.1.6 Quantitative Real Time PCR 
 
Quantitative Real-Time PCR (RT-PCR) was used to quantify mCherry as part of 
the transgene integrated into the genomic DNA of the transgenic mice I created. This 
was important in order to distinguish heterozygous from homozygous Eµ-PKCβII tg 
mice. To do this I used the 5 x HOT FIREPol® EvaGreen® qPCR Mix plus (ROX) (Solis 
Bio Dyne). This kit is an optimised ready-to-use solution for real-time quantitative PCR 
assays and consists of: HOT FIREPol® DNA polymerase, ultrapure dNTPs, MgCl2 and 
EvaGreen® dye. The EvaGreen® is a DNA-binding dye which has a similar spectrum to 
SYBER® Green, but is more stable dye and inhibits PCR less. The PCR reaction was 
prepared according to a slightly modified version of the manufacture’s instruction 
described in table 2-11. Firstly, extracted genomic DNA was placed in the bottom of flat-
bottomed 96 plate and the master mix was added. The reaction plate was sealed with a 
provided adhesive sticker using a plate sealer tool, centrifuged briefly and placed into a 
Phire ® Animal Tissue 






























real-time thermal cycler, Mx3005P Q-PCR system (Agilent Technologies). The 
quantification of the transgene by q-PCR is extensively discussed in section 4.7. 
 
 
Table 2-11.Real Time PCR cycles (A) and reaction mix (B) used for quantification of the 
transgene in E-PKCβII transgenic mice. 
 
2.2 Techniques involved in phenotypic analysis of the E-
PKCII tg mice  
 
2.2.1 Cell lines used and cell culture 
 
Two cell lines were used in this project, A20 and MEC-1 cells. The A20 cell line is 
a BALB/c-derived B cell lymphoma line purchased from the American Type Culture 
Collection (ATCC). MEC-1 is the cell line originating from the peripheral blood (PB) of a 
patient with B-CLL who was undergoing pro-lymphcytic transformation. MEC-1 cells 
were purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(DSMZ). These cell lines were grown according the manufactures’ instructions. The 
recommended media for growing A-20 cells was Roswell Park Memorial Institute 1641 
(RPMI 1641) supplemented with 10% Fetal bovine serum (FBS), and for MEC-1 was 
HOT FIREPol® EvaGreen® 
qPCR Mix Plus 
Temp. Time cycles












HOT FIREPol® EvaGreen® 
qPCR Mix Plus 
4 µl
Forward Primer 80-250 nM
Reverse Primer 80-250 nM
DNA template 50-250 µg




90% Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS( see 
Section 3.4.2). 
 
2.2.2 Introducing DNA plasmid into mammalian cells using 
Nucleofection 
 
Nucleofection was used as a transfection method to introduce plasmid DNA into 
mammalian cells. This method employs an electroporation cell and special buffers that 
are included within a Nucleofection kit (Lonza Biologics plc, Tewkesbury UK). Briefly, 2 x 
106 cells were transfected using the Amaxa solution V transfection kit according to the 
manufacturer’s protocol. The cell suspension was mixed with 2 µg of DNA, transferred into 
the provided cuvette, placed in Nucleofector® device and electroporated with the 
appropriate programme (U-013 for A20 cell line and X-001 for MEC-1 cell line). Following 
transfection the cells were transferred into the relevant pre-heated media, and incubated in 
a humidified incubator at 37C for an appropriate period of time (24 hours for A20 and 48 
hours for MEC-1 cell lines). A plasmid encoding maxGFP (Lonza), a green fluorescent 
protein, was used to aid analysis of the transfection efficiency. 
 
2.2.3 Tissue isolation and preparation of single cell suspensions 
 
2.2.3.1 Tissue isolation 
The tissues I isolated from mice were spleen, peritoneum, bone marrow and 
peripheral blood. Single cell suspensions were prepared from each of these tissues for 
FACS analysis. In the following sections I describe isolation for each individual tissue 
mentioned above: 
 
2.2.3.1.1 Peripheral Blood 
Blood collection was performed immediately after sacrificing the mice with CO2 by 
performing a cardiac puncture in which the needle (19 g) was inserted at a 20-30 degree 
angle from the horizontal axis of the sternum into the heart of the dead animal. 
56 
 
Approximately 500-1000 µl of peripheral blood was collected, and this was enough to 
perform FACS analysis. 
 
2.2.3.1.2 Peritoneum 
Following blood collection the mouse was laid down on its right side, the outer 
skin was swabbed with 70% Ethanol and an incision was made with scissors so that the 
outer skin could be pulled back using forceps to expose the inner skin covering the 
peritoneal cavity. In the next step, 10 ml of ice cold modified Phosphate buffered saline 
(PBC) (1% BSA + 0.1% Sodium Azide, pH 7.2) was injected gently into the peritoneum 
cavity using a 27g needle and then the peritoneal cavity was gently massaged. This was 
followed by insertion of the needle back into the cavity and the fluid was collected 
carefully avoiding clogging the needle with fat tissue or other organs. To collect as much 
peritoneal fluid as possible, an incision was then made in the inner skin of the 
peritoneum and the skin held up with forceps so that a plastic Pasteur pipette could be 
used to collect the remaining peritoneal fluid from the cavity (Figure 2-2).  
 
 
Figure 2-2. Isolation of Peritoneal cells in mouse. This figure shows how cells are isolated 
from peritoneum following lavage with modified PBS. A plastic Pasteur pipette is used in the final 




The spleen is located on the left side of the abdominal cavity, above the kidney 
and below the heart. Thus, after opening the abdominal cavity the spleen was found. In 
the next step the spleen was lifted by holding the surrounding fat pads with forceps and 
then  isolating the spleen from these surrounding fat pads and placing it in a petri dish 
containing 5 ml of medium (RPMI). The isolated spleen was divided into three pieces: 
one piece was snap frozen in liquid nitrogen for protein extraction (see Section 2.2.4), 
one piece was formalin fixed and then paraffin embedded for histochemistry analysis 
(see Section 2.2.6) and the final piece was used to prepared a single cell suspension for 
FACS analysis. The single cell suspension was prepared by physically dissociating 
(titrating) the spleen with a Pasteur pipette in the petri dish containing 5 ml medium. The 
titration was continued until there was homogenous suspension of splenic tissue, then 
the connective tissue of the spleen was manually removed and red blood cells were 
lysed (Figure 2-3).  
 
Figure 2-3. Isolation of spleen from body cavity in mouse. This figure shows dissection of 
the mouse with the purpose of obtaining the spleen. The spleen in this figure is held by the 
forceps.  
 
2.2.3.1.4 Bone Marrow 
To isolate bone marrow cells the skin surrounding the lower part of the mouse 
body, including the legs, was removed completely. Then, the femur was dissected from 
the tibia and hip by scissors (Figure 2-4A) and separated from the body. The remaining 
tissues were removed from dissected femora bone to avoid contamination of bone 
marrow cells with other cell types (Figure 2-4B). A 5 cc syringe with a 25g needle 
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containing 5 ml of modified PBS was inserted into the broken end of the femora (Figure 
2-4AC) and cavity gently flushed the modified PBS. The PBS containing bone marrow 
cells was transferred into a fresh 15 ml tube. The bone marrow cell suspension was 
topped with modified PBS up to 15 ml, and well mixed by pipetting up and down to 
ensure that I have a homogenous suspension of bone marrow cells. 
 
  
Figure 2-4. Isolation of Bone Marrow cells from Femora in mouse. This figure shows 
dissection of the femur from the mouse (A), removal of surrounding muscle and connective 
tissue (B) and isolation of marrow using a syringe (C). 
 
2.2.3.2 Single cell suspension 
After the cells were isolated from peripheral blood, peritoneum, spleen and bone 
marrow they were transferred into 15 ml tubes and topped-up with 15 ml of the RPMI 
medium. The cell suspensions were mixed well with a pasteur pipette to achieve a 
homogenous population of the cells. Then, the cell suspension was centrifuged at 1500 
rpm (150xg) for 3-5 minutes, the supernatant was decanted, then 1-2 ml 0.83% 
Ammonium chloride (in water) was added and the pellet re-suspended and incubated at 
RT for 2-5 minutes to lyse red blood cells. Then, the samples were topped-up with RPMI 
medium to 5ml and then centrifuged at 1500 rpm for 5 minutes and re-suspended into 
fresh media containing 90% RPMI and 10% FCS. In the end, the cell suspension was 
counted and incubated on ice overnight and the FACS experiment was performed the 




2.2.4 Protein extraction from cells 
 
Protein extraction from tissue 
To extract the protein from tissues (Spleen, Kidney, Heart and Liver) of mice I 
took snap-frozen tissue samples and powdered them with a mortar and pestle under 
liquid N2. It was important to prevent warming the tissues, therefore I constantly topped-
up the liquid N2 level until the tissues were completely powdered. In next step the 
powdered tissues were re-suspended in 3x packed volume of Buffer C (see table 2.2-1) 
and were subjected to 3 cycles of freezing with liquid N2 and subsequent thawing on ice 
in order to homogenize the tissues. This was followed by centrifugation at maximum 
speed for 10 minutes at 4°C, and the supernatant was transferred into a fresh 1.5 ml 
tube. Protein determination was performed using a Bradford assay. 
 
 
Table 2-12. Recipes for the buffers used for protein extraction from the tissue. 
 
Protein sample preparation and quantification (Bradford assay) 
To perform a protein determination using the Bradford Assay a series of protein 
standards were prepared consisting of 20, 10, 5, 2.5, 1.25, 0.625 and 0.3125 mg/ml of 
bovine serum albumin (BSA) dissolved in buffer lysate C. Then 2µl of supernatant 
containing the protein extracted from the tissue or 2l of protein standard at each 
concentration were added to 1 ml of Bradford reagent (BioRad-diluted in 1 in 5 water). 
This was vortexed for a short time. The presence of protein was detected in the Bradford 
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reagent with a change in spectral properties of Coomassie Brilliant Blue G-250 that can 
be measured by light absorbance at 595 nm. Protein concentration of the sample is 
determined from a graph constructed from the absorbance readings of the protein 
standards. The samples were then prepared to a concentration of 25-50 µg/20µl in 
sample buffer, incubated at 95C for 5 min, and then stored at -80°C. 
 
Protein extraction from cell lines 
To extract protein from cell lines 2 x 106 cells were pelleted, then washed in PBS 
and lysed with 200µl of lysis buffer (125mM Tris pH 6.8 + 5 mM EDTA +1% SDS). The 
cell lysates were then sonicated and incubated for 5-10 minutes at 95°C. This was 
followed by centrifugation of the cell lysate at 12,000 rpm for 5 minutes, then the 
supernatant was transferred in a fresh micro tube and protein determination was 
performed. The protein lysate was kept at -20°C. 
 
2.2.5 SDS-PAGE and Western blotting 
 
In this project Western blotting was used for detection of transgene at the protein 
level, and also for the quantification of PKCβII in both Eµ-PKCβII tg and wt mice. Thus, 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate the proteins of splenic tissue (25-50 µg) based on their molecular weight. The 
recipes for the solutions used in for Western blotting are described in table 2-13. To 
prepare the gel, resolving gel mixture was poured into a glass cassette sandwich at an 
appropriate percentage of acrylamide (usually 10-12%), and topped-up with water to 
avoid drying the gel. The gel was allowed to polymerize for approximately 30 minutes. 
Then the water was poured off, and stacking gel mixture was loaded on top of the lower 
resolving gel. This was followed immediately by gentle insertion of a comb into the 
stacking gel that allowed for the formation of sample wells. Then the gel was allowed to 
set for 5-10 minutes. Once the gel was completely polymerised, the comb was carefully 
removed, and the gel cassette was placed in the electrophoresis tank in a vertical 
position. In the meantime, an appropriate amount of protein sample was defrosted on 
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ice, boiled at 100°C for 5 minutes, then vortexed and centrifuged at 16,000 x g for 4 
minutes at 4°C. Then, the protein lysate was loaded on to the gel, the tank filled with 
running buffer and protein was separated in the gel when current at 30mA/gel was 
applied for approximately 60 minutes. 
The next step was to transfer separated proteins from the lysate on to 
Immobilon
TM
 Transfer Membrane (Millipore, Fisher Scientific UK Ltd, Loughborough, UK), a 
polyvinyldifluoride polymer (PVDF) membrane. Blotting cassettes were assembled 
together and consisted of -ve electrode-fibre pad-whatman paper-gel-PVDF membrane-
whatman paper-fibre pad-+ve electrode, all  pre-soaked in transfer buffer. The cassette was 
then placed in a gel tank containing transfer buffer and an ice block, and transfer was 
facilitated by application of an electric current of 400mA for 60 minutes. The sandwich was 
disassembled once the transfer was completed, and, at this point, the membrane was 
stained with Ponceau S solution (0.1% (w/v) in 5% acetic acid – Sigma-Aldrich) in order to 
visualize the pattern of protein distribution and ensure equal protein loading and that transfer 
was even. 
The membrane was then blocked with in a solution of 5% non-fat dry milk (Marvel) 
dissolved in wash buffer for an hour at RT on an orbital shaker. After blocking, the 
membrane was incubated with primary antibody (at a dilution of 1:1000) prepared in 5% milk 
solution for an hour at RT or overnight at 4°C on an orbital shaker. This was followed by 
washing the membrane with TBS-T (Tris-Buffered Saline and Tween 20) buffer using a 
protocol of 2 x 30 sec, 2 x 5 min and 1 x 15 min washes. Then, the membrane was probed 
with horse radish peroxidase (HRP)-conjugated secondary antibody (1/5000) dissolved in 
milk solution for 1 hour at R/T with shaking. This was followed by a wash cycle similar to that 
performed after primary antibody incubation. Finally, the membrane was developed with 
ECL-advance (Electrochemiluminescence) Western Blotting Detection reagents. 
Chemiluminescence was read using a Fujifilm LAS-1000 Image Analyser. Equal protein 
loading was assessed by probing the membrane with anti β-Actin antibodies used at 
1/10000 dilution (see Sections 3.4.2 and 5.2.1). The list of all the antibodies used in this 




Table 2-13. Recipes for gel/buffers used for Western Blotting. 
 
2.2.6 Immunohistochemistry (IHC) 
 
Immunohistochemistry (IHC) was used to detect the transgene in splenic tissue of 
Eµ-PKCβII tg mice. Formalin fixed and paraffin embedded splenic tissues were 
sectioned to a thickness of 4 µm using a microtome, and applied to a glass microscope 
slide. To remove the paraffin, rehydrate the tissue slice and retrieve the epitope a PT 
Link device (DAKO) was used. The procedures used followed the manufacturer's 
instructions. Thus, a rack of slides containing the tissue slices were placed in a 65°C 
pre-heated PT Link tank within the DAKO target retrieval solution (TRS). A preparation 
programme that takes approximately 1 hour was initiated and here the temperature 
increased up to 96°C and then decreased to 65°C. Following this preparation step, 
samples were placed into room temperature TBS wash buffer for 5 minutes to cool 
down. To stain the sections, the DAKO Auto-stainer was used which is an automated 
slide processing system designed to perform IHC staining automatically. To stain the 
section a EnVision™ FLEX/HRP (DAKO, K8012) kit was used which consisted of 
Peroxidase-Blocking Reagent(DM821), secondary rabbit antibodies (also called rabbit 
LINKER, K8019), EnVision™ FLEX DAB+ Chromogen (which contains, a concentrated 
diaminobenzidine (DAB) solution(DM827) and EnVision™ FLEX Substrate Buffer 
Gel/buffer used for 
Western Blotting
Component\
SDS-PAGE running buffer Tris 25mM, Glycine 192mM, SDS 0.1%(w/v)
Resolving gel buffer (4x): Tris (pH 8.8) 1.5M, SDS 0.4%(w/v) [Purchased from National diagnostics, Hessle
Hull, England]
Resolving gel: Acrylamide Varied (usually 10%), 4x Running gel buffer 25% , TEMED 0.01% 
Ammonium persulphate 0.04%(w/v), Made up to 100% with ddH2O
Stacking gel buffer Tris (pH 6.8) 0.5M, SDS 0.4%(w/v) [Purchased from National diagnostics, Hessle
Hull, England
Stacking gel (5%) Acrylamide 5%, Stacking gel buffer 25%, TEMED 0.1%,Ammonium persulphate
0.08%(w/v), Made up to 100% with ddH2O.
Transfer buffer (10X) Tris (pH 6.8) 0.25M , Glycine 1.92M [Purchased from National diagnostics, 
Hessle Hull, England] 
TBS-T Tris(pH 7.4) 10mM, Sodium chloride 150mM, Tween-20 0.1% 
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(DM823)) and Wash Buffer (20x) (DM831). Thus, the rack containing my glass slides 
were placed in the autostainer and an appropriate programme was applied.  
Once staining of the section was completed, the sections were counter stained 
with Haematoxylin solution and then rinsed with tap water until it ran clear. This was 
followed by dipping the sections in acid alcohol, and rinsing again with tap water. Finally, 
the sections were dipped in ammonia water for 30 seconds, rinsed with tap water and 
returned to a bath of dH2O. The slides were then dehydrated through five changes of 
Industrial Methylated Spirit (IMS), cleared in two changes of Xylene before mounting the 
slides in DPX (Sigma-Aldrich). IHC results are discussed in section 5.3. 
 
2.2.7 Haematoxylin and eosin (H&E) Staining 
 
Haematoxylin and Eosin (H&E) staining was used to morphologically assess the 
spleen of Eµ-PKCβII tg mice compared with wild type mice. In H&E staining 
Haematoxylin colours basophilic structures such as the cell nucleus blue-purple. On the 
other hand, Eosin colours eosinophilic structures such as cytoplasm of the spleen bright 
pink. This allows high-resolution study of the morphology of tissues. Thus, the slides 
containing tissue slices were placed in a rack and placed in a bath containing xylene for 
5 minutes to eliminate paraffin. Slides were agitating for 30 seconds and transferred into 
2 subsequent xylene chambers in order to fully remove all trace of paraffin. Then the 
sections were subjected 3 X 30 second washes using different 100% IMS chambers. 
This was followed by another wash in a 70% IMS chamber, and finally a rinse with tap 
water. The sections were placed in Haematoxylin for 5 minutes, and then rinsed with 
running tap water until the water ran clear. The slide was agitated for 30 seconds in acid 
water, rinsed again with running tap water, and then agitated in 100% IMS for 30 
seconds before placing in eosin for 2 minutes. To remove excess eosin the sections 
were washed in the following manner; 2x30s washes with 100% IMS, then 2x30s 





2.2.8 Flow cytometry analysis 
 
The multi-colour flow cytometric analysis used to characterize B cell subsets in 
Eµ-PKCβII transgenic mice is comprehensively discussed in Section 5.4. The technical 
procedure used for staining and preparation for flow cytometry is as follows. In general, 
approximately 2-5 x 106 cells were suspended in 200µl of modified PBS (supplemented 
with 1% BSA and 0.1% sodium azide, pH7.2), then an appropriate concentration of 
antibody (see Appendix C) was added and the cell suspension was incubated in a FACS 
tube on ice for 20-30 minutes in the dark. Following this the cell suspension was topped-
up to 500 µl with modified PBS, and then centrifuged at 2000 rpm at 4°C for 2 minutes. 
The supernatant was decanted and the pellet was re-suspended in 100-200µl of fresh 
modified PBS and 100μl FACS flow (BD biosciences). Now the cell suspension was ready 
to run in the flow cytometer. The list of all the antibodies used for flow cytometry is 




2.3.1 Basic Local Alignment Search Tool (BLAST) 
The Basic Local Alignment Search Tool or BLAST is an algorithm that compares 
primary biological sequences and aligns them with known nucleotide or protein 
sequences. In this project, BLAST searches were used for two main purposes: 1. To 
align data from DNA sequencing against a database, mainly the mouse genome. 2. To 
compare the query sequence with my own input material such as vector sequences. 
Website: http://blast.ncbi.nlm.nih.gov/  
 
2.3.2 Translation tool (ExPASy) 
To translate nucleotide sequences into their associated amino acid code, I used 
the ExPASy Translation tool. This tool was specifically used to check if my 
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recombinant/amplified DNA sequences were in frame, and also to check if any un-




2.3.3 Reverse complement 
To design reverse primers I used the following tool that calculated the reverse 
complementary sequence of DNA. This tool was practically useful prior to ordering 
reverse primers. 
Website: http://www.bioinformatics.org/sms/rev_comp.html  
 
2.3.4 Restriction site mapping (NEBcutter) 
To choose an appropriate restriction enzyme for DNA cloning the NEBcutter tool 
was used. This online tool maps the restriction sites within a query DNA sequence, and 
is useful for applications such as cloning, and for finding an appropriate restriction 
enzyme to fragment genomic DNA for Southern blotting applications. 
Website: http://rna.lundberg.gu.se/cutter2/ 
 
2.3.5 Chromatogram analysis (Sequence Scanner) 
To open the chromatogram files containing sequencing data for the samples sent 
to GATC Biotech, Sequence Scanner Software version 1.0 (Applied Bio systems) was 
used. The sequencing data files are represented with the suffix of .ab1. Inspection of the 
sequence was performed in two ways; the sequence data from my samples were 
compared to known standard sequences using the BLAST tool. If a mutation in this 
query sequence was found, I inspected the relevant chromatogram to confirm that this 
mutation was genuine rather than being a base miscall. If this mutation was real, then 
the query sequence was translated to its polypeptide sequence using the ExPASy 




2.3.6 Statistical analysis  
The statistical significance was calculated using either a Student’s t-test or a 
Mann-Whitney U-test as indicated in the Figure legends. This analysis was performed 
using SPSS™ ver20 software. 
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3 Chapter III: Construction of a plasmid highly 




3.1 Cloning Strategy 
 
To generate PKCII transgenic mice, the first step was to design a plasmid that 
highly expresses PKCII specifically in mouse B cells. This construct was injected into 
pro-nuclei of fertilized ova isolated from pregnant mice. The injected ova were then 
transferred to recipient mice in order to generate potential founder mice. I used the 
pBSVE6BK plasmid designed by Frederick Alt (Shaw, et al 1999) which exploits the VH 
promoter and the IgH-enhancer to specifically direct expression of target genes in B 
cells. This vector is commonly referred to as the pEµ vector and is based on a 
pBluescript® backbone that also includes a poly (A) site of the human β-globin gene 
(Appendix B). 
 Before sub-cloning the PKCII gene into pEµ, I tagged the gene with Human 
influenza hemagglutinin (HA). The HA sequence codes for a short polypeptide sequence 
that has no bioactivity and allows for detection and isolation of the gene of interest (in 
this case human PKCβII) within transgenic cells that express this protein. The HA 
sequence was introduced at the 3 end of the sequence coding for human PKCβII, and 
was planned to yield a protein that would express the tag as an addition to the C-
terminus and therefore it would not potentially interfere with pseudo-substrate binding to 
the active pocket when the PKC enzyme was at rest.  
I also added a gene coding for the fluorescent protein mCherry to this construct. 
This was done to create a visualization tool to identify transgenic B cells in live animals 
by imaging. For this purpose, mCherry was a good candidate because its excitation and 
emission profiles allow for deep tissue visualisation that allowed internal structures such 
as the spleen and lymph nodes to be observed without having to sacrifice the animal. In 
order to ensure equal expression of PKCβII and mCherry from my pEµ plasmid, I 
inserted an IRES (internal ribosome entry site) sequence between the PKCII and 
mCherry genes. An IRES sequence allows for multiple gene expression from a single 
promoter and was therefore a useful tool for ensuring expression of multiple transgenes 
from a single promoter(Pelletier and Sonenberg 1988). 
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The cloning of the ultimate construct for the generation of Eµ-PKCII transgenic 
mice consists of three steps (Figure3.1): 
 
I. Sub-cloning PKCII into Eµ vector 
II. Sub-cloning of IRES sequence into pm-Cherry vector 









Figure 3-1. Cloning strategy for generation of plasmid construct for generation of Eµ-
PKCII tg mice. (A) Sub-cloning strategy to introduce PKCII into the Eµ vector (B) Sub-cloning 
strategy to introduce IRES sequence into pm-Cherry vector (C) Sub-cloning strategy to introduce 
IRES/mCherry into the Eµ:PKCII HA plasmid. 
 
 
Thus, the final plasmid construct for generation of PKCβII obtains five important 
components: the Eµ promoter, PKCIIHA, IRES, pm-Cherry and β-globin (haemoglobin 












The starting material for this study was human PKCβII tagged with EGFP 
(Enhanced Green Fluorescent Protein) that was encoded within the Phagemid vector 
pBK-CMV (See Appendix B). This plasmid was sent for sequencing to ensure there was 
no significant change within the PKCβII coding sequence. BLAST software (see Section 
2.3.1) was used for pair sequencing with the standard human PKCβII sequence 
(PRKCB1). Figure 3-2 shows this comparison, and illustrates two conservative changes 
within the nucleotide sequence; T1191C and G1726A (Table 3-1). The nucleotide 
sequence was then translated into the peptide sequence (see Section 2.3.2) and again 
submitted for comparison with the standard human PKCβII peptide sequence using 
BLAST software. Figure 3-3 shows that the two nucleotide changes detected do not 
change the amino acid sequence encoded by the starting plasmid. Thus, although there 
were some mutations in rhw coding sequence of wild type PKCβII, they were all silent 




Figure 3-2. Alignments of nucleic acid sequence of PKCβII within the Phagemid vector 
pBK-CMV (highlighted green) with standard nucleic acid sequence of PKCβII (highlighted 
with blue) using the BLAST software (Zhang, et al 2000). The starting material for DNA 
cloning in this study was human PKCβII-EGFP encoded within the Phagemid vector pBK-CMV. 
The probe sequence is highlighted green and compared with the standard nucleotide sequence 
for human PKCII (accession number), highlighted blue. BLAST software was used for 
comparison analysis. The yellow highlights indicate where a mutation was detected in the probe 






Mutation position 1191 1726 
Nucleotide t/C g/A 




Figure 3-3.Comparison of amino acid sequence of PKCβII within the Phagemid vector 
pBK-CMV with the standard amino acid sequence for PKCβII using BLAST software 
(Altschul, et al 1997). The nucleotide sequence of PKCβII within the phagmid was translated 
into the peptide sequence (highlighted green), and then compared with the human standard 
amino acid sequence for PKCβII using BLAST software (highlighted with blue).  
 
3.2.2 PCR optimisation of PKCβII 
 
In the first step of cloning, the coding sequence for PKCβII was amplified by PCR. 
Thus, PCR optimisation was performed to increase specificity and reduce the 
introduction of unwanted random mutations. Optimisation involved establishing the 
optimal annealing temperature using a temperature gradient, determining the optimal 
amount of DNA template to use and ascertaining the optimal number of cycles to find 
the minimum required for PKCβII amplification. 
Forward and Reverse primers were designed to introduce restriction sites for Cla-
I and Sal-I restriction enzymes to the respective 5 and 3 ends of the PKCβII sequence. 
The reasons for choosing Cla-I and Sal-I were that neither of them cut within the PKCβII 
coding sequence, and they were within the multiple cloning region of the final Eµ vector. 
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In designing the primer for the 3 end, an additional coding sequence for HA tag was 
also introduced before the Sal-l restriction site. The detail of these primers is listed in 
Appendix A. These primers were then used in the optimisation experiments described 
below. 
Figure 3-4 shows the effect of an annealing temperature gradient from 52 to 62ºC 
on the amplification of the PKCβII coding sequence. There was no significant difference 
in relation to the efficiency of the reaction at the various temperatures of the gradient. 
Therefore, a temperature of 60.3°C was chosen because this temperature was high 




Figure 3-4. Effect of annealing temperature on PCR amplification of the PKCβII coding 
sequence.  Different annealing temperatures (indicated) were used to amplify annealing the 
PKCβII coding sequence from the vector pBK-CMV. Illustrated is a 0.7% agarose gel separation 
of the PCR products that were generated. The PKCII band was approximately 2kB in size. “W” 
indicates a PCR reaction performed on water as a negative control. 
 
Figure 3-5 shows the effect of different amounts of DNA template and numbers of 
PCR cycles on the amplification of the PKCβII coding sequence. 0.1,1 and 10ng of DNA 
template and 5, 15, 20 and 30 PCR cycles were chosen for this reaction. Water was 
chosen as a control reaction, and showed no amplification, even when 30 PCR cycles 
was used. I found that optimal amplification was achieved using 10ng of template and 
15 PCR cycles.  
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Thus, to amplify the PKCβII coding sequence from the template DNA, I used the 
following conditions: 10ng of template, an annealing temperature of 60.3°C, elongation 
time was 1 min at 72C followed by denaturation at 95C for 30s. This cycle was 
repeated 15 times and at the final cycle an elongation time of 5min was imposed to 
finish off all reactions. At the termination of the PCR reaction, the temperature was 
reduced to 4C. 
 
Figure 3-5. PCR optimisation of the PKCβII coding sequence for DNA template and cycle 
number.  The PCR optimisation of PKCβII sequence was performed for DNA template and cycle 
number. For this purpose, 0.1,1 and 10ng of DNA template and 5, 15, 20 and 30 PCR cycles 
were chosen. Illustrated is a 0.7% agarose gel separation of the PCR products that were 
generated. The PKCII band was approximately 2kB in size. 
 
3.2.3 Insertion of PKCβII coding sequence into PCR2.1 
 
3.2.3.1 Strategy 
The initial target plasmid for the amplified PKCβII coding sequence was PCR2.1, 
a TA vector that allows direct insertion of a PCR amplicon. TA cloning is a “sub-cloning 
technique” that does not use restriction enzymes. The technique is based on the 
hybridization/ligation of complementary base pairs of adenine (A) and thymine (T) on 
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different DNA fragments, which is mediated by ligase. So, firstly, PKCβII was amplified 
by Taq DNA polymerase, an enzyme that preferentially adds an adenine to the 3' end of 
the PKCβII coding sequence. This was then added to linearized TA vector that has 
complementary 3' thymidine overhangs, and ligation proceeds when DNA ligase is 
added. The use of TA cloning helps to boost ligation efficacy (Figure3-6).  
 
Figure 3-6. Sub-cloning of PKCβII into PCR2.1 by TA cloning. In the TA cloning,  PKCβII 
coding sequence was amplified by Taq DNA polymerase which preferentially adds an adenine to 
the 3' end of the PKCβII coding sequence. Then, amplified PKCβII was ligated with linearized 
TA vector that has complementary 3' thymine overhangs and this was mediated by ligase. 
 
This completes the optimisation protocol to ensure efficient amplification of the 
PKCβII coding sequence for subsequent cloning steps. Thus, after insertion of the 
PKCβII coding sequence within PCR2.1, and appropriate sequencing to ensure integrity, 
the pPKCβII-PCR2.1 is then digested with Sal-I and Cla-I to release the coding 
sequence which would be then inserted into prepared pEµ plasmid (pre-digested with 
Sal-I and Cla-I) by ligation. Figure 3-7 shows a schematic of how this was done. In this 




Figure 3-7. Sub-cloning of PKCβIIHA into pBSVR6BK (Eμ) vector. The PKCβII coding 
sequence was firstly inserted into a PCR2.1 vector by TA cloning.  PPKCβIIHA-PCR2.1 is then 
digested with Sal-I and Cla-I to release the PKCβII coding sequence which is then inserted into 
a prepared Sal-I and Cla-I pre-digested pEµ plasmid by ligation. 
 
The PKCβIIHA PCR product was amplified from pEGFP-PKCβII using the 
plasmids, primers and procedure described above. I used a 0.7% high quality agarose 
gel and isolated the 2kb PKCβIIHA band (product of the correct size) by scalpel. I then 
extracted the DNA from this gel slice using a GENE CLEAN kit (see Section 2.1.2.5). 
After gel extraction, the DNA coding sequence for PKCβII was again run in a gel to 
estimate its concentration. Figure 3-8 shows that the PKCβII PCR product ran as a 
single band with an approximate 2kb size. Concentration of this product was estimated 
by comparing the density of the 1636b band in the DNA ladder with that of the DNA for 
PKCβII. The 1636b band is associated with 100ng of DNA. Thus, I was able to estimate 




Figure 3-8. Amplified PKCβIIHA for use in subsequent cloning steps is of the correct size 
and runs as a single band. Agarose gel separation of the PKCβIIHA PCR product extracted 
from the agarose gel used to purify the PCR products ran as a single band of approximately 2kb 
size (product of the correct size). Amount of PKCβIIHA PCR product was estimated by 
comparing the density of the PKCIIHA band with the MW standard band running at 1636b. 
 
The next step involved ligating the PKCβIIHA PCR product into PCR2.1. This was 
done by taking 10ng of the PKCβIIHA PCR product and adding this to 25ng of PCR2.1 
vector. T4 DNA ligase was then added and the reaction was incubated at 14°C for 8 hrs. 
(See Section2.1.4.4).The product of the ligation reaction was then transformed into 
TOP10 competent cells by heat-shock (see Section 2.1.1.2). Bacterial cells containing 
the PKCβIIHA/PCR2.1 plasmid were selected by culturing the cells on Lysogeny broth 
(LB) agar plates containing kanamycin. Transformation efficiency was estimated by 
using pUC vector which was a standard plasmid for determination of transformation 
efficiency. The transformation efficiency for the ligation of PKCβIIHA/PCR2.1 into 
TOP10 competent cells was 108 colony forming units (cfu)/µg of DNA used for ligation. 
Ten colonies from the culture plates were randomly picked in order to characterise 
whether the created plasmids were correct. These colonies were grown in liquid LB 
broth under kanamycin selection pressure in overnight cultures that were vigorously 
mixed and maintained at a temperature of 37°C. 
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The formation of a clone did not necessary mean that ligation of PKCβIIHA into 
the PCR2.1 vector had been successful. In order to ensure correct insertion, I exploited 
two EcoRI restriction sites within the MCS of PCR2.1. Within my cloning strategy, these 
sites come just before and just after the site of insertion for PKCβII, and digestion of 
PCR2.1 containing PKCβII with EcoRI would result in the generation of two bands; 
PKCβIIHA (2kb) and PCR2.1 vector backbone (4kb). There was also an additional 
EcoRI site within the PKCβIIHA coding sequence, at position 1963. This additional site 
did not have influence on my screening protocol because the end digestion product was 
slightly less than the expected 2kb product. Figure 3-9 shows the results of this 
experiment, clone numbers 1,2,3,5,6,7,8 and 10 had 2kb and 4kb bands, indicating the 
presence of the PKCβIIHA insert and vector backbone, respectively. In contrast, clones 
number 4 and 9 had only a single 4kb band, indicating presence of only the PCR 2.1 
backbone. Thus, clone numbers 1 and 2 (designated pPKCβIIHA-wt-1/PCR2.1 and 
pPKCβIIHA-wt-2/PCR2.1) were chosen for further cloning purposes. 
 
 
Figure 3-9. Screening the PKCβII/PCR2.1 colonies using EcoRI restriction enzyme. 
Agarose gel separation of EcoRI digests PKCIIHA/PCR2.1 plasmids isolated from 10 colonies 
of the ligation reaction. The generation of two bands; PKCβII (2kb) and PCR2.1 vector backbone 
(4kb) indicated success of the ligation. 
 
In the next step, the PKCβIIHA coding sequence was sub-cloned into the Eµ 
vector. This was done by digesting pPKCβIIHA-wt-1/PCR2.1 with Cla-I and Sal-I to 
release PKCβIIHA-wt-1. The Eµ vector was also digested with Cla-I and Sal-I to prepare 
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it to receive the PKCβIIHA coding sequence from pPKCβIIHA-wt-1/PCR2.1. Figure 3-10 
shows that the digestion of pPKCβIHAI-wt-1/PCR2.1 by Cla-1 and Sal-I was not initially 
successful and PKCβIIHA was not separated from the PCR2.1 backbone vector. 
Digestion of pPKCβIIHA-wt-1/PCR2.1 with Cla-I alone revealed that the plasmid was not 
digested with this restriction enzyme. A possible explanation for the failure of Cla-I to 
digest pPKCβIIHA-wt-1/PCR2.1 was dam-methylation catalysed by the methylase 
enzyme encoded by the dam gene and is known to inhibit Cla-I DNA digestion (Figure 3-
11) (NEB). Methylation of this site may have occurred as a consequence of the cloning 
strategy used when PKCβIIHA was amplified with the forward PCR primer. 
 
 
Figure 3-10. Cla-I does not digest PKCβIIHA-wt-1/PCR2.1. Agarose gel analysis of 
PKCβIIHA-wt-1/PCR2.1 digested with Cla-I / Sal-I or Cla-I alone. Buffer 3 and 4 refer to the 








Figure 3-11. Dam-methylation site within Cla-I restriction site potentially affecting 
digestion of the PCR2.1/PKCβII-wt-1. Dam-methylation is catalysed by a methylase enzyme 
encoded by the dam gene. This methylase transfers a methyl group from S-adenosylmethionine 
to the adenine residue within a GATC sequence which is a part of the restriction site for Cla-1. 
Creation of this site may have occurred as a consequence of the cloning strategy used, and 
created a situation where the plasmid could not be digested with Cla-I.  
 
3.2.4 Using dam-dcm- competent cells for transformation pPKCβII-
wt/PCR2.1 
To prevent the occurrence of methylation, pPKCβIIHA-wt-1/PCR2.1 was 
transformed into dam-dcm- E. coli (C2925, NEB) which are competent cells that are 
used to grow plasmids which are free of dam/dcm methylation. Figure 3-12A shows that 
pPKCβIIHA-wt-1/PCR2.1 could be successfully digested by Cla-I and Sal-I following 
isolation of this plasmid from transformed dam-/dcm- competent bacteria. This figure was 
photographed without the PKCβIIHA and Eµ plasmid bands that resulted from digestion 
in order to reduce possible UV light-induced mutation caused by the system we used for 
visualisation. Figure 3-12B shows a sampling of the purified band products (using a 
GENECLEAN kit) isolated from the bands in Figure 3-12A The PKCβIIHA coding 
sequence is represented by the 2kb band whereas the prepared pEµ (plasmid) is 




Figure 3-12. Cla-I / Sal-I completely digest PKCβIIHA-wt-1/PCR2.1 extracted from dam-
/dcm- competent cells. Agarose gel analysis of PKCβIIHA-wt-1/PCR2.1 plasmid digested with 
Cla-I / Sal-I. The PKCβII-wt-1/PCR2.1 plasmid was extracted from dam-/dcm- competent 
cells. (A) Bands corresponding to PKCβIIHA and pEµ were excised by scalpel and explains the 
missing band images (B) PKCβIIHA and pEµ  bands were of the correct size following 
GENECLEAN purification from the gel slices taken in part A. 
 
The digested Eµ plasmid was prepared for ligation by treating with Antarctic 
phosphatase to remove 5 phosphate residues (see Section 2.1.4.2), and then it was 
ligated with the PKCβII coding sequence. The product of this ligation was transformed 
into dam-/dcm- competent E coli, and then grown in LB-Agar plates overnight. 30 
colonies were taken for screening using Cla-I/Sal-I to digest the plasmid that was 
purified from cultures of these isolates. Figure 3-13 partially illustrates this procedure, 
and shows that the PKCβIIHA coding sequence was successfully ligated into the pEµ 
plasmid in clones 27, 28 and 29. Cla-I/Sal-I digests of the isolated plasmids from these 
clones showed three bands; partially digested pEµ-PKCβIIHA and fully digested pEµ 
vector and PKCβII coding sequence. These clones were taken and stored for later use. 
Clone number 29 (PKCβIIHA-wt-1/Eµ-29) was selected for sequencing to ensure 
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integrity of the cloning procedure. The results of this sequencing showed that the 
PKCβIIHA-wt coding sequence was successfully cloned into the pEµ vector in the 
correct orientation and had the same sequence as the PKCβII-HA starting material. 
 
 
Figure 3-13. Integration of PKCβIIHA into pE. Agarose gel analysis of the PKCIIHA-pE 
ligation product digested with Cla-I and Sal-I. The PKCIIHA-pE ligation product was grown in 
dam-/dcm- bacteria to ensure successful digestion with Cla-I. Clones numbered 27, 28 and 29 
showed the correct digestion products for PKCIIHA (2kB) and pE (6kB).  
 
3.3 Sub-cloning of an IRES sequence into pmCherry 
 
The aim of this step was to sub-clone an Intra Ribosomal Entry Site (IRES) 
coding sequence that would allow dual expression of PKCβII and mCherry from the Eµ 
promoter. Thus, the goal of these preparative procedures was to sub-clone the IRES 
sequence into the vicinity of the coding sequence for mCherry (Figure 3-14), with the 
eventual goal of placing the IRES/mCherry construct into the PKCβII/Eµ vector. 
The steps involved are shown in Figure 3-14 and consisted of PCR amplification 
of the IRES sequence, sub-cloning into the PCR2.1 intermediate vector and final 
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insertion of the IRES sequence into a plasmid containing mCherry (see Appendix B). 
The PCR amplification step also involved the addition of Sal-I and BamHI restriction 
sites into the IRES coding sequence to ease the process of sub-cloning. Thus, the 
forward PCR primer also contained an additional Sal-I restriction site added to its 5 
sequence, while the reverse PCR primer contained a BamHI restriction site added to its 
3 sequence (detail of the primers is in Appendix A). Sal-I and Bam-HI were chosen 
because these restriction enzymes do not cut the IRES coding sequence, and also allow 
for efficient sub-cloning into the final pEµ-PKCβIIwt-HA plasmid construct. 
 
 
Figure 3-14. Schematic showing the sub-cloning of the IRES sequence into the m-Cherry 
vector. The IRES coding sequence was first inserted into the PCR2.1 vector. The IRES-PCR2.1 
was digested with Sal-I and BamHI to release the IRES coding sequence. The IRES sequence 
was then inserted into Sal-I and BamHI pre-digested pmCherry plasmid by ligation. 
 
3.3.1 PCR optimisation of IRES 
 
In the first step of cloning, the coding sequence for IRES was amplified by PCR. 
Figure 3-15 shows that optimal amplification of the IRES coding sequence was achieved 
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using 30ng of template and 20 PCR cycles using the following conditions: an annealing 
temperature of 62°C, an elongation time of 1 min at 72C being followed by a 
denaturation step at 95C for 30s. The last PCR cycle included a final elongation time of 
5 min to finish off all reactions. At the termination of the PCR reaction, the temperature 




Figure 3-15. PCR optimization for DNA template and cycle number for amplification of the 
IRES coding sequence. PCR optimisation of the IRES sequence was performed for DNA 
template and cycle number. For this purpose 10, 30 and 100ng of DNA template and 10, 20 and 
30 PCR cycles were chosen. Illustrated is a 1.5% agarose gel separation of the PCR products 
that were generated. The IRES band is 590b in size. 
  
3.3.2 Sub cloning of IRES into pCR2.1 and pmCherry 
 
The amplified IRES coding sequence was ligated into a linearized TA vector 
using the same conditions that were used for the cloning of PKCβII (see Section 3.2.3). 
The IRES/PCR2.1 ligation reaction was transformed into TOP10 competent cells, the 
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cells cultured on Kanamycin selection plates overnight, and ten colonies were randomly 
chosen for plasmid purification. DNA extracted from these clones was then digested by 
EcoRI, and then separated by electrophoresis using a 1.5% agarose gel to see which 
clones contained the IRES sequence. Figure 3-16 shows that all the clones contained 
the IRES coding sequence. Clones #4, 7 and 9 were selected for glycerol storage as the 
digestion patterns were the cleanest. Clone #9 was selected for future cloning steps 
(designated IRES-9) and was sent for sequencing to ensure sequence integrity. Results 
from this sequencing showed that my cloning operations did not introduce any mutations 
into the IRES coding sequence (data not shown). 
 
 
Figure 3-16. Screening the IRES/pCR2 colonies using EcoRI restriction enzyme. Agarose 
gel separation of EcoRI digests of IRES/PCR2.1 plasmids isolated from 10 colonies of the 
ligation reaction. The generation of two bands; IRES (590b) and PCR2.1 vector backbone (4kb) 
indicated success of the ligation.    
 
The IRES coding sequence was then sub-cloned from pCR2.1 into the pmCherry 
vector by first releasing the IRES sequence from PCR2.1 and preparing the pmCherry 
plasmid by digestion of both with Bam HI /Sal-I. Figure 3-17 show the results of these 
digestions, the IRES coding sequence ran as a 590 bp band and pmCherry ran as a 






IRES/PCR2.1 Ligation reaction cut y EcoR-I
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3344 bp band in an agarose gel. The IRES coding sequence was then ligated into the 




Figure 3-17. Digestion of IRES and pm-Cherry with Bam-HI and SalI before ligation. To 
ligate IRES into pmCherry vector, the IRES was released from PCR2.1 vector backbone by 
BamHI/SalI digestion. The pmCherry was prepared by digestion of BamHI/SalI restriction 
enzymes. Bands corresponding to IRES and mCherry were excised by scalpel and purified from 
agarose gel. This figure is the agarose gel analysis of 2µl digested IRES and mCherry that 
extracted from the gel, and illustrates that IRES (590bp) and mCherry (3344bp) were of the 
correct size following GENECLEAN purification from the gel slices. 
 
The ligation reaction was allowed to proceed overnight and then it was 
transformed into TOP10 competent cells which were grown on ampicillin selection 
plates. The reason ampicillin was used for selection was the mCherry plasmid contains 
the gene resistant to ampicillin. The transformation efficacy was 5 x 108 cfu/µg and 13 
colonies were selected for analysis. DNA extracted from these clones were then 
digested by BamH-I and Sal-I to see which clones contained the IRES/mCherry 
sequence, and I found that clones #2, 6 and 7 contained this sequence (Data not 
shown). The DNA from these colonies was further test digested to ensure the presence 
of the insert (Figure 3-18). Single digestion with either BamHI or Sal-I resulted in a 
single band with an expected size of approximately 4 kb. Digestion with the combination 
of BamH1 and Sal-I resulted in the generation of a 590bp band associated with the 
IRES coding sequence and a 3344bp band associated with the mCherry plasmid. 








plasmid, designated by the appearance of a 1.5 kb band. Taken together, these 
observations demonstrate that ligation of IRES into the mCherry vector was successful. 
Clone number 6 (IRES9/mCherry-6) was selected for the ligation into PKCβIIwtHA-1/Eµ-
29 in the next step of cloning. 
 
 
Figure 3-18. Integration of IRES into pmCherry. Agarose gel analysis of clones 4, 6 and 7 
containing the IRES-pmCherry ligation product. DNA was digested with SalI, BamHI, BamHI/Sal-
I and Sal-I/NotI restriction enzymes to ensure IRES was successfully integrated within the 
pmCherry vector.   
 
3.4 Sub-cloning of IRES/mCherry into Eµ: PKCIIHA 
 
The final stage of cloning involved taking the IRES9-mCherry coding sequence 
and placing it in a 5’→3’ unilateral fashion between the PKCβIIHA and β-poly-globin 
coding sequences within the Eµ vector (Figure 3-19). The methodology involved an 
initial digestion of pIRES9-mCherry with Not-I followed by blunting of the 3’-end with 
Klenow, which is a 3’-5’ exonuclease (see Section 2.1.4.3). The next step involved 
preparing the pEµ-PKCβIIwt-HA vector to receive the IRES9-mCherry coding sequence. 
This was done by first digesting with Apa-I, which cut between the β-poly-globin and 
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PKCβIIHA coding sequences. The digested plasmid was then blunted by Klenow, and 
this was followed by digestion with Sal-I to create the acceptor sites for the IRES9-
mCherry coding sequence. Final ligation and transformation created the pEµ-PKCβIIwt-




Figure 3-19. Schematic showing sub-cloning of IRES-9/mCherry-6 into PKCβIIHA-wt1/Eµ-
29. The IRES9-mCherry coding sequence was first digested with NotI followed by blunting of the 
3’-end with Klenow. On the other hand, the pEµ-PKCβII-HA-wt1 vector was digested with Apa-I, 
and also blunted by Klenow. Both IRES9-mCherry and pEµ-PKCβII-HA-wt1 were then digested 
with SalI to to release IRES-mCherry from the former plasmid, and create the complementary 
sites for receiving IRES9-mCherry in the latter plasmid. Finally, the IRES-mCherry coding 





Figure 3-20. Preparation of PKCβIIwtHA-1/Eµ-29 and IRES9/mCherry-6 for the ligation. 
This figure is an agarose gel analysis of the preparation of PKCβIIwtHA-1/Eµ-29 and 
IRES9/mCherry-6 as described in Figure 3-19. This illustrates that PKCβIIwtHA-1/Eµ-29 
(~7.6kb) and the IRES-mCherry coding sequence (1.2kb) were of the correct size following 
GENECLEAN purification from the gel slices. 
 
Figure 3-20 shows the digestion products of the reaction described above after 
GEANCLEAN. The IRES-mCherry coding sequence ran as a 1.2kb band and the pEµ-
PKCβIIHA backbone ran as a ~7.6kb band. Thus, after extraction from the gel the IRES-
mCherry coding sequence was ligated into PKCβIIwtHA-1/Eµ-29 in the presence of DNA 
Ligase (see Section 2.1.4.4). The transformation efficiency was 1x107 cfu/µg. Twenty 
clones were selected for screening, plasmid DNA was isolated and subjected to test 
digestions with either EcoRV (single nuclease digestion) or with Not-I/Sal-I (double 
nuclease digestion). Figure 3-21 shows a cartoon representation of the correct digestion 
pattern using this test digest approach. With EcoRV, correct insertion of the 
IRES/mCherry coding sequence would produce bands of 1.8kb and 7.2 kb. With the 
Not-I/Sal-I, double digestions correct insertion of the IRES/mCherry coding sequence 
would produce bands of 1.5kb and 6kb. The apparent 1.5kb loss in plasmid size using 
this approach was because Not-I cuts the pEµ-PKCβIIHA plasmid within the PKCβIIHA 
coding sequence as well as just before the Eµpromoter to yield a 1.5kb band.  
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Figure 3-22 shows the results of these test digests on the plasmid DNA purified 
from clones 11 – 19. Clones #13, #14, #17, #18 and #19 showed correct insertion of the 
IRES-mCherry coding sequence into the pEµ-PKCβIIHA plasmid because of the 
appearance of bands with the correct sizes following digestion with EcoRV, or with Not-
I/Sal-I (Figure 3-21 C). However, clones #11, #15 and #16 showed that the IRES-
mCherry coding sequence was not inserted into the pEµ-PKCβIIHA plasmid because 
the incorrect size of the plasmid backbone (5.8kb for EcoRV and 4.6kb for NotI/Sal-I). 
Clone number 18 was taken as my desired plasmid, pEµ-PKCβIIHA-IRES-mCherry, and 

























Figure 3-21. Strategies used for designing the test digestions for detecting colonies 
containing pEµ-PKCβIIHA-IRES-mCherry. In order to detect those colonies in which IRES-
mCherry was successfully integrated into the Eµ/PKCβIIHA vector, the DNA is digested with 
either EcoRV or Not-I/SalI. (A) The schematic map of the restriction sites for EcoRV and for Not-
I/SalI in a plasmid in which ligation of IRES-mCherry into the Eµ/PKCβIIHA vector was 
successful. (B) The schematic map of restriction sites for EcoRV or Not-I/SalI in a plasmid that 
only contains Eµ/PKCβIIHA. (C) This table lists the size of bands produced as a result of 






Figure 3-22. Integration of IRES-mCherry into the Eµ/PKCβIIHAwt1-29 vector. Agarose gel 
analysis of ten clones numbered 11 to 20 containing the pEµ-PKCβIIHA-IRES-mCherry ligation 
product. This DNA was digested with either EcoRV or with NotI/SalI.   
 
3.4.1 Sequencing the pEµ-PKCβIIHA-IRES-mCherry plasmid 
 
The pEµ-PKCβIIHA-IRES-mCherry plasmid was sent for sequencing to ensure 
that all the components of the transgene were present:  the Eµ promoter, PKCβIIHA, 
IRES, mCherry and β-globin poly-A coding sequences. The vector backbone for the final 
plasmid was pBluescript in which there are recognition sites for the universal primers T3 
and T7 just before and just after the multiple cloning sites (MSC). I used these primers 
to sequence the Eµ promoter (T3) and the β-globin poly-A (T7). In addition, I used 
PKCP5B and PKCP4 primers (see Appendix A) to respectively sequence the 5’ and 3’ 
ends of PKCβII (Figure 3-23). The sequencing data produced by using the above 
primers was subjected to a BLAST search of both human (for PKCβII) and mouse (for 
the Eµ promoter and β-globin) genomes (see Section 2.3.1).  
Figure 3-24 shows the results of this sequencing and analysis. BLAST analysis of 
the sequences produced by the T3 and T7 primers showed that the Eµ promoter (Figure 
3-24 B, C) and HbA-Sen50 beta globin (HBB) coding sequences (Figure 3-24 D) were 
present and intact within the pEµ-PKCβIIHA-IRES-mCherry plasmid. Sequences 
produced by the PKCP5B primer demonstrated that the PKCβII coding sequence was 
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contiguous with the Eµ promoter region (Figure 3-24 A, B). The sequence produced by 
the PKCP4 primer demonstrated that the PKCβII coding sequence was contiguous with 
the full sequence of IRES and mCherry (Figure 3-24 E, F, G). In conclusion, the 
digestion test and sequencing results demonstrated that the pEµ-PKCβIIHA-IRES-
mCherry plasmid was complete and ready for expression analysis with the final goal of 





Figure 3-23. Primers used for sequencing the pEµ-PKCβIIHA-IRES-mCherry plasmid. The 
pEµ-PKCβIIHA-IRES-mCherry plasmid has five components: Eµ promoter, PKCβIIHA, IRES, 
mCherry and β-globin poly-A coding sequences. The T3 and T7 primers were used to sequence 
the Eµ promoter and the β-globin poly-A respectively. PKCP5B and PKCP4 primers were used 













Figure 3-24. Sequencing the pEµ-PKCβIIHA-IRES-mCherry plasmid. Four primers were 
used to sequence the pEµ-PKCβIIHA-IRES-mCherry plasmid. The sequencing data produced 
by using these primers were subjected to a BLAST search of both human (for PKCβII) and 
mouse (for the Eµ promoter and βglobin) genomes. A) Sequence comparison of the PKCP5B 
sequence product with the human genome. B) Sequence comparison of the PKCP5B sequence 
product with the mouse genome. C) Sequence comparison of the T3 sequence product with the 
mouse genome. D) Sequence comparison of the T7 sequence product with the mouse genome.  
E) Sequence comparison of the PKCP4 sequence product and the IRES coding sequence, F) 
Sequence comparison of the PKCP4 sequence product and the mCherry coding sequence, G) 





3.4.2 Analysis of transgene expression in a mouse B cell line using 
transient transfection 
 
To ensure that the pEµ-PKCβIIwtHA-IRES-mCherry plasmid was functional prior 
to the making of a transgenic mouse, I tested whether expression of this gene could be 
observed in a mouse cell line of B cell origin. The mouse cell line I used was A20 cells 
(see Appendix B), which are a B lymphoma cell line derived from a spontaneously 
occurring reticulum cell neoplasm(Kim, et al 1979) that have been used in many studies 
of mouse B cell biology. To transfect A20 cells, I used Nucleofection™ which is an 
electroporation methodology that combines different DNA encapsulating agents with 
different electric pulses to achieve optimal cell transfection (see Section 2.2.2). 
Transfected A20 cells were then analysed by Western blot to detect expression of the 
PKCβII transgene, and by confocal microscopy to detect the expression of mCherry. 
The pathway of this investigation is illustrated Figure 3-25. 
 
Figure 3-25. Testing transgene expression. The A20 cells are transfected with pEµ-
PKCβIIHA-IRES-mCherry plasmid by Nucleofection, then the cell lysate is prepared for Western 
blotting to detect expression of PKCβIIHA. Also, live transfected A20 cells were imaged by 
confocal microscopy to detect mCherry expressing A20 cells. 
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I used the recommended protocol for performing Nucleofection in A20 cells, this 
involved solution V and programme U-15. I initially tested the efficiency of this 
transfection protocol with a plasmid containing a GFP gene under the control of a CMV 
promoter. Figure 3-26 shows flow cytometry traces of GFP expression in un-transfected 
and transfected cells, and indicated that I could achieve 70% transfection of A20 cells. 
 
 
Figure 3-26. Determination of transfection efficiency in A20 cells by using flow cytometry. 
Flow cytometry analysis of GFP in untransfected A20 cells and A20 cells transfected with 
pEGFP.  
 
I next tested the pEµ-PKCβIIHA-IRES-mCherry plasmid. 2x106 A20 cells were 
transfected with 2µg of this plasmid using the U-15 nucleofection protocol. Following 24h 
incubation the cells were harvested and analysed for expression of the genes coded for 
by pEµ-PKCβIIHA-IRES-mCherry. Figure 3-27 shows Western blot analysis of HA 
expression in lysates of A20 cells transfected with pEµ-PKCβIIHA-IRES-mCherry 
plasmid and compared to cells transfected with either pCEP4-PKCβIIHA or pPKCβII-
GFP. The PKCβIIHA gene codes for a protein of approximately 80kD and only A20 cells 
transfected with pEµ-PKCβIIHA-IRES-mCherry or with pCEP4-PKCβIIHA show a band 
at this molecular weight that is reactive with the HA antibody. The band associated with 
the A20 cells transfected with pCEP4-PKCβIIwtHA was more intense than in A20 cells 
transfected with pEµ-PKCβIIHA-IRES-mCherry. This is possibly because the pCEP4 
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vector uses a CMV promoter to drive expression of inserted genes (see Appendix B). 
The relative strength of the CMV and Eµ promoters was therefore likely reflected in the 
relative amounts of PKCβIIHA that was expressed. Nevertheless, this experiment shows 
that PKCβIIHA protein expression could be driven from the pEµ-PKCβIIHA-IRES-
mCherry plasmid I prepared.  
 
 
Figure 3-27. Detection of HA protein in transfected A20 cells with pEµ-PKCβIIHA-IRES-
mCherry by Western blot. Western blot analysis of A20 cell lyates transfected in the indicated 
manner. 10g of protein was analysed in each case. -actin is used as a loading control.  
 
I next analysed transfected A20 cells for expression of the mCherry gene. I 
performed this using confocal microscopy equipped with a 561nm laser to excite the 
fluorphore. Figure 3-28 shows that a large number of A20 cells transfected with pEµ-
PKCβIIHA-IRES-mCherry expressed mCherry. These data, taken together with the 
experiments showing expression of PKCβIIHA, indicate that the pEµ-PKCβIIHA-IRES-





Figure 3-28. Detection of mCherry protein in A20 cells transfected with pEµ-PKCβIIHA-
IRES-mCherry using a confocal microscope. The untransfected A20 cells and A20 cells 
transfected with pEµ-PKCβIIHA-IRES-mCherry were imaged by confocal microscopy using a 





























































The first step of making a transgenic mouse was injection of the pEµ-PKCβIIHA-
IRES-mCherry transgene into the pro-nuclei of fertilized eggs. This was followed by 
transferring the injected eggs into the oviducts of pseudo-pregnant mice where they 
would develop. The litters born from these foster mother mice were then screened in 
order to identify which of the animals carries the transgene. The mice that carried the 
transgene were known as founder mice. These founder mice were then backcrossed 
with wild type mice to establish the transgenic line. This chapter is concerned with 
describing the generation of a mouse that was transgenic for PKCβII expression 
specifically in B cells using the pEµ-PKCβIIHA-IRES-mCherry plasmid made in Chapter 
3. 
 
4.2 Gel-Based DNA purification of the pEµ-PKCβIIHA-IRES-
mCherry transgene  
 
In Chapter 2, I show that transfection of the pEµ-PKCβIIHA-IRES-mCherry 
plasmid into a mouse B cell line (A20 cells) results in expression of both PKCβIIHA and 
mCherry in these cells. This demonstrates that the quality of the plasmid was high. To 
prepare the Eµ-PKCβIIHA-IRES-mCherry coding sequence for injection, it must first be 
digested from the host plasmid (pBluescript II SK). This is because long stretches of 
DNA, such as the non-coding vector sequence, are toxic to mouse zygotes and this 
could lead to death of the embryo and/or poor efficiency in generating transgenic mice. 
To isolate the Eµ-PKCβIIHA-IRES-mCherry transgene from its vector backbone, I 
used Pvu-I and Spe-I in a double digestion of the pEµ-PKCβIIHA-IRES-mCherry 
plasmid. Figure 4-1A shows the map of the intended results of this digestion; the Eµ-
PKCβIIHA-IRES-mCherry coding sequence will have an approximate 6kb band size, 
whereas the vector backbone will run as two bands of 1.7 and 1.1kb. Figure 4-1B shows 
that this was indeed the case in the actual digestion of pEµ-PKCβIIHA-IRES-mCherry. 
Thus, the 6kb Eµ-PKCβIIHA-IRES-mCherry band was excised from the agarose gel 
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(Figure 4-1C), and the concentration of the isolated DNA was estimated from a 6108bp 
band (containing 100ng DNA) that was within the DNA ladder that was also run 
concomitantly with the purified Eµ-PKCβIIHA-IRES-mCherry DNA (Figure 4.2-1D). Thus, 
2µl of the Eµ-PKCβIIHA-IRES-mCherry coding sequence preparation contained 100ng 














Figure 4-1. Preparation of transgene for pro-nuclei injection. Before injection into fertilized 
eggs, the Eµ-PKCβIIHA-IRES-mCherry transgene was isolated from its vector backbone by 
digestion with Pvu-I and Spe-I restriction enzymes. A) The schematic showing the map of the 
intended results of Eµ-PKCβIIHA-IRES-mCherry plasmid digestion with Pvu-I/Spe-I. B) Actual 
digestion of pEµ-PKCβIIHA-IRES-mCherry with Pvu-I and Spe-I. C) To prepare the transgene 
for Pro-nuclei injection, the 6kb Eµ-PKCβIIHA-IRES-mCherry band was excised from the 
agarose gel, D) Extracted DNA from the gel was purified using GENECLEAN, and then 2µl the 
Eµ-PKCβIIHA-IRES-mCherry coding sequence was run on the gel to estimate DNA 




4.3 Preparation of Fertilized Eggs for Microinjection 
 
 Immediately following fertilization the nuclei containing chromosomes derived 
from the male (sperm) and female (egg) partners, called pro-nuclei, eventually fuse at 
the centre of the egg cell to form a single nucleus (Figure 4-2). Microinjection of 
transgenic DNA is best accomplished at this pro-nuclei stage. This is a very narrow 
window of opportunity, and needs to be precisely timed in order to ensure efficient 
isolation of early fertilized egg cells. 
In order to prepare the fertilized eggs, female mice were injected with Pregnant 
Mare’s Serum Gonadotropin (PMSG) and human chorionic gonadotropin (HCG, 
Intervet) intra-peritoneally. These two hormones cause super ovulation of eggs in the 
mouse ovary, and after approximately 24h this female was mated with a stud male 
mouse. Mating success was observed by the appearance of a “plug” where the vulva of 
the female mouse became distended following intercourse. 
Mice having this plugged appearance were sacrificed, and the entire ovary and 
oviduct were dissected from the body cavity by cutting them from the upper part of the 
uterus. The ovary and oviduct was then transferred into medium containing 
hyaluronidase, and zygotic egg cells were released by gently squeezing the ampulla 
using micro-dissection forceps. Zygotic cells were isolated from cumulus cells by 
appearance; healthy cells were selected and transferred to another petridish, whereas 
cells with an abnormal appearance were excluded. 
In the first attempt to generate PKCβII transgenic mice, 167 zygotes were 
harvested from 5 super-ovulated female mice, and of these zygotes 130 were healthy 
enough for transgene injection. Table 4-1 summarizes the total number of the isolated 






Figure 4-2. Pro-nuclei stage in fertilization. In the first stage of fertilisation which is called the 
pro-nuclei stage, the nuclei containing chromosomes derived from the male (sperm) fuse to 
female (egg) partners at the centre of the egg cell to form a single nucleus. Each of these pro-
nuclei contains nucleolus. In this stage, the zygotic cell is surrounded by a membrane called the 
zona pellucida. 
 
4.4 Pro-nuclei microinjection of the transgene into mouse 
zygotes 
 
There are several parameters that are important for transgene integration into the 
mouse genome. The optimal concentration of injected transgene is one of them; too 
high a concentration could lead to lysis of the zygotes, whereas too low a concentration 
may result in lack of integration into the host genome. I used a DNA concentration of 2 
ng/µl for microinjection as it is known that this concentration gives the most efficient 
integration of transgene into a genome. In addition, injection performance is another 
important factor in transgene integration and should be performed in a gentle and 
prompt way to minimize the possibility of damage to the zygotes. Last but not least, the 
timing of the microinjection should be precisely followed because the optimal window for 




injection window of 11 to 13hrs  was used following insemination of donor female mice. 
And this is the time that pro-nuclei are visible and the transgene can be injected into 
them. 
The microinjection procedure was performed using a specialised microscope unit 
consisting of an inverted microscope equipped with micromanipulators, injectors and 
other peripheral equipment. The procedure begins by fixing egg cells into position with a 
holding pipette. The injection needle, containing the DNA transgene (at a concentration 
of 2ng/µl) was then pushed through the plasma membrane of the egg cell into the 
vicinity of the pronuclei membrane, and preferably the male pronuclei because of its 
bigger size compared to its female counterpart. It was important to avoid touching visible 
nucleoli, and it is common that the injection needles stick to nucleosomes and need to 
be replaced before moving on. The microinjection procedure was stopped after 
observation of a slight swelling of the pronucleus (Fiqure 4-3). After injection, the 
fertilized eggs were incubated at 37°C for 24 hrs to let the cells undergo a first round of 
cell division. This was done to ensure that the injected fertilized eggs were healthy and 









4.5 Oviduct transfer 
 
The injected fertilized eggs as healthy embryos are then surgically transferred 
into the oviducts of recipient female mice (foster mice). Thus, intended recipient female 
mice were anesthetized and placed on an operation platform. A small incision was made 
in the skin of the mouse dorso-laterally just below the rib cage. The skin was opened 
with scissors to make an opening of approximately 6 – 8 mm. The body wall was lifted 
with forceps and opened with a second incision that was made in the same direction as 
the first and avoiding obvious blood vessels. The upper lip of the body wall was held 
open with a suture, and the exposed ovary, oviduct and uterus could be pulled out by 
lifting up the fat pad attached to the ovary. The uterus was located beneath the ovary 
and the infundibulum “a funnel-like end of the mammalian oviduct” was visible just 
above the uterus. At this stage, the mouse was transferred to a dissecting microscope 
and the procedure was performed under 15-20 X magnification. The prepared embryos 
were placed into the infundibulum using a transfer pipette that was prepared in such a 
way that successful deposition of the embryos could be ensured. After completion of the 
transfer, the pipet was removed, and the mouse was placed back on to the operation 
platform. The uterus, oviduct and ovary were repositioned back into the body cavity 
which was then sutured, the skin incision was closed using a wound clip. Depending on 
the number of embryos to be injected, this procedure was performed either unilaterally 
or bilaterally. 
Table 4-1 summarizes the details of four consecutive attempts to inject prepared 
embryos for the generation of transgenic animals. In general, eighteen recipient female 
mice were subjected to oviduct transfer, using up to 130 prepared embryos. Following 







Table 4-1. Details of four consecutive attempts to inject prepared embryos into oviduct of 
recipient mice for generation of the Eµ-PKCβII transgenic mice. 
 
4.6 Genotyping transgenic founder mice 
 
The pups born from foster mice were weaned at three weeks of age. Tissue 
samples were taken from these animals by clipping either the tail or the ear, and were 
used for subsequent genotypic screening.  
Screening for presence of the transgene and identification of founder mice 
involved both PCR and Southern blot methods as described below. Both these methods 
were used because PCR screening quickly gives information about the presence of the 
transgene, whereas Southern blotting also gives information about the copy number of 
the transgene inserted into the genome. Importantly, both methods are complementary 
and can be used to validate each other. For example, there is a risk of obtaining false 
positive or false negative results when animals are screened only by PCR. In my 
approach, I initially used Southern blotting to identify founder animals. In subsequent 














11/02/11 5 167 130 FT-1 24(Two Sides)
FT-2 24(Two Sides)
FT-3 24(Two Sides)
17/02/11 4 83 50 FT-4 20(Two Sides)
FT-5 20(Two Sides)
24/02/11 5 81 20 FT-6 10(One Side)
FT-7 10(One Side)




4.6.1 Southern blot strategy for detecting founder mice   
 
The technique developed by Southern (Southern 1975), known as Southern 
blotting, consists of DNA isolation from tissues, fragmentation of this DNA by restriction 
endonuclease digestion, separation of the DNA fragments by electrophoresis, transfer of 
separated DNA fragments to a nylon membrane and hybridization with a probe 
oligonucleotide whose sequence is complementary to the gene of interest (see Section 
2.1.3.3). In the present study, my probe was developed using a sequence that was 
found only in the transgene and not in the genome of wild type mice. Thus, I used the 
mCherry coding sequence contained within my transgene for this purpose. PCR was 
used to prepare the mCherry probe, and primers were designed that would amplify a 
717bp sequence from the transgene template I constructed previously (Figure 4-4A). 
After amplifying this product, it was labelled with 32P-dCTP using Klenow DNA 
polymerase. This labelled probe was then used for hybridization with DNA isolated from 
mouse tissues (see Section 2.1.3.3).  
I used EcoRI to fragment the DNA isolated from the transgenic mice I generated. 
This is because this restriction enzyme cuts twice within the transgene sequence of the 
Eµ-PKCβIIHA-IRES-mCherry construct, but does not cut into the coding sequence of 
mCherry. Using this strategy, it is now possible to isolate a 2.1kb band containing 
mCherry following fragment separation of genomic DNA by electrophoresis (Figure 4-
4B, C).  
The next consideration is the copy number of the incorporated transgene. In the 
majority of cases micro-injected transgenes integrate into host DNA in a head-to-tail 
concatemer fashion. Therefore, anywhere from one copy of the gene, to multiple copies 
of the gene may be present. This can be estimated following the hybridization reaction 
by using the intensity of the detected band because this depends on the number of 
copies of transgene present. Importantly, band intensity can be used to discriminate 
between animals that are heterozygous or homozygous for the transgene, but also band 
intensity can be used at the founder stage to estimate the number of copies of 
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transgene that integrated into the genome. Thus, in my experiments digestion with 
EcoRI of genomic DNA from a founder mouse containing the Eµ-PKCβIIHA-IRES-
mCherry transgene would result in the generation of a 2.1kb band, the intensity of which 
could be used to determine the copy number of integrated transgenic DNA (Figure 4-4D, 









Figure 4-4. Southern blotting strategy used for detecting potential founder mice. A) 
Agarose gel analysis of the PCR product derived from primers that were designed to amplify the 
mCherry (717bp) sequence from the Eµ-PKCβIIHA-IRES-mCherry plasmid. This product was to 
be used as a probe for Southern blotting. B) A schematic of the EcoRI digestion of the the Eµ-
PKCβIIHA-IRES-mCherry plasmid showing that the mCherry coding sequence is intact.  C) 
Agarose gel analysis of a EcoRI digestion of pEµ-PKCβIIHA-IRES-mCherry. D) Schematic 
showing where the mCherry PCR probe would bind transgenic DNA. E) Schematic showing 
potential transgene integration within the genomic DNA in concatemer fashion. Here, the 
intensity of the 2.1kb band would determine the copy number of transgene. 
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4.6.2 Calculation of transgene copy numbers  
 
To estimate the number of copies of transgene integrated into the host genome, 
the formula illustrated in Figure 4-5 was used. The calculation of the formula is based on 
the fact that the potential founder mice are hemizygous, meaning that the transgene 
integrates randomly into the DNA of one chromosome of any chromosome pair. 
Calculation of copy number must take into account the haploid size of the mouse 
genome. Thus, Mass of transgene DNA is a function of the size of the transgene (in bp) 
X the amount of genomic DNA used (g) in the reaction divided by the haploid size of 
the mouse genome (which is 3 x 109 base pairs). From this formula I calculated that 
19pg of transgenic / 10g of genomic DNA is equivalent to 1 copy of the transgene 
present in the genome. To estimate copy number following the hybridization reaction, I 
used 1.9, 19, 190, 360 and 720 pg amounts of the Eµ-PKCβIIwtHA-IRES-mCherry 
coding sequence on the same electrophoresis gel to act as a standard curve. These 
amounts of standard DNA correspond to 0.1, 1, 10, 20 and 40 copies of transgene per 
genome. (Figure 4-5) In order to accurately estimate single integration of the transgene, 
the standard curve must accommodate a corresponding value that is less than 1 but 





Figure 4-5. Example of calculation for transgene copy number 
 
4.6.2.1 Detection of the founder mouse  
In total, 31 potential founder mice were born from foster mice following nine 
oviduct transfers of injected fertilized eggs containing the transgene. As indicated above, 
genomic DNA was isolated either from tail or ear tissue clips taken from the pups. This 
extracted DNA was then digested by EcoRI. At this stage it was important to ensure 
complete digestion of the genomic DNA to ensure that false negative results were 
avoided. Complete digestion of DNA was judged based on the appearance of a smear. 
Undigested or partially digested DNA clumps at the top of the gel, whereas DNA that is 
degraded prior to digestion lacks either of these attributes. Figure 4-6A shows the 
results of EcoRI digestion of genomic DNA isolated from the 31 potential transgenic 
animals. DNA from mouse 47-2, 49-1 and 49-4 appeared either degraded or partially 
digested and these animals were excluded from further study. The DNA from the rest of 
the animals showed an appropriate smear, indicating complete digestion.  
Mass of transgene DNA
N mg genomic DNA
N bp transgene DNA
3 x 109 bp genomic DNA
=
Mass of transgene DNA
1µg of genomic DNA 
5900bp transgene DNA
3 x 109 bp genomic DNA
=
or
Mass of transgene DNA (5900bp transgene DNA)
3 x 109 bp genomic DNA
=
X (10µg of genomic DNA) 
or
Mass of transgene DNA = 19 picoograms per 10 μg genomic DNA
-Thus, 19 pg transgene should be added to 10 µg of genomic DNA
Thus:
0.1copy 1.9 pg
1  copy 19  pg 
10 copy 190 pg 
20 copy 380 pg 
40 copy            760 pg
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Figure 4-6B shows the Southern blot of the DNA isolated from the 31 potential 
transgenic animals. The Southern blot was prepared by hybridizing the DNA transferred 
to nylon membranes with the mCherry probe I prepared. The expected 2.1kb band 
corresponding to the transgene containing mCherry was only observed in mouse 
number 45-2, a female mouse. It is noteworthy that there were two additional bands 
sized 4 and 6 kb also detected in the DNA of this mouse. The presence of these two 
bands likely represents the junction between integrated transgene concatemer and 
flanking chromosome DNA. Thus, mouse 45-2 was considered as a founder mouse. 
Estimation of the copy number of transgene integrated into the genome of mouse 45-2 
suggested that there were less than 10 copies, but more than 1. For comparative 











Figure 4-6. Detection of the trasngene in the mouse pups born from foster mice by 
Southern blot. 31 potential founder mice were born from foster mice following nine oviduct 
transfers of injected fertilized eggs in the foster mice. The genomic DNA was extracted from tail 
of these mice and Southern blotting was performed on these samples to detect the 2.1kb band 
carrying mCherry. A) Agarose gel representation of EcoRI digestion of genomic DNA isolated 
from the mouse pups. B) The EcoRI fragmented genomic DNA was probed for the presence of 
mCherry using Southern blotting. 
 
4.6.3 Establishing the PKCII transgenic mouse line 
 
After establishing that mouse 45-2 was a founder mouse for the Eμ-PKCβII 
transgenic line, the next step was to back cross this animal with C57BL/6 wild type mice 
to generate Eμ-PKCβII homozygous mice. Figure 4-7 shows a schematic relating to the 
establishment of first-generation Eμ-PKCβII heterozygous mice. In this schematic, I 
show the attempts at generating the transgenic founder mouse, followed by the results 
118 
 
of the multiple matings needed for the heterozygous mice. What follows is a description 




Figure 4-7. The time table for generation of  Eμ-PKCβII transgenic mice. 
 
 
The mice born from the first generation litters were screened for the presence of 
the E-PKCII transgene by both Southern blot and PCR. For PCR screening, I recycled 
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mCherry. Thus, I used the IRES forward primer and mCherry reverse primer in this 
reaction to amplify an IRES-mCherry coding sequence of 1.2kb in length from genomic 
DNA isolated from first generation transgenic animals. For Southern blot screening of 
these animals, and as described above, I searched for the presence of a 2.1kb band. 
These methods were complementary and fairly easy to carry out because Southern blot 
analysis requires approximately 10g of DNA whereas the PCR method requires less 
than 1g.  
Figure 4-8 illustrates the results of my initial attempts to analyse for the presence 
of the E-PKCII transgene in the founder mouse and first two litters from this mouse 
using the PCR method I developed. As a positive control for the PCR reaction, I used 
the pEµ-PKCβIIHA-IRES-mCherry plasmid and was able to show successful 
amplification of a 1.2kb IRES-mCherry band. I next analysed DNA isolated from the 
founder mouse (45-2) and 2 mice negative for the presence of the transgene (analysed 
by Southern blot, see Figure 4-6). As expected, I was able to amplify the 1.2kb IRES-
mCherry band from mouse 45-2 but not from mice 44-1 nor 45-4. Analysis of DNA 
isolated from the progeny in the first and second litters from mouse 45-2 shows 
amplification of the IRES-mCherry band in mice numbered 98-1, 98-3, 99-4 and 101-3. 
Unfortunately, I was not able to perform Southern blot analysis for these animals 
because I did not have enough DNA. Nevertheless, based on the results I received from 
my positive and negative controls in this experiment, I could be fairly confident that this 






Figure 4-8. Detection of the transgene in 45-2 founder mouse and its progeny using PCR. 
IRES forward and mCherry reverse primers were used to amplify an IRES-mCherry coding 
sequence of 1.2kb in length (arrowed red) from genomic DNA isolated from transgenic animals. 
This figure is an agarose gel analysis screening the founder mouse 45-2 and its first two litters 
for detection of the transgene (IRES-mCherry) using PCR. As  a positive control 1 and 10 copies 
of pEµ-PKCβIIHA-IRES-mCherry were amplified. 
 
I used the PCR method to screen the progeny of the third and fourth litters that 
were born from the founder mouse (45-2). Figure 4-9A shows that mice numbered 102-
1,102-3,102-4,103-1,103-3 and 104-1 appeared to carry the E-PKCII transgene, and 
Figure 4-9B shows that these results are confirmed using the Southern blot method. 
Importantly, mouse 102-2 was classified as undefined because the DNA isolated from 
this animal was degraded (Figure 4-9B).   
 
 
Litters born from 









Figure 4-9. Detection of transgene in the third and fourth litters born from 45-2 founder 
mouse. The mouse pups born in the third and fourth litters of founder mouse 45-2 were 
screened for the presence of IRES-mCherry using PCR, and for the presence of mCherry using 
Southern blotting. A) Genomic DNA isolated from these mice was subjected to PCR to detect 
IRES-mCherry. B) Genomic DNA isolated from these animals was fragmented with EcoRI 
(upper figure), and then probed for the presence of mCherry using Southern blotting (lower 
figure).  
 
4.6.3.1 Genomic DNA digestion with EcoRI versus Sph-I  
Screening of the fifth litter revealed a technical problem with respect to partial 
digestion of isolated genomic DNA. This was a surprising problem to arise because 
EcoRI was a robust restriction enzyme that is relatively insensitive to DNA quality. As I 
had a limited source of genomic DNA for each sample, I decided a second strategy 
using a different restriction enzyme for DNA digestion was required for southern blotting. 
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For this purpose, I chose Sph-I because this restriction enzyme cuts once within the 
transgene sequence. A comparison of DNA digestion using EcoRI and Sph-I showed 
that Sph-I was more effective at complete digestion of the genomic DNA (Figure 4-10). 
Thus, I decided to replace EcoRI with Sph-I for digesting genomic DNA isolated from the 
animals of the fifth litter. Because Sph-I cuts differently than EcoRI, I needed to 
determine the size of the band carrying the transgene. Sph-I cuts the Eµ-PKCβIIHA-
IRES-mCherry plasmid at a single site which was in the 3’ end of the PKCβII coding 
sequence, producing a single band sized 9kb. This 9kb band contains the transgene 
(6kb) and the Eµ vector backbone (3kb) (Figure 4-11 A and B). With respect to the 
Southern blot, I again probed with the mCherry probe and expected a band sized 
approximately 6kb band containing entire sequence of the transgene because of the 
way Sph-I cut within the concatemer transgene integrated into genomic DNA (Figure 4-
11 C and D). In this way, I was able to detect the presence and number of copies of 
transgene in the genomic DNA of the transgenic animals. Importantly, EcoRI remained 
the restriction enzyme of choice, and Sph-I was used only in cases where EcoRI could 







Figure 4-10. Comparison of EcoRI and SphI restriction enzymes in their ability in 
digesting mouse genomic DNA. 1µg of genomic DNA of the mice # 1-1, 1-2, 1-3, 1-4, 2-1, 2-2 
and 2-3 were digested with EcoRI and Sph-I restriction enzymes. A) Agarose gel analysis of the 
genomic DNA of these mice digested by Sph-I, B) and EcoR-I.    
Genomic DNA digested by SphI Genomic DNA digested by EcoRI
Completely digested DNA
Uncut DNA





Figure 4-11. Developing a secondary Southern blotting strategy for detecting transgene 
(mCherry). A) Schematic map showing the single Sph-I site within the Eµ-PKCβIIHA-IRES-
mCherry plasmid, B) Actual digestion of pEµ-PKCβIIHA-IRES-mCherry with Sph-I. C) 
Schematic showing the Sph-I cutting site with the Eµ-PKCβIIHA-IRES-mCherry transgene., D) 
Schematic showing the Sph-I cutting sites and expected fragment size in the case where 
transgene is integrated within genomic DNA in concatemer fashion. 
 
Screening of the fifth and sixth litters was conducted using this new strategy. 
Figure 4-12 A and B shows the PCR and Southern blot analysis for litter 5. PCR 
analysis identified animals 1-1, 1-2, 1-3, 1-4 and 2-2 as carrying the transgene within 
this litter. Southern blot analysis using Sph-I to digest the genomic DNA confirmed that 
animals 1-1, 1-2 and 2-3 carried the transgene in sufficient copy number (which was 
Eµ:PKC IIHA– IRES –mCherry
~ 9 kb
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greater than 1 but less than 10).Thus, the Southern blot result for 2-3 was not correlated 
with the PCR result. Animals 1-3 and 1-4 from this litter were excluded from further 
analysis because of failure within the Southern blot. Figure 4-12 C and D shows the 
PCR and Southern blot analysis for litter 6. Here animals 4-1, 4-2 and 4-3 showed 
presence of the transgene within the PCR analysis, and the presence of the transgene 
in animals 4-1 and 4-2 was confirmed in the Southern blot. With respect to this latter 









Figure 4-12. Detection of transgene in fifth and sixth litters born from founder mouse 45-
2. The mouse pups born in the fifth and sixth litters of founder mouse 45-2 were screened for the 
presence of the transgene using PCR and Southern blotting. For performing the Southern 
blotting on DNA isolated from animals of the fifth litter, genomic DNA was fragmented by Sph-I, 
whereas EcoRI was used for digestion of genomic DNA isolated from animals of the sixth litter. 
A) Agrose gel separation for PCR screening the genomic DNA isolated from fifth litter for 
detecting the transgene by PCR. B) The genomic DNA isolated from the mouse pups born in the 
fifth litter was fragmented with Sph-I, and then probed for the presence of mCherry using 
Southern blotting. C) Agarose gel separation for PCR screening the genomic DNA isolated from 
the mouse pups born in the from sixth litter for detecting the transgene using PCR. D) The 
genomic DNA isolated from the mouse pups born in the of fifth litter was fragmented with EcoRI, 
and then probed for the presence of mCherry using Southern blotting.  
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4.6.4 Inter-crossing PKCII heterozygous transgenic animals to 
generate homozygous animals 
 
The results from my experiments described above show that I have generated a 
PKCII transgenic founder mouse, and that the transgene is transferred to F1 progeny. 
The next step was to generate animals which were homozygous for the Eµ-
PKCβIIwtHA-IRES-mCherry transgene. Figure 4-13 shows the mating strategy I 
employed: heterozygous animals were paired (het x het) and, based on Mandelian rules, 
one quarter of the animals born from such inter-crossings are predicted to be  
homozygous for the PKCII transgene. Half of the progeny would be heterozygous, and 
the final quarter of these animals would have a wildtype genotype. The generation of 
wildtype animlas was important because they would be used as littermate controls 
during chracterization of the trangenic animals. For the inter-crossing I set up four pairs 
of PKCII transgenic animals which were: 98-1( )x 99-4( ), 98-3( )x 101-3( ), 102-







Figure 4-13. Inter-crossing heterozygous Eμ-PKCβII transgenic mice to generate 
homozygous Eμ-PKCβII transgenic mice. This figure illustrates a schematic of expected 
results based on Mendalian rules. 
 
The result of inter-crossing resulted in the birth of 64 pups. Initially, I screened 
these animals by PCR (analysing for IRES-mCherry) in order to detect the presence of 
the PKCII transgene. Figure 4-14 shows the results of this screening on 60 of these 
pups. To ensure experimental validity I used wt animals (to ensure specificity) and ran 
these samples at various places within my analysis. I also ran a water sample 
(designated w) to ensure sensitivity, and two amounts of the transgene corresponding to 
1 copy [T (1c)] and 10 copies [T (10c)]. The transgene was detected in the animals 
whose designation number is marked in red in the figure 4-14. In total there were 12 
animals without the transgene likely bearing a wild type genotype, and 48 animals which 
contained the transgene. This means that approximately 1/5 of the animals reverted to 







Figure 4-14. PCR-based detection of the transgene (IRES-mCherry) in mice born from 
inter-crossing heterozygous Eμ-PKCβII transgenic mice. 60 mouse pups were born from the 
inter-crossing of heterozygous Eμ-PKCβII transgenic mice. Genomic DNA isolated from these 
mouse pups was screened for the presence of the IRES-mCherry transgene using PCR. T (1c) 
and T (10c) refer to control amounts of pE-PKCIIHA-IRES-mCherry which correspond, 
respectively to 1 copy and 10 copies.  wt refers to a known wild type control, and w refers to a 
water control. The case numbers highlighted in red carry the transgene. 
 
I also screened the animals using Southern blot because I wanted to confirm the 
PCR results, and also estimate the zygosity status of these animals (Figure 4-15). 
Zygosity status was determined based on the intensity of the 2.1kb band carrying the 
E-PKCIIHA (wt)-IRES-mCherry transgene, and animals were categorized as potential 
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homozygous, heterozygous and littermate control (wt animals). Therefore, potential 
homozygous animals contained approximately two fold more transgene than potential 
heterozygous animals, and wt animals contained no detectable transgene. Screening 
using Southern blot largely confirmed my results with PCR; nearly all the animals 
showing the presence of a PCR product in Figure 4-15 showed the presence of a 2.1kb 
band carrying the transgene. There was a discrepancy between Southern blot and PCR 
result in animal 19-3, in which the transgene was detected by Southern blot whereas no 
transgene was observed by PCR. It should be noted that the DNA isolated for animals 
6-1, 6-4, 7-3, 10-2, 17-2, 18-2 and 25-1 were degraded, thus I was not able to confirm 
the PCR result by Southern blot, and these animals were excluded from the further 
analysis. 
In my Southern blot, I detected seven animals that did not carry the transgene; 
the identity of these animals is marked in green in Figure 4-15. Where the transgene 
was present, a comparison of band intensities suggested that 22 of the mice were 
potential homozygous (marked in red) and 25 of the animals were potential 
heterozygous (marked in purple).  As a positive control I used DNA isolated from mice 
numbered 4-2, 102-4, 101-3 and 104-1 (marked in brown), as these animals were 
definitely heterozygous because they are F1 progeny of the founder mouse. To confirm 





Figure 4-15. Detection of the transgene in mice born from the inter-crossing of 
heterozygous Eμ-PKCβII transgenic mice by Southern blotting. A, B, C and D represent 
agarose gel electrophoresis of EcoRI-digested genomic DNA isolated from the mice born from 
the inter-crossing of heterozygous Eμ-PKCβII transgenic mice (upper figure). Screening for the 
presence of transgene (a 2.1kb band containing mCherry) using Southern blot is represented in 
the lower figure of A, B, C and D. Mice that did not carry the transgene are marked in green; 
mice which are potentially homozygous Eµ-PKCβII tg mice are marked in red; potentially 
heterozygous Eµ-PKCβII tg mice are marked in purple and mice that were used as positive 
controls are marked in brown.  
132 
 
4.7 Quantification of the E-PKCIIHA (wt)-IRES-mCherry 
transgene by quantitative real time PCR 
 
Quantitative real time PCR (qrtPCR) is a more reliable method for distinguishing 
between homozygous and heterozygous transgenic animals. This method is based on 
the detection of a fluorescent dye (SYBER green) that specifically binds to the double–
stranded PCR product that is amplified by DNA polymerase during the PCR reaction. 
Binding and detection of this dye is proportional to the amount of dsDNA present, and 
can therefore be used for quantification (see section 2.1.6). This quantification is done 
by the PCR instrument which measures the Ct value, which is the number of cycles 
required for the detected fluorescence signal to cross a threshold and exceed 
background levels. To quantify the transgene I used the same primers I used for cloning 
mCherry in Chapter 3. These primers produced a PCR product that was sized 
approximately 500bp. The PCR amplification of the mCherry transgene was normalized 
to a reference gene, gapdh, a house keeping gene expected to have homozygous 
representation in the mouse genome. The amount of mCherry transgene can then be 
determined by calculating the ΔCT value which is:  
 
ΔCT = CT, mCherry (mouse A) -CT, gapdh (mouse A) 
 
To distinguish between homozygous and heterozygous animals I calculated a 
ΔΔCT value which compares the ΔCT value from a known heterozygous animal (mouse 
B) with that of my unknown transgenic (mouse A). Because each cycle of the PCR 
reaction creates twice as much dsDNA as the previous cycle, the fold difference in 
transgene between two animals can be determined using the power function 2-ΔΔCT.  The 
equations I used are listed below using the example of a comparison between a 






ΔΔCT= ΔCT (A) –  ΔCT (B) (CT, mCherry (A) – CT, GAPDH (A)) – (CT, mCherry (B) – CT, GAPDH (B))                      
or 
ΔΔCT= (CT, mCherry (HOM) – CT, GAPDH (HOM)) – (CT, mCherry (HET) – CT, GAPDH (HET)) = -1 
Fold difference = 2-ΔΔCT = 2
1 = 2 
Example: 4-2: known heterozygous 15-4: Unknown 
ΔΔCT= ΔCT (15-4) – ΔCT (4-2) = (23.78-18.44)-(25.64-18.85) =5.34 – 6.79 =-1.45   
Fold difference = 2-ΔΔCT = 2
(-)-1.45 = 2.7 
 
Thus, using the method I have described the ΔΔCT value of homozygous transgenic 
animals should approximate -1, whereas heterozygous animals should have a value 
close to zero. In the example I present I compare mouse 4-2 (which is a known 
heterozygous animal because it is an F1 progeny) with mouse 15-4 (F2 progeny that 
contains the transgene and is suggested to be homozygous from the Southern blot 
result). The calculated ΔΔCT value equals -1.45, which when substituted into the 2
-ΔΔC
T 
equation yields a value of 2.7. This means that mouse 15-4 contains 2.7 fold more 
transgene than mouse 4-2, and that mouse 15-4 is likely to be homozygous. Figure 4-16 
shows the result of a typical PCR run using this method, indicating both the specificity 
and sensitivity of the primers used, as well as the dissociation curves to ensure that 





Figure 4-16. Amplification of mCherry and gapdh by using qrtPCR. A) Agarose gel 
separation for a typical qrtPCR performed for amplification of mCherry and gapdh in Eµ-PKCβII 
tg and wild type mice. B) Dissociation curve for mCherry and gapdh amplifications. 
 
Figure 4-17A summarizes the quantification of transgene in the F2 progeny that 
were generated. The results are all relative to a known heterozygous control animal, 
mouse 4-2. Using this method 18 of the animals were determined to be homozygous, 
and are indicated as purple bars in the presented histogram. Moreover, 25 of the mice 
were determined to be heterozygous for the transgene, and are indicated as blue bars in 
the presented histogram. Figure 4-17B shows the distribution of 2-ΔΔCT values obtained 
for homozygous and heterozygous animals. This illustration is important because it 
shows that transgene content was approximately 2-fold greater in homozygous 
compared with heterozygous animals. Table 4-2 compares the Southern blot and 
qrtPCR methods for distinguishing between homozygous and heterozygous animals. 
Both methods largely confirmed each other with the exception of animals numbered 6-3, 
7-1, 14-2, 14-3, 15-1, 16-2, 17-2, 19-3, 20-1, 20-2, 20-3 and 26-3. These animals were 





Figure 4-17. The quantification of transgene (mCherry) in the F2 progeny of Eµ-PKCβII tg 
mice using qrtPCR. A) The graphical representation for transgene quantification in the F2 
progeny of Eµ-PKCβII transgenic mice by qrtPCR. This quantification was relative to a known 
heterozygous control animal, mouse 4-2 (highlighted in red). The potential homozygous Eµ-
PKCβII tg mice are highlighted in purple, and the potential heterozygous Eµ-PKCβII tg mice are 
highlighted in blue. B) Box plot representation of the distribution of 2-ΔΔCT values obtained for 
homozygous and heterozygous mice. 
 
As a final assurance that the homozygous animals we generated were indeed 
homozygous we backcrossed these animals with wild type mice. I selected seven 
animals where Southern blot and qrtPCR results were confirmatory. These animals were 
13-1, 15-3, 15-4, 17-1, 19-4, 21-2 and 22-2. Figure 4-18 illustrates PCR analysis of 
IRES-mCherry presence in the progeny of the backcross of these animals with wt mice. 
The transgene was detected in all the pups that were born from mice numbered 13-1, 
15-3, 17-1 and 21-2 demonstrating that these animals are homozygous for the 
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transgene. However, mice numbered 15-4, 19-4 and 22-2 delivered progeny that did not 
consistently carry the transgene. This result could be due to technical reasons or 
because the animals are heterozygous, in any event they were excluded from further 
study. 
 
Figure 4-18. Detection of the transgene (IRES-mCherry) in the mouse pups born from the 
backcrossing the potential homozygous Eµ-PKCβII tg mice with wild type mice using 
PCR. To confirm homozygosity of potential homozygous Eµ-PKCβII tg mice, these mice were 
back-crossed with wild type mice, and then the genomic DNA extracted from the tail of the 
mouse pups born from this back-crossing were screened for the presence of the transgene 
(IRES-mCherry) by using PCR. 
 
Table 4-2 presents a summary of all the screening methods used for generating 
the transgene animals in this study. Based on this table I could safely conclude that 
mice numbered 13-1(male) and 17-1(female) are homozygous for the E-PKCIIHA 
(wt)-IRES-mCherry transgene, and that the progeny generated from crossing these 
animals would also be homozygous. Crossing these animals generated 47 mice, 20 of 
these animal were kept and aged for phenotypic analysis (called hom-1 to hom20), while 
25 mice were sent for cryopreservation.  
At this stage the generation of the E-PKCIIHA (wt)-IRES-mCherry transgenic 
mouse is now complete. Figure 4-19 shows a schematic summary of the process 
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involved in generating this mouse. In the next chapter, I will describe the phenotype that 




Table 4-2. Summary of all the screening methods used for screening/generating Eµ-













6-3 +/+? + (+/-)
6-4 +
7-1 +/+? + (+/-)
7-2 +/- + (+/-)
7-3 +
10-1 +/+ + (+/+)
10-2 -
10-3 +/- + (+/-)
11-1 +/- + (+/-)
11-2 +/- + (+/-)?
12-1 +/- + (+/-)
12-2 +/+ + (+/+)
13-1 +/+? + (+/+) (+/+)
13-2 +/- +
13-3 +/- + (+/-)
14-1 - -







14-3 +/- + (+/+)
15-1 +/+? + (+/-) (+/-)
15-2 +/- + (+/-) (+/-)
15-3 +/+ + (+/+) (+/+)
15-4 +/+ + (+/+) (+/+)?
16-1 +/- + (+/-)
16-2 +/- + (+/+)
16-3 +/- + (+/-)
17-1 +/+ + (+/-) (+/+)
17-2 - +
17-3 +/- + (+/-)
18-1 - -
18-2 +/- +
19-1 +/- + (+/-)
19-2 - -
19-3 +/- - (+/+)
19-4 +/+ + (+/+) (+/+)?
20-1 +/+? + (+/-) (+/-)
20-2 +/- + (+/+)
20-3 +/+? + (+/-)
21-1 - -














23-3 +/+? + (+/+)
24-1 +/- + (+/-)
24-2 +/+? + (+/+)
25-1 +
25-2 +/- + (+/-)
25-3 +/- + (+/-)
26-1 +/+ + (+/+)
26-2 +/+ + (+/+)
26-3 +/+ + (+/-)























1.1 (+/-) + (+/-)









4-1 +/- + (+/-)





























































The ultimate goal of this project was to generate homozygous Eµ-PKCβIIHA (wt)-
IRES-mCherry (abbreviated from now on as Eµ-PKCβII) transgenic mice. Thus, I 
constructed the transgene Eµ-PKCβIIHA(wt)-IRES-mCherry by DNA cloning, tested this 
construct to ensure that it was functional (see Section 3.4.2), and then generated a 
homozygous line expressing this transgene by inter-crossing heterozygous F-1 progeny 
born from the founder mouse mice described in chapter 4. Thus, I used homozygous 
animals from the F-2 progeny to expand the numbers of E-PKCII mice I would need 
for phenotypic characterization. I also selected wild type animals from the F-2 progeny 
to be used as littermate controls. I aged the Eµ-PKCβII transgenic mice for 6 and 14 
months. For the wild type littermate controls there were a limited number of mice 
generated, these mice were aged for 14 months. For the mice aged only 6 months, non-
littermate control animals were used. Therefore, in this section of my thesis, I have 
made comparisons between the wild type littermate and non-littermate mice in order to 
establish similarity. All animals were sacrificed at their designated ages, and then 
characterized. 
Characterization of the mice I generated involved first establishing that the 
transgene was expressed by the transgenic mice, that this expression was B cell-
specific, and ascertaining that the homozygous Eµ-PKCβII transgenic mice were healthy 
and aged normally. The transgenic animals were assessed to see if they developed a 
CLL-like phenotype in B cell rich organs (spleen, peritoneum, peripheral blood and bone 
marrow), and B cell subsets were analysed in these organs to note any changes.  
The structure of this chapter is arranged in three sections: 
 
1. Detection and quantification of the transgene   
2. Pathological/Morphological study of the spleen of the transgenic mice  





5.2 Detection of transgenic PKCIIHA by Western blot 
 
To establish whether the Eµ-PKCβIIHA (wt)-IRES-mCherry transgene was 
expressed in the homozygous animals I first used Western blot to ascertain the 
presence of transgenic PKCβII tagged with HA and mCherry. For this purpose, the 
spleens of transgenic and wt mice were isolated and protein lysates were prepared. A 
protein determination was carried out and equal amounts of protein were separated by 
SDS-PAGE. Finally, the separated proteins were transferred to PVDF membranes and 
probed for PKCIIHA and mCherry using specific antibodies.  
Figure 5-1 shows a comparison of transgene expression in PKCII transgenic 
and wt mice. I used two different mouse monoclonal HA antibodies, clones numbered 
6B12 and 12CAS, to detect the HA tag attached to PKCβII in the transgene (Figure 5-1A 
and B). Thus, transgenically expressed PKCβIIHA was detected as an approximate 80 
kDa band only in transgenic mice. This 80kDa band was recognised by both antibodies, 
but with the 12CAS antibody there were additional faster running bands which were non-
specific because they also appeared in the lysate derived from the wt mouse. This 
80kDa band was also detected by a PKCII specific antibody (Figure 5-1C), thus in this 
representation, PKCIIHA ran as a slower migrating band to endogenous PKCII. 
Interestingly, all three antibodies, the 2 HA-specific and 1 PKCII-specific antibody, 
detected an additional band running slightly faster than the 175kDa molecular weight 
marker in transgenic mice. This suggests that this high molecular weight band is also 
transgenic PKCIIHA that is possibly migrating as a dimer because it is approximately 





Figure 5-1. Detection of transgenic PKCβIIHA in the spleen of Eµ-PKCβII tg mice. The 
protein lysates of the spleen of Eµ-PKCβII tg and wild type mice were prepared and probed for 
the presence of the transgenic PKCβIIHA using Western blotting. A) Detection of transgenic 
PKCIIHA using anti-HA mAb 6B12. B) Detection of transgenic PKCIIHA using anti-HA mAb 
12CAS. (C) Detection of endogenous and transgenic PKCII using the anti-PKCII mAb F-7 
(Hom-3: homozygous number 3). 
 
 
Figure 5-1 suggested that antibody 6B12 would be optimal for the detection of 
transgenic PKCβII-HA. Therefore, I used this antibody to investigate expression of 
PKCII-HA in lysate of splenic tissue isolated from the founder mouse (#45-2) and some 
of its progeny where we were sure the transgene was present as detected by Southern 
blot and PCR (mice numbered 1-1, 1-2, 3-2 and 7-1; See Section 4.6.3)(Figure 5-2). The 
lanes marked Ct-3 and Ct-4 were samples derived from splenic tissue from two aged 
matched wild type mice. As positive control I used whole cell lysates of Mec1 cells in 
which PKCβIIHA was stably expressed. In Figure 5-2, PKCII-HA was identified as a 
band running slightly faster than the 100kD molecular weight marker. This faint band 
was present in the founder mouse as well as progeny. However, there was a strong 
band running slightly slower than the 100kD molecular weight marker that was present 
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in all samples with the exception of Mec1 cells. This strong band was likely to be non-
specific, and this made it difficult to make strong conclusions regarding the expression of 




Figure 5-2. Detection of HA protein in splenic tissue of the Eµ-PKCβII tg founder mouse 
and its F-1 progeny. HA antibody (6B12) was used for detecting transgenic PKCβIIHA in 
lysates of splenic tissue derived from the founder mouse 45-2 and its progeny: 1-1, 1-2, 3-2 and 
7-1. The spleen lysates of wild type mice ct-3 and ct-4 were used as negative controls. The cell 
lysate of stable PKCβIIHA Mec-I cell line was used as a positive control.  
 
Ultimately, it is very important to be able to analyse tissue lysates for 
unambiguous expression of the transgene. The mouse monoclonal antibodies 
suggested that the PKCII-HA transgene was present, but because of the appearance 
of non-specific bands that could potentially interfere with interpretation I needed an 
antibody which had greater specificity. To do this I employed a monoclonal Rabbit anti-
HA antibody (C29F4). Figure 5-3 shows a Western blot analysis of tissue lysates 
derived from spleens isolated from transgenic heterozygous and homozygous mice, and 
from wild-type littermate controls. As positive control, I used the lysate of A20 cells that 
had been transiently transfected with pEµ-PKCβIIHA (wt)-IRES-mCherry. A single band 
migrating with an apparent molecular weight corresponding to PKCII (approximately 
80kD) was detected in the transgenic mice and positive control, but was not present in 
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the wild-type littermate control animals. Importantly, the higher molecular weight band I 
suggested is a dimer of PKCIIHA (Figure 5-1) is not present, suggesting that this higher 
molecular weight band reflects non-specific reactivity with the second layer (anti-mouse) 
antibodies I used to process the Western blot. Taken together, the single band reactivity 
of the rabbit anti-HA antibody indicated that this antibody was specific for the detection 
of HA-tagged epitopes in my system and could therefore be used in subsequent 
analyses of tissue-specific expression of the PKCII-HA transgene. 
 
Figure 5-3. Detection of HA in F-2 progeny of Eµ-PKCβII tg mice. Western blot was 
performed on cell lysates of splenic tissue isolated from heterozygous (17-2) and homozygous 
(15-3, 17-1, hom-10, hom-16 and re-hom-I) Eµ-PKCβII tg mice as well as wild type mice (non-
littermate (sp-7) and littermate (2-1 and 3-3)) in order to detect HA protein. The cell lysate of A20 
cells transfected with pEµ-PKCβIIHA-IRES-mCherry was used as a positive control. 
 
Because expression of PKCII-HA is under the control of the E promoter, 
expression of this protein should be restricted to B cell-rich tissues. To show tissue 
specificity of the transgene, I probed protein lysates derived from spleen and liver, an 
organ in which B cells are not normally found. Figure 5-4 shows the results of this 
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comparison using homozygous transgenic animals 17-1 (14 month aged mouse) and 
hom-10 ( 6 month aged mouse). I found that expression of transgenic PKCII-HA was 
only present in splenic tissue and not in liver. This suggests that expression of the 
transgene is likely to be B cell specific. 
 
 
Figure 5-4. Comparison of transgenic PKCβIIHA expression in liver and splenic tissue of 
the Eµ-PKCβII transgenic mice. Cell lysates from the spleen and liver of homozygous Eµ-
PKCβIII tg mice 17-1 (14 month aged mouse) and hom-10 (6 month aged mouse) were probed 


















5.2.1 Quantification of the PKCβII 
 
The rationale for generation of the Eµ-PKCβII transgenic mice was to over-
express PKCβII in B cells. Thus, I performed Western blot analysis on whole lysates 
derived from the splenic tissue of transgenic and wild mice to compare PKCβII 
expression levels between these animals. For this purpose I used a Rabbit polyclonal 
PKCβII antibody (C-18: sc-210), and Figure 5-5A and B shows that PKCβII expression 
in the founder mouse (#45-2) and its progeny (#1-2, 3-2 and 7-1) was significantly 
(p=0.03) higher compared with that in three non-littermate wild type control mice (#ct-1, 
ct-2 and ct-3). A comparison of PKCβII levels in homozygous Eµ-PKCβII transgenic 
mice (#15-3, 21-2, hom-16, and re-hom-1 (F-2 progeny)) with that in three wild type 
control mice (#2-1 and 3-3 are wild type littermate controls and #sp-6 is a wild type non-
littermate control) also showed significantly higher (p=0.03) expression of PKCII 
(Figure 5-5C and D). These results suggest that PKCII is overexpressed in the 
transgenic mice. This overexpression is also observed in histo-chemical staining of 
splenic tissue using the same antibody. This result will be introduced and discussed 












Figure 5-5. Quantification of total expression of PKCβII protein in splenic lysate isolated 
from E-PKCII tg and wild type mice. Protein lysates isolated from splenic tissue of Eµ-
PKCβII tg and wild type mice were probed with Rabbit polyclonal PKCβII antibody and -actin 
antibody (lower blot) in order to quantify total PKCβII protein. A) Western blot analysis 
comparing total PKCβII (upper blot) and -actin (lower blot) expression in the founder mouse 
(#45-2) and its progeny (#1-2, 3-2 and 7-1) with non-littermate wild type mice (# ct-1, ct-2 and ct-
3). B) Box plot representation of part A using the PKCβII/β-actin ratio determined by 
densitometry. C) Western blot comparison of PKCβII levels in homozygous Eµ-PKCβII tg mice 
(#15-3, 21-2, hom-16, and re-hom-1 (F-2 progeny)) with 3 wild type control mice (#2-1 and 3-3 
are wild type littermate controls and #sp-6 is a wild type non-littermate control. D) Box plot 
representation of part C using the PKCβII/β-actin ratio determined by densitometry. Statistical 




5.2.2 Detection of mCherry 
 
The Eµ-PKCβIIHA (wt)-IRES-mCherry transgene also contains a gene for 
mCherry that is separated from the PKCII coding sequence by IRES (intra-ribosomal 
entry site). This means that a goal for the generation of the Eµ-PKCβII transgenic mice 
was also the expression of mCherry. MCherry is a monomeric fluorescent protein whose 
fluorescence emission at 610nm can be stimulated by light at 587nm. These excitation 
and emission qualities can be measured in a flow cytometer that is equipped with at a 
560nm yellow-green laser and appropriate filters for measuring emission at 610nm.  
I prepared a single cell suspension of spleen tissue from a homozygous Eµ-
PKCβII transgenic mouse and a wild type littermate control. I analysed these cells using 
a Becton Dickinson LSR-Fortessa analytical flow cytometer equipped with a yellow-
green laser and detectors capable of measuring emission at 610nm. As positive control 
for this experiment I used A20 cells that had been transfected with pEµ-PKCβIIHA (wt)-
IRES-mCherry. Figure 5-6A shows that transfected A20 cells expressed mCherry as is 
demonstrated by the shift in detected fluorescence. However, cells isolated from a 
PKCII-transgenic mouse showed similar fluorescence to those isolated from a wild type 
littermate control mouse (Figure 5-6B). There are two possible explanations for this: 
either mCherry is not expressed or the expression levels are too low to be detected 
using FACS analysis. To address these questions I used Western blot to probe lysates 
of splenic tissue and bone marrow isolated from PKCII-transgenic and wild type mice 
with a mCherry monoclonal mouse antibody (Clontech). Figure 5-6C shows that a 27kD 
band corresponding to mCherry could be detected in bone marrow of a homozygous 
PKCII transgenic mouse. This band was at best very weakly present in lysates from 
splenic tissue from heterozygous PKCII transgenic mice, and was absent in the wild 
type mouse. Analysis of splenic tissue from homozygous PKCII transgenic mice 
showed that mCherry was weakly expressed (Figure 5-6D). The band corresponding to 
mCherry was only present in lysates derived from splenic tissue but not in lysates 
derived from either the liver or kidney. From these experiments I concluded that 
mCherry is weakly expressed, but that the levels are insufficient for detection using 
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fluorescence technologies. This is in keeping with recognised weaknesses of dual gene 
expression within the IRES system, efficient expression of the gene following the IRES 
sequence is not always guaranteed(Kozak 2005). 
 
 
Figure 5-6. Detection of mCherry in Eµ-PKCβII tg mice. A) Flow cytometric analysis of 
untransfected A20 cells (blue line), and A20 cells transfected with Eµ- PKCβIIHA-IRES-mCherry 
(black line). B) Flow cytometric analysis of single cell suspensions prepared from spleen isolated 
from a homozygous Eµ-PKCβII tg (black line) and wild type (blue line) mice. C) Splenic and 
bone marrow lysate of Eµ-PKCβII tg (1-1, 1-2 and 7-1) and splenic lystae of wild type mice (ct-8) 
were probed for the presence of mCherry using Western blotting. D) The protein lysate of 
spleen, kidney and liver of Eµ-PKCβII tg mice (15-3, 17-1, hom-10, hom-16 and re-hom-I) were 
probed for the presence of mCherry using Western blotting. The cell lysate of A20 cells 




5.3 Detection of transgenic PKCIIHA by 
immunohistochemistry (IHC) 
 
Using Western blot analysis I have established that PKCIIHA is expressed in the 
spleen of transgenic mice. However, this analysis is disadvantaged because it only 
detects the presence of the transgene and does not indicate where in the spleen high or 
low expression may be present. Therefore, in order to confirm the results of my Western 
blot analysis and show the pattern of transgene expression within splenic tissue I used 
immunohistochemistry (IHC). 
The microscopic structure of spleen consists of two areas, the white and red pulp. 
The white pulp takes arterial blood and is structured around a “tree” of branched arterial 
vessels where smaller arterioles are surrounded by lymphoid tissue that is called the 
peri-arteriolar lymphoid sheath (PALS). The PALS has three regions, a T cell rich area 
adjacent to the arteriole, a B cell rich area called the follicle and the marginal zone which 
surrounds the entire white pulp. It is in this area that humoral immunity is generated. In 
contrast, the red pulp is associated with the venous system and acts as a filter for the 
blood where antigens, microorganisms and aged/defective blood cells are removed. 
Figure 5-7 shows a haematoxylin-eosin stain (H&E stain) of splenic tissue from an E-
PKCIIHA transgenic mouse. Part A shows a low power magnification (4X) showing 
white and red pulp. Part B shows a higher magnification (10X) and illustrates the T cell, 
B cell and marginal zone of the white pulp. Part C shows this fine structure as a 





Figure 5-7. Microscopic structure of the spleen. The spleen consists of two areas, the white 
and red pulps. The white pulp contains the peri-arteriolar lymphoid sheath (PALS) which 
surrounds the arterioles. There are three regions in the PALS, a T cell rich area adjacent to the 
arteriole, a B cell rich area called the follicle and the marginal zone which surrounds the entire 
white pulp. A) Low power magnification (4X) showing white and red pulps in splenic tissue of a 
E-PKCIIHA transgenic mouse. B) a higher magnification (10X) illustrating the arteriole (A), 
follicle (F) and marginal zone (MZ) of the white pulp, as well as the red pulp (RP). C) Schematic 
diagram of spleen structure. RP: red pulp, MZ: marginal zone, F: follicle, A: artery. 
 
I next investigated expression of the PKCIIHA transgene in splenic tissue of 
transgenic and wild type control mice. This was done using a monoclonal Rabbit anti-HA 
antibody (C29F4) and a rabbit anti-PKCII antibody. Figure 5-8 compares anti-HA 
antibody reactivity with splenic tissue derived from wild type littermate (#3-3) and non-
littermate control (#Ct-8) mice (Parts A and B) with splenic tissue from two homozygous 
E-PKCIIHA transgenic mice (#Hom-3 and #Hom-4, Parts C and D respectively). 
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There is some background staining associated with the red pulp in both wild type and 
transgenic mice, and this was taken to be non-specific because of the high level of 
macrophage-associated peroxidase activity that is associated with the red pulp. In 
contrast, transgenic mice additionally showed a specific pattern of HA antibody reactivity 
associated with the white pulp. In particular, HA expression (highlighted with the yellow 
arrow in the higher magnified images) appeared to be associated with the follicle area of 
the PALS which is a B cell rich area of white pulp. This result confirms the Western blot 







Figure 5-8. Immunohistochemical staining of the spleen from Eµ-PKCβII tg and wild type  
mice. Sectioned slices of paraffin-imbedded spleen were stained for the presence of HA using 
rabbit anti-HA antibody (C29F4). A) wild type mouse 3-3 (littermate control), B) wild type mouse 
ct-8 (non-litter mate control), C) E-PKCII tg mouse Hom-3 and D) E-PKCII tg mouse Hom-
4(Homozygous Eµ-PKCβII transgenic mice).Note:total number of the mice used for this 
experiment:Non littermate: 7, littermate: 5, and transgenic mice: 15. 
 
I next analysed for PKCβII expression in splenic tissues from wild type and 
transgenic mice. Figure 5-9 A and B shows the pattern of PKCII expression in wild type 
littermate (#3-3) and non-littermate (#Sp-7) control mice. PKCII expression is easily 
detectable and shows staining of the marginal zone as well as concentrated staining to 
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one end of the PALS. We considered that this area of concentrated PKCII expression 
was associated with the follicle. PKCII expression in splenic tissue from E-PKCIIHA 
transgenic mice showed a similar pattern of staining (Figure 5-9C and D) to wild type 
mice, but the intensity of staining was much greater. Importantly, PKCII antibody 
reactivity was restricted to the marginal zone surrounding the PALS and to the region we 
anticipate is the B cell rich follicle.  
Considering that the anti-HA and anti-PKCII antibodies had similar patterns of 
reactivity with splenic tissue from transgenic mice, I next analysed serial slices of splenic 
tissue to establish co-reactivity. Figure 5-10 shows in transgenic animals that the areas 
of white pulp that stained strongly for PKCII also had reactivity with the anti-HA 
antibody. In particular, concentrated staining of anti-HA and anti-PKCII was associated 
with the follicular area of the white pulp. The follicular region of white pulp can contain 
germinal centres where B cells undergo rapid proliferation. A second analysis of serial 
spleen sections to include Ki67 as a marker of proliferating cells showed that anti-HA 
reactivity in transgenic mice was associated with anti-Ki67 and with strong anti-PKCII 
reactivity (Figure 5-11). Taken together, these data show expression of the PKCIIHA 
transgene, that expression of PKCII is higher in transgenic than in wild type mice, and 






Figure 5-9. Immunohistochemical staining of the spleen of Eµ-PKCβII tg and wild type 
mice with polyclonal rabbit anti-PKCβII antibody.  The sectioned slices of the spleen of A) 
wild type littermate (#6-2), B) non-littermate (#Sp-7) control mice, C) Homozygous  Eµ-
PKCβII tg mice Hom-3, and D) Hom-9 were stained with polyclonal rabbit anti-PKCβII antibody 
for the detection of PKCβII protein. The upper images are low magnification (4X) and the lower 
images are higher magnification (10X). Note:total number of the mice used for this 









Figure 5-10. Immunohistochemical staining of sequential spleen sections from Eµ-PKCβII 
tg and wild type mice with anti-HA and anti-PKCβII antibodies. Sequential sectioned slices 
of spleen from A) 3-3 (Littermate control mouse), B, C, D) Hom-3 (6 month old homozygous 
 Eµ-PKCβII tg mouse) were stained with rabbit anti-PKCβII antibody (upper images) and 
rabbit anti-HA antibody (lower images). Corresponding follicles within the white pulp of each 
section is highlighted with the yellow arrow. The magnification used for these images in 10X. 
Note:total number of the mice used for this experiment:Non littermate: 7, littermate: 5, and 





Figure 5-11. Immunohistochemical staining of sequential spleen sections from Eµ-PKCβII 
tg and wild type mice for PKCβII, HA and Ki-67. Sequential sectioned slices of spleen from 
(A) 3-3 (Littermate control mouse), (B) Hom-9 (6 month old homozygous Eµ-PKCβII tg mice) 
and (C) 17-1 (14 month old homozygous Eµ-PKCβII tg mice) were stained with rabbit anti-
PKCβII antibody (upper images), rabbit anti-HA antibody (middle images) and Ki67 antibody 
(lower images). Corresponding follicles within the white pulp of each section is highlighted with 
the yellow arrow. The magnification used for these images in 10X. Note:total number of the mice 
used for this experiment:Non littermate: 7, littermate: 5, and transgenic mice: 15. 
159 
 
5.3.1 B cell-specific expression of PKCII results in a structural 
change within the white pulp of spleens from transgenic mice                                  
To complete the microscopic analysis of splenic tissue isolated from Eµ-PKCβII 
transgenic mice I stained tissue slices with haematoxylin and eosin stain (H&E). H&E 
staining discriminates the different structures of splenic tissue, and white pulp and red 
pulp are easily identifiable. Moreover, the structure of the follicle becomes more highly 
defined and structures such as the marginal zone can be easily observed.  Figure 5-12 
shows a comparison of H&E staining of splenic tissue isolated from a littermate control 
(6-2), non-littermate control (sp-11) and two Eµ-PKCβII tg transgenic mice (hom-9 and 
hom-10). A major difference between wild type and transgenic mice is the structure of 
the marginal zone. The marginal zone seemed much thicker in Eµ-PKCβII tg mice than 
in wild type mice. This is the same area that stains heavily for PKCII (Figure 5-13A and 
B) and confirms the pattern of staining observed in Figures 5-9, 5-10 and 5-11.   
Further analysis of this expanded marginal zone in splenic tissue from Eµ-PKCβII 
tg mice shows that it is positive for IgM, indicating that these cells are likely MZ B cells 
(Figure 5-13C and D). Thus, these results suggest that overexpression of PKCII in B 
cells results in expansion of the MZ B cell population in the spleen.  
In conclusion, my results so far demonstrate that transgenic mouse I have 
generated expresses PKCII specifically in B cells, and suggests that such expression 





Figure 5-12. H&E staining of splenic tissue from Eµ-PKCβII transgenic and wild type mice.  
Morphological study of the spleen using H&E staining. A) Splenic tissue from a littermate control 
mouse (6-2), B) Splenic tissue from a non-littermate control mouse (sp-11), C and D) Splenic 
tissue from Eµ-PKCβII transgenic mice hom-9 and hom-10, respectively. Note:total number of 






Figure 5-13. Immunohistochemical staining of spleen sections from Eµ-PKCβII tg and wild 
type mice by H&E, PKCβII and IgM antibodies. Sequential sectioned slices of spleen from a 
Eµ-PKCβII tg mouse was stained with A) H&E, B) PKCβII antibody. C and D) A comparison of 
rabbit anti-IgM staining in splenic tissue from a wild type littermate mouse (C) and E-PKCII tg 







5.4 Flow cytometric characterization of B cell subsets in wild 
type and E-PKCII transgenic mice 
 
The peripheral B cell compartment of mice and men comprises several distinct 
subpopulations. In mice these include B-1a, B-1b, B-2, marginal zone (MZ), 
transitional/immature and follicular B cells. The B cells within each of these 
compartments can be differentiated from each other based on a characteristic 
expression of cell surface markers (Table 5-1). Flow cytometry is an excellent tool that is 
able to identify cells carrying these markers, and in this section I used a Becton 
Dickinson LSR-Fortessa analytical flow cytometer for this purpose. This machine, 
referred to previously in section 3.4.2 is equipped with 5 lasers including a UV laser 
(355nm), violet laser (405nm), blue laser (488nm), yellow-green laser (561nm) and red 
laser (640nm). This machine is capable of simultaneously detecting 18 fluorophores plus 
forward and side scatter making it a very powerful analytical tool for my purposes. 
 
 
Table 5-1. B cell subset markers. This table is the list of the surface markers expressing on the 
different B cell subsets in mouse, consisting of transitional type 1 and 2, marginal zone, follicular, 
germinal centre and B-1 (a, b) B cells. 
 
Cell population Phenotype 
Transitional type 1 B220+ CD21l-/lo CD23- CD24+ IgM+ IgD-
Transitional type 2 B220+  CD21mid CD23+ CD24+ IgM+ IgD-
Marginal zone precursor B220+ CD21+ CD23+  IgM+ IgD+
Marginal zone B220+ CD21+ CD23- CD24+  IgM+ IgDlo
Follicular type B220+ CD21mid CD23+CD24lo  IgMlow
IgDhigh
Germinal center B220+ CD43- CD24+
B1a B220+ IgM+ CD43+ CD5+
B1b B220+ IgM+ CD43+ CD5-
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I characterised B cell subset composition in the spleen, peritoneum, peripheral 
blood and bone marrow of both Eµ-PKCβII transgenic and wild-type mice. These cells 
were isolated from their respective tissues and single cell suspensions were prepared. 
Isolated cells were incubated with antibodies conjugated with fluorophore for 20min on 
ice, and then excess antibody was washed away and data were collected during flow 
cytometric analysis. 
In order to perform simultaneous multichannel analysis I had to choose the 
fluorophores that were conjugated to my antibodies carefully. This is because the 
emission spectrum for each fluorophore can sometimes leak into the channel of other 
fluorophores. This spectral overlap fluorescence is proportional to the emission in the 
primary channel, and can therefore be estimated and subtracted from the overall 
fluorescence collected in a given channel to allow precise detection and quantitation. 
The process of subtraction of this overlapped fluorescence is called Fluorescence 
compensation. Prior to each run the flow cytometer is standardized with beads bearing 
fluorophores similar to the conjugated antibodies I used in my analysis. I then ran a 
series of samples that were stained with only one fluorophore, and this is called the 
compensation sample. FACS data for each compensation sample allowed for stained 
and non-stained cells to be defined, and based on this definition multichannel analysis 
could then be performed and this was calculated by the software package (known as 
Diva version 2.0) that accompanied the LSR-Fortessa. Collected data was analysed 
using FlowJo software and is represented in each figure as a contour plot with outliers in 
order to ensure the best possible resolution. Table 5-2 lists the antibody cocktail I used 





Table 5-2. Fluorochrome conjugated antibodies used for flow cytometry analysis of B cell 
subsets in the Eµ-PKCβII tg and wild type mice. This table is a list of the fluorochrome-
conjugated antibodies that were used for characterization of B cell subsets in this study. 
 
In designing this panel of antibodies I chose the brightest fluorophore, 
phycoerytherin (PE) for B220 expression because this is the primary maker for gating B 
cells. This is important to ensure that I detect all the B220 expressing cells in the tissues 
I analysed. I also selected bright fluorophores for proteins which were expected to have 
lower expression. For instance, CD5, CD21 and CD24 are not expressed highly on 
normal B cells. Detection of IgD is also important and so required a bright fluorophore. 
For detecting IgM and CD43 I used APC-Cy7 and FITC fluorophores which have 
moderate stain indexes as I believed that these two markers are expressed highly on B 
cells and did not need bright fluorophores. 
Another important consideration in designing the antibody panel was to avoid 
using two fluorophores whose fluorescence properties have overlap, especially when 
the antibodies react with the same B cell subset. For example, the majority of B cell 
subsets express both IgD and IgM to some degree, so to avoid significant compensation 
that may influence my interpretation I chose IgD conjugated with APC and IgM 
conjugated with APC-Cy7 because there is only 2.9% of APC-Cy7 leakage on to the 
Marker Conjugated Fluorophore
B220 PE anti-mouse/human CD45R/B220 Antibody
IgD APC anti-mouse IgD Antibody(
IgM APC/Cy7 anti-mouse IgM Antibody
CD43 FITC anti-mouse CD43 Antibody
CD5 PE/Cy5 anti-mouse CD5 Antibody
CD21 PE/Cy7 anti-mouse CD21/CD35
CD23 Pacific Blue™ anti-mouse CD23 Antibody
CD24 PerCP/Cy5.5 anti-mouse CD24 Antibody
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APC channel, and this is negligible. However, with some antibodies this was not 
possible because of limited availability of conjugates and compensation was performed. 
In this section of my thesis I have split the flow cytometric analysis into four subsections: 




The main B cell subsets contained by the spleen include Follicular (FO) B cells, 
immature/transitional (Imm) B cells, marginal zone (MZ) B cells and B-1 B cells. For my 
analysis I gated on live lymphocytes that were B220 positive (Figure 5-14A). I then used 
my panel of antibodies to identify the B cell subsets within this population of B220+ cells 
based on a sequential gating strategy illustrated in Figure 5-14B. Thus, FO B cells were 
differentiated from MZ/Imm/B-1 B cells based on IgD and IgM expression. FO B cells 
which express high levels of IgD were then further characterised for CD21, CD23 and 
CD24 expression. IgM positive MZ/Imm B cells were differentiated from B-1 B cells 
based on CD43 expression and B-1 B cells further differentiated between B-1a and B-1b 
based on CD5 expression. MZ B cells were differentiated from Imm B cells based on 
strong expression of CD21 and CD24 which marks mature MZ B cells. Imm B cells were 
CD21 negative, CD23 weak and CD24 positive. It was not always possible to gain clear 
results when I analysed for CD43, CD23 and CD5. This is because I experienced 
difficulties with respect to compensation during multicolour analysis in the early stages 
of this study. What was reliable was discriminating between FO B cells and IgM+ B cells. 
Thus, statistical comparisons of B cell populations between wild type and transgenic 
mice were performed on these two populations and using a Mann-Whitney U-Test to 






Figure 5-14.Schematic of the FACS gating strategy used for characterization of splenic B 
cells in Eµ-PKCβII tg and wild type mice. A) In order to characterize the B cell subsets in the 
spleen of Eµ-PKCβII tg and wild type mice the initial gating focused on live lymphocytes (right 
hand panel), and this was followed by further gating these cells for B220 expression (left hand 
panel). B) Then, sequential gating was performed on live B220+ cells to detect Follicular (FO) B 
cells (B220+IgMlowIgDhighCD21midCD24lo), immature/transitional (Imm) B cells (B220+IgM+IgD-




Figure 5-15 shows a typical FACS analysis of splenic tissue according to the 
protocol illustrated in Figure 5-14 B. The data represented in Figure 5-15A and B were 
derived from 2 wild type control mice, and in Figure 5-15C and D from 2 homozygous 
Eµ-PKCβII transgenic mice. Figure 5-15 clearly shows that the staining protocol I used 
can discriminate and identify each of the B cell subsets of the spleen. Thus, I could 
identify FO B cells, MZ B cells, Imm B cells and B-1a and B-1b cells. Although this is the 
optimal analysis I wished to achieve, this was not possible in my early analysis which 
reliably only discriminated between FO B cells and IgM+ B cells (which includes all Imm, 
MZ and B-1 B cells). 
With respect to the wild type control mice, one was a littermate control aged for 
14 months (mouse #6-2, Figure 5-15A), whereas the second was a non-littermate 
mouse aged for 6 months (mouse# sp-10, Figure 5-15B). The reason for taking non-
littermate animals is because young littermate mice were unavailable, and because I 
reasoned that if there were no significant differences between littermate and non-
littermate animals the data derived from them could be assessed as a single group 
(Figure 5-16). Thus, a comparison of percentage B cells in the FO and IgM+ B cell 
compartments showed that wild type littermate and non-littermate animals were largely 
similar. Within the wild type littermate mice there was a slight increase in the numbers of 
FO B cells, but this difference was not significant. This indicates that the data I 
generated using the non-littermate and littermate wild type mice can be used as a single 
group of wild type mice for the purposes of this study (Figure 5-16).  
With respect to the homozygous Eµ-PKCβII trangenic mice, both these animals 
were aged for 6 months. The most striking difference between transgenic and wildtype 
mice is the increased percentage of IgM+ B cells and decreased percentage of FO B 
cells observed in the transgenic mice (Figure 5-15). This difference is significant in both 
comparisons as is illustrated in Figure 5-17 and seems to be proportional suggesting 
that the increase in IgM+ cells represents a shift in B cell population rather than 
lymphocytosis. This increase in IgM+ B cells using FACS analysis is in agreement with 
our histochemical data showing that IgM+ B cells are overrepresented in the spleens of 
transgenic animals. Taken together, these results suggest that expression of transgenic 
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PKCII leads to a shift in B cell subpopulations that favours the development of IgM+ B 
cells.  
 Interestingly, the optimal analysis represented in Figure 5-15 shows that the 
percentage of MZ B cells increased in comparison to the wild type mice, and that the 
majority of B-1 B cells from transgenic mice were of the B-1a (CD5+) phenotype. In 
contrast, in the wild type animals there was a more or less equal distribution of B-1a and 
B-1b B cells. Although statistical analysis cannot be performed on these data, they 
nevertheless provide support for the central hypothesis of my thesis that overexpression 

















Figure 5-15. FACS analysis of splenic B cells of Eµ-PKCβII tg and wild type mice. Single 
cell suspensions prepared from spleens isolated from Eµ-PKCβII tg and wild type mice were 
stained with a cocktail of antibodies described in Figure 5-14B, and then analysed by flow 
cytometry. (A) Spleen cells from a wildtype littermate control mouse (6-2, 14 months old), (B) 
Spleen cells from a wildtype non-littermate control mouse (sp-10, 6 months old). (C and D) 






Figure 5-16. Statistical comparison of IgDdimIgM+ and Follicular B cells in non-littermate 
and littermate wild type mice. Box plot representation comparing percentage of  A) IgDdimIgM+ 
cells, and B) IgDhiIgMlo/- (FO B cells) cells in the B220+ population of cells isolated from splenic 
tissue of 5 non-littermate and 3 littermate wild type mice. Statistical significance was assessed 
using a Mann-Whitney U test. 
 
Figure 5-17. Statistical comparison of IgDdimIgM+ and Follicular B cells in wild type and 
Eµ-PKCβII tg mice. Box plot representation comparing percentage of A) IgDdimIgM+ cells, and 
B) IgDhiIgMlo/- (FO B cells) cells in the B220+ population of cells isolated from splenic tissue of 7 
wild type and 10 Eµ-PKCβII tg mice. Statistical significance was assessed using a Mann-





 To analyse the B cell subpopulations in the peritoneum I employed a slightly 
different gating strategy than what I used for the spleen. This strategy is illustrated in 
Figure 5-18 and shows how I discriminated between B cells and B-1 B cells, the major 
subsets within peritoneum. Like with the splenic cells I gated on live lymphocytes and 
took only cells that were B220+ for further analysis. I then used IgD and IgM to 
differentiate FO (B220hiIgDhighIgMlow/-) B cells from IgDloIgM+ B cells. FO B cells were 
then further characterised based on CD21 and CD24 expression. In this analysis I also 
show B220 expression on FO B cells because this is known to be strong and sharp (Hua 
Gu 2004). The IgDloIgM+ B cells were further gated for the expression of CD24 and 
CD43 to separate B-1 B cells (CD24hiCD43+) from Imm B cells (CD24+CD43-). The 
population that was CD24hiCD43+ was further analysed for CD5 expression, 
distinguishing B-1a (CD5+) from B-1b cells (CD5-). B220 expression on the entire 
population of B-1 B cells is shown to confirm that its expression, as is reported, is 





Figure 5-18. The schematic of the FACS gating strategy for characterization of B cells in 
peritoneum of Eµ-PKCβII tg and wild type mice. To characterize the peritoneal B cells, IgM, 
IgD, CD5, CD21, CD24, CD43 markers were used.  Sequential gating was performed on live 
cells gated for B220+ cells to detect Follicular (FO) B cells (B220+IgMlowIgDhighCD21midCD24lo), 
immature/transitional (Imm) B cells (B220+IgM+IgD-CD21-/+CD24+), and B-1 cells 
(B220+IgM+IgDloCD21+CD24+CD5+/-) in the Eµ-PKCβII tg and wild type mice.  
 
Figure 5-19 shows a typical FACS analysis of peritoneal cells according to the 
protocol illustrated in Figure 5-18. The data represented in Figure 5-19A and B, like with 
my analysis of splenic cells, was derived from 2 wild type control mice; one a 14 month 
littermate control and the second a 6 month old non-littermate mouse. Figure 5-19C 
shows analysis of cells derived from of a 6 month old homozygous E-PKCII 
transgenic mouse. These analyses clearly show that the staining protocol I used can 
discriminate and identify each of the major B cell subsets of the peritoneum. Thus, I 
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could identify FO B cells, Imm B cells and B-1 B cells. A comparison of the littermate 
and non-littermate wild type mice showed that there is a difference in the FO B cell 
population, the littermate wild type mice showed a reduction in the percentage of cells 
within the defined parameters. Also, the pattern of the distribution of the IgDdimIgM+ 
population was different between the littermate and non-littermate wild type mice. In this 
case the B220+ cells derived from the littermate mouse showed weaker IgM expression 
than did the B220+ cells from the non-littermate control mouse. However, further gating 
of these cells with CD24, CD43 and CD5 showed that despite low IgM expression on the 
cells derived from the littermate mouse, the population percentage of B-1 B cells were 
largely similar in both littermate and non-littermate mice. Statistical comparison of B cell 
populations between littermate and non-littermate mice was not possible because data 
was derived from only two littermate control mice. I reasoned that because the B-1 B cell 
populations of the littermate and non-littermate control mice were similar in terms of 
percentages, they could be considered as a single group. Therefore, for comparative 
study with the transgenic mouse I have excluded the FO B cell compartment and 
compared only the B-1 B cell populations.   
With respect to the homozygous Eµ-PKCβII trangenic mice the most striking 
difference to wildtype mice is the significant increase in IgM+ B cells (Figure 5-20A). 
Further analysis of this population showed that the majority of IgM+ B cells were B-1a 
cells, and that the increased percentage associated with transgenic mice was also 
significant (Figure 5-20B). Although I do not perform a statistical comparison of the FO B 
cell population between transgenic and wildtype mice, there seems to be a much lower 
percentage of FO B cells observed in E-PKCII transgenic mice. This is similar to what 
I observe in the spleen, therefore, I can conclude that this data suggest that expression 










Figure 5-19. FACS analysis of peritoneal B cells in Eµ-PKCβII tg and wild type mice. Single 
cell suspensions of peritoneal cells were prepared from Eµ-PKCβII tg and wild type mice, and 
were stained with a cocktail of antibodies described in Figure 5-18. This was followed by flow 
cytometry. The FACS was performed in the mice (A) Peritoneal cells from a wild type littermate 
control mouse (6-2), (B) Peritoneal cells from a wild type non-littermate control mouse (sp-5), (C) 




Figure 5-20. Statistical comparison of IgM+ and B-1 B cells in wild type and Eµ-PKCβII tg 
mice. Box plot representation comparing percentage of A) IgM+ B cells, and B) B-1 cells in the 
B220+ population of cells isolated from peritoneum of 6 wild type and 11 11 Eµ-PKCβII tg mice. 
Statistical significance was assessed using a Mann-Whitney U test.  
 
5.4.3 Peripheral Blood 
 
B cell characterisation in peripheral blood followed the same protocol as for 
spleen and peritoneum, that is, I gated on live lymphocytes that were B220+. I then did 
two separate analysis; one analysing the expression of IgD and IgM and a second 
measuring CD5 expression on B220+ cells. I did this because the antibody I used split 
the analysis so that simultaneous analysis of IgM and CD5 was not possible. For this 
analysis littermate control mice were unavailable and so all comparisons are made using 
the non-littermate wild type mice. 
Figure 5-21 shows the FACS traces of the analysis I performed, comparing a 
single non-littermate wild type mouse with two homozygous PKCII transgenic mice. 
The most striking observation is the large increase in percentage of IgDdimIgM+/- B cells 
in transgenic compared to wild type mice (Figure 5-21A). This increase of IgDdimIgM+/- B 
cells in transgenic mice corresponded with a significant decrease in the percentage of 
IgDhiIgM- cells compared to wild type mice (Figure 5-21B). These data show that B cell 
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subpopulations differ in the peripheral blood of wild type and transgenic mice, and 
suggest that it is overexpression of PKCII that forces this shift. 
Further analysis of B220+ cells using CD5 expression showed that transgenic 
mice have an increase in the numbers of CD5+/B220+ cells (Figure 5-21). These 
CD5+/B220+ cells are likely to be B-1a cells because of the lower expression of B220 
compared to the CD5-/B220sharp cells located in the lower right hand corner of the FACS 
trace (Figure 5-21). An informative statistical comparison of CD5+/B220+ cells was not 
possible between transgenic and wildtype mice because of insufficient numbers of 
wildtype mice. However, the boxplots shown in Figure 5-22  suggests the populaton of 
immature B cells (IgDdimIgM+/-) was significanly increased (part B) whereas the FO B 
cells (IgD+IgM-) was significantly decreased (part A ). Thus,  the B-1a B cell population 
was expanded in transgenic mice and this is supported by the significant expansion of 
IgDdimIgM+/-B cells in these mice. B-1 cells are typically IgDdimIgM+/- (Hua Gu 2004). 
Thus, transgenic expression of PKCII results in a shift in peripheral blood B cells 






Figure 5-21. FACS analysis of peripheral blood B cells in wild type and Eµ-PKCβII tg mice.  
The purpose of the FACS analysis of peripheral blood B cells was to detect (FO) B cells 
(B220+IgMlowIgDhigh) and B-1 cells (B220+IgM+IgDloCD5+/-) in the wild type and Eµ-PKCβII tg 
mice. Thus, the single cell suspension of peripheral blood cells was prepared from Eµ-PKCβII tg 
and wild type mice, and then, the samples were stained with B220, IgM, IgD and CD5 markers. 
This was followed by flow cytometry analysis. (A) Peripheral blood cells from a wild type non-
littermate control mouse (sp-10), (B) and (C) Peripheral blood cells from Eµ-PKCβII tg mice 






Figure 5-22. Statistical comparison of mature and immature B cell populations in 
peripheral blood of wild type and Eµ-PKCβII tg mice. Box plot representation comparing 
percentage of A) mature B cells (IgD+IgM-), and B) immature B cells (IgDdimIgM+/-) in the B220+ 
population of cells isolated from peripheral blood of 3 wild type and 11 Eµ-PKCβII tg mice. 
Statistical significance was assessed using a Mann-Whitney U test.  
 
5.4.4 Bone Marrow 
 
 The bone marrow has a more complex compartment of B cell subsets and 
consists of pro B cells, pre B cells, immature B cells and mature naïve B cells. It was not 
possible to identify these compartments using the antibody staining protocol that was 
available. Because B-1 cells are highly represented in the peritoneum and peripheral 
blood of transgenic mice, I reasoned that these cells may be also highly represented in 
the bone marrow. Figure 5-23 shows the trace associated with my FACS analysis, and 
compares a non-littermate wild type control mouse with 2 homozygous EPKCII tg 
mice. I initially analysed for B220 and CD43 expression. From this analysis two 
populations of cells were visible; the first population consisted of B220sharp cells which 
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were CD43 negative, and a second population that were B220low that also showed some 
degree of CD43 positivity. Further analysis of the B220low cells showed that they were 
largely CD5 and IgM positive, indicating that they were B-1a cells. The B220hi cells were 
also analysed for IgD and IgM expression.  
A comparison of percentage B-1a cells in wild type and EPKCII tg mice 
showed that this population increased in the transgenic mice. Statistical analysis was 
not possible because of insufficient numbers of control mice. However, the percentage 
of B-1a cells in the wild type animals is in line with reported values (Hardy and 
Hayakawa 2001, Hua Gu 2004) . Therefore, the increased percentage of these cells in 
transgenic mice is likely to reflect a shift in population, particularly because we observe 
a similar shift in the peritoneum and peripheral blood. Therefore, from this result I 
suggest that transgenic expression of PKCII results in a shift in B cell development 
favouring the formation of B-1a cells. 
A comparison of IgD and IgM expression on the B220sharp population of cells 
between wild type and EPKCII tg mice also showed a difference. Thus, the EPKCII 
tg mice saw the emergence of a IgM+/IgDdim population of B cells that was not present in 
the wild type mouse. This particular comparison was only done once and further 
investigation is necessary to draw a strong conclusion. Nevertheless, it still provides 
support for my conclusion that transgenic expression of PKCII induces a shift in B cell 
populations.  




Figure 5-23. FACS analysis of bone marrow B cells in wild type and Eµ-PKCβII tg mice.  
The purpose of the FACS analysis of bone marrow B cells was to detect (FO) B cells 
(B220+IgMlowIgDhi) and B-1a cells (B220+IgM+IgDloCD5+CD43+) in the wild type and Eµ-PKCβII tg 
mice. Thus, the single cell suspension of bone marrow cells was prepared from Eµ-PKCβII tg 
and wild type mice, and then the samples were stained with B220, IgM, IgD, CD5 and CD43 
markers. This was followed by flow cytometry analysis. (A) Bone marrow cells from a wild type 
non-littermate control mouse (sp-10), (B) bone marrow cells from Eµ-PKCβII tg mice hom-18.   
 
5.4.5 Comparison of old and young PKCII transgenic mice  
 
 So far my analysis has concentrated on comparing EPKCII tg mice with wild 
type controls. However, I generated a cohort of aged transgenic mice (14 months) and 
young transgenic mice (6 months). Here I analyse only splenic tissue. FACS analysis of 
splenic cells isolated from these mice showed that the population of IgDlowIgM+ cells 
were more highly represented in older than in younger EPKCII tg mice. However, 
analysis of CD43 expression on IgDlowIgM+ cells showed a significant shift in the older 
EPKCII tg mice (Figure 5-24), suggesting that in these animals the spleen was being 
colonised with B-1 cells. Importantly, the number of IgDlow/-IgM+CD43+ cells in EPKCII 
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tg mice was always greater than that observed in the littermate control mice (Figure 5-
24). Also, in young EPKCII tg mice there is a distinct presence of MZ B cells (See 
section 5.4.1). Taken together, these results therefore suggest that as EPKCII tg mice 
age there is a shift towards colonisation of the spleen with B-1 cells. 
 
 
Figure 5-24. FACS analysis of splenic B cells of young, old Eµ-PKCβII tg and wild type 
mice. This figure shows FACS analysis of cell suspensions prepared from splenic tissue of wild 
type and Eµ-PKCβII tg mice, with the purpose of identifying B-1 cells (IgDlow/-IgM+CD43+) in cells 
already gated for IgDlowIgM+. (A) Splenic cells from a wild type littermate control mouse (3-3, 14 
month old). (B) Splenic cells from a young Eµ-PKCβII tg mouse (hom-17, 6 months old). (C) 
Splenic cells from a old Eµ-PKCβII tg mouse (17-1 14 month old).  
 
5.5 Functional Assay  
 
So far my characterisation of the EPKCII tg mouse shows that transgenic 
expression of PKCβII in B cells causes changes in the B cell populations of the spleen, 
peritoneum, peripheral blood and bone marrow. The next important question that 
needed to be addressed was whether transgenic PKCβII was functional. One role of 
PKCβII in B cells is to interact and regulate channel-mediated Ca2+ entry in B cells 
during antigen receptor (B cell receptor, BCR) engagement(Numaga, et al 2010). To 
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measure intracellular Ca2+ in splenic cells isolated from wild type and EPKCII tg mice I 
used the green-fluorescent calcium indicator Fluo-4. To identify B cells within the splenic 
cells I gated on CD20+ cells. Figure 5-25 shows a comparison of basal Fluo-4 
expression in splenic CD20+ cells isolated from EPKCII tg and wild type mice. What is 
clear is the increased level of basal fluorescence associated with cells isolated from 
EPKCII tg mice. This shift was reproducible across 4 EPKCII tg mice compared to 
2 wild type mice. Fluo-4 is not suitable for absolute quantification of intracellular calcium 
levels in cells. This suggests that basal calcium levels may be higher in cells over-
expressing PKCII.  
 
Figure 5-25. Intracellular Ca2+ levels in CD20+ cells isolated from splenic tissue of Eµ-
PKCβII tg and wild type mice. Intracellular Ca2+ in CD20+ splenic cells was measured using 
the green-fluorescent calcium indicator Fluo-4. This figure is an overlay histogram comparing 
fluorescence associated with Fluo-4 detection of calcium in cells from E-PKCII tg (green line) 
and wild type mice (brown line). This figure is representative of measurements in cells from 4 








5.6 PKCβII expression in the MDR-KO mouse model of CLL 
 
In this final section of my thesis I analysed the MDR-KO mouse model for 
expression of PKCII. This has not until now been previously done and is important to 
understand the role in PKCII in the pathogenesis of the CLL like disease in these mice. 
In total, four MDR-KO mice were analysed and one of them developed splenomegaly 
(Figure 5-26A). FACS analysis of live lymphocytes derived from MDR-KO and age-
matched control wild type mice showed that the population of CD5+ B-1 B cells was 
expanded in the spleen, peritoneum and peripheral blood of the MDR-KO mice 
confirming the results of the original paper( Figure 5-26B). Analysis of protein lysates 
prepared from spleen tissue of four MDR-KO mice and two aged matched control wild 
type mice by Western blot showed that PKCII was more highly expressed in MDR-KO 
mice than in the wild type mice (Figure 5-26C and D). To conclude, these data show that 
PKCβII expression is up-regulated in MDR-KO mice and suggest a parallel with human 
CLL where PKCII is also overexpressed.  
This completes the characterization of the EPKCtg mouse I have generated. 
The implications of my findings regarding the phenotype of this mouse I will now discuss 







Figure 5-26. PKCβII expression in MDR-KO mice. (A) A photograph taken from the spleen 
tissues isolated from 4 MDR-KO and 2 age-matched wild type mice. (B) FACS analysis of live 
lymphocytes derived from spleen, peripheral blood and peritoneum of MDR-KO and age-
matched wild type mice for the detection of B-1 cells (B220loCD5+). (C) Western blot analysis of 
protein lysates of splenic tissue isolated from four MDR-KO mice and two aged matched wild 



























































 Genetic engineering of mice by transgene insertion and deletion is a powerful 
approach in the investigation of gene function in mouse development and disease 
pathogenesis. In particular, mice with particular transgenic changes have been used to 
model human disease and as preclinical platforms for the testing of new drugs. With 
respect to CLL there are several mouse models, with each exploiting a different 
pathological feature of human CLL cells. For instance, mice that are transgenic for the 
gene Tcl-1 develop an aggressive form of CLL (Bichi, et al 2002), whereas transgenic 
mice that have had the genes coding for miR-15a/16-1 deleted have a more indolent 
disease (Klein, et al 2010). Interestingly, the strain of New Zealand Black mice that 
spontaneously develops CLL also has defects in the expression of miR-15a/16-1 
(Raveche, et al 2007). In almost all CLL mouse models, the CLL-like malignancy 
develops from an initial expansion of IgM+CD5+ B-1 cells (Oppezzo 2012). This is 
important because in human CLL it is proposed that the malignant cells develop from a 
similar expansion of B-1 cells (Chiorazzi and Ferrarini 2003, Seifert, et al 2012). 
Importantly, the malignant cells in both human and the mouse models of CLL 
congregate in lymphoid tissues such as the spleen and in peritoneum, and eventually 
lymphocytosis is observed in the peripheral blood (Chiorazzi, et al 2005, Oppezzo 
2012).  
 Previous work from this Department has shown that the malignant cells from 
patients with CLL express high levels of PKCβII compared to peripheral blood B cells 
isolated from normal age-matched subjects (Abrams, et al 2007). In the present thesis I 
have found that this PKC isoform is highly expressed in the malignant cells of MDR 
mice, indicating that overexpressed PKCII is also a feature of this mouse model of CLL. 
PKCII may contribute to the pathogenesis of CLL because it plays an important role in 
regulating BCR signaling and because BCR signaling plays a role in the pathogenesis of 
this disease (Burger and Chiorazzi 2013, Oppezzo and Dighiero 2013). This hypothesis 
is supported by a study showing that when the Tcl-1 transgenic mouse is crossed with 
PKCβII knock-out mice, CLL-like disease does not develop (Holler, et al 2009). The 
failure to develop disease in this Tcl1tg/PKC-KO model could be because IgM+CD5+ B-
1 cells from which the malignant cells develop are not present due to the disruption of 
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PKC expression, and/or because the microenvironment does not support growth of the 
malignant clone as has been suggested in a recent study by Luzny et al (Lutzny G 
2013).  
 The aim of this thesis was to generate a PKCβII transgenic mouse in which (over) 
expression of PKCβII occurs specifically in B cells. Because of the role of PKC in 
regulating BCR signaling, and because B-1 cells are specifically deleted in mice where 
the gene coding for PKC has been disrupted (Holler, et al 2009), I hypothesized that 
specific overexpression of PKCII in B cells would lead to expansion of the B-1 cell 
compartment in transgenic mice, and possibly to the development of CLL at a later 
stage.  
 In Chapter 3, I describe construction of the expression construct I used to 
generate Eµ-PKCβII tg mice. This construct contained an E promoter so that 
expression of the gene would only occur in B cells. The genes to be expressed under 
the control of the E promoter were PKCII and mCherry. Transgenic PKCII was 
tagged with HA so that I would be able to discriminate transgenic from endogenous 
protein. The gene coding for mCherry fluorescent protein was including for imaging 
purposes, and the PKCIIHA and mCherry genes were separated from each other by an 
internal ribosomal entry site (IRES) so that both genes would be expressed from the E 
promoter. This expression construct was then tested in a mouse B cell line (A20 cells), 
and it was shown to be functional; both PKCIIHA and mCherry were expressed in the 
cell line that was generated. Thus, my expression construct was ready for injection into 
fertilized egg cells to generate founder mice.  
 Chapter 4 describes establishment of a homozygous Eµ-PKCβII tg mouse line. I 
injected the E-PKCIIHA-IRES-mCherry construct into fertilized mouse egg cells, and 
transferred these cells into the oviduct of recipient foster mice. The mouse pups born 
from these recipient mice were screened for the presence of the transgene using two 
techniques, Southern blotting and PCR detection of the transgene. Both techniques are 
complementary and reduce the chance of a false positive or negative. One founder 
mouse, a female, was detected. An approximation of the number of transgene copies 
inserted into her genome was made and determined to be between 5 and 10. This 
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mouse was then used to back-cross with wild type mice in order to generate F-1 
progeny. F-1 progeny were screened for presence of the transgene, again using PCR 
and Southern blotting, and those animals carrying the transgene in their genomic DNA 
were kept and used for inter-crossing and generation of homozygous E-PKCII tg mice 
within the F-2 progeny. With respect to the generation of the F-2 progeny I expected a 
Mendelian ratio of 25% wild type: 50% heterozygous E-PKCII tg: 25% homozygous 
E-PKCII tg. My screening of the F-2 progeny showed that this was in fact the case 
suggesting that my transgene was inserted at a single site within the autosomal 
chromosomes. Here I additionally used quantitative PCR to distinguish between 
heterozygous and homozygous E-PKCII tg mice. Detected homozygous E-PKCII tg 
mice were confirmed by crossing these animals with wild type mice. The litters of these 
crossings were expected to be all heterozygous for the transgene. I found that most of 
the animals I had designated homozygous for the transgene were, in fact, homozygous. 
Thus, I had generated a homozygous E-PKCII tg mouse line which was now ready for 
phenotypic analysis. 
 Chapter 5 of my thesis describes the phenotype of the E-PKCII tg mouse line I 
generated, and the rest of this section of my thesis will discuss what I found. Importantly, 
although the animals were allowed to age for 14 months there was no notable 
development of disease, CLL-like or otherwise. This could be because development of 
disease in this model is indolent, and the detection of disease may have required more 
animals than were available to me. In all CLL mouse models that have been generated 
so far, CLL-like disease takes at least 12 months to develop with models of indolent 
disease taking longer. In the model of indolent CLL developed by Klein et al detection of 
disease required a comparison of 34 homozygous with 23 wild type mice(Klein, et al 
2010). For my thesis I was only able to age 4 homozygous and 3 heterozygous E-
PKCII tg mice, and 3 wild type littermate controls to 14 months. Generation of a larger 
cohort of older mice was unavailable due to structural changes of the animal holding 
facilities at the University of Liverpool, and to mistakes made by the staff of the holding 
facility. Thus, the rest of this Chapter is concerned with discussing the phenotype of 
mice where PKCII is overexpressed within B cells.   
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  The first step in my analysis of the phenotype of E-PKCII tg mice was to detect 
expression of the transgene. I prepared protein lysates of splenic tissue from E-PKCII 
tg and wild type mice, and probed these lysates by Western blot for the presence of 
PKCIIHA and mCherry. Whereas I could detect PKCIIHA both as HA-tagged protein 
and as overexpressed PKCII, I could not easily detect mCherry. A possible explanation 
for the failure to detect mCherry comes from a recent review about variability of 
expression when genes are separated within a plasmid by an IRES sequence. This 
review argues that expression of the secondary gene was not always efficient because 
of variable transcription from the IRES sequence. (Kozak 2005).When building the E-
PKCIIHA-IRES-mCherry expression construct I ensured it was functional within a 
mouse B cell line, and I determined that PKCIIHA and mCherry proteins were 
expressed. However, expression of genes following an IRES sequence might be cell 
specific, and mCherry was only very weakly expressed in the differentiating B cells of 
the transgenic mouse I generated.  
In contrast to mCherry, PKCIIHA was expressed in B cell-rich tissues of the E-
PKCIIHA tg mouse. This determination was made by comparing Western blots of 
protein lysates prepared from spleen and liver; splenic tissue expressed PKCIIHA 
protein and liver tissue did not. Immunohistochemistry was used to confirm expression 
of PKCIIHA in B cell-rich tissues. Here, staining for either HA or for PKCII showed that 
high expression of these epitopes in splenic tissue of E-PKCII tg mice located to the 
white pulp, and specifically to the follicular region. I used sequential slices of splenic 
tissue to show that HA and high expression of PKCII was co-localized. This is 
important because endogenously-expressed PKCII in splenic tissue needs to be 
differentiated from transgenic PKCIIHA, and demonstration of overexpressed PKCII 
co-localizing with HA staining indicates specificity with respect to expression of the 
transgene, and demonstrates successful generation of a mouse which expresses 
transgenic PKCII.  
The central hypothesis of this thesis is that over-expression of PKCII in 
developing B cells will shift development to favour the generation of transitional B cells 
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and expand the B-1 and MZ B cell populations. This hypothesis is based on a paradigm 
whereby Btk determines B cell developmental fate through its role in regulating BCR 
signaling (Cariappa, et al 2001, Pillai and Cariappa 2009), and on findings reported by 
Leitges et al who have generated a mouse model in which the gene encoding for PKCβII 
was disrupted. Disruption of PKC expression results in the generation of mice which 
showed a reduction of splenic B-cells, a reduction of serum IgM and a significant 
decrease in IgM+CD5+ B-1 cells in the peritoneum (Leitges, et al 1996). This phenotype 
and impaired B-cell activation are reminiscent of both X-linked immunodeficiency (XID) 
in mice in which a single amino acid substitution introduced into the pleckstrin homology 
domain of Btk blocks its membrane association and effective activation (Kerner, et al 
1995), and mice in which Btk expression has been genetically (Maas and Hendriks 
2001) disrupted (Khan, et al 1995). This similarity links PKC to the regulation of Btk 
function, and to a B cell developmental pathway. 
Where Btk is important in determining B cell fate in bone marrow is at the first 
immune tolerance checkpoint. Here, auto-reactive B cells become susceptible to 
apoptosis because of strong BCR engagement, and Btk plays a very important role in 
providing pro-apoptotic signaling as demonstrated in studies of Btk containing a E41K 
gain-of-function mutation. This mutation results in a structural change in Btk that allows 
constitutive association with the plasma membrane leading to activation of the kinase 
(Li, et al 1995, Varnai, et al 1999). In transgenic mice where expression of Btk (E41K) is 
controlled by the promoter for CD19, B cell development is arrested at the stage where 
immature B cells that are IgMlow differentiate to IgMhi B cells. The reason why all B cell 
development is impaired at this point is because the constitutive activity of Btk (E41K) 
mimics strong antigen receptor engagement (Maas, et al 1999, Maas and Hendriks 
2001). 
PKC is linked to Btk function through an ability to phosphorylate serine 180 
within the Tec homology domain of Btk and promote its dissociation from the plasma 
membrane, an action which leads to down regulation of Btk activity (Kang, et al 2001) . 
Thus, in the absence of PKC BCR signaling is stronger due to release of feedback 
inhibition of Btk (Kang, et al 2001). The reason why the phenotype in PKC KO mice 
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resembles that of Btk KO or Xid mice is unclear. A greater proportion of developing B 
cells should be deleted at the first immune tolerance checkpoint (Paul 2003) because 
the increased strength of Btk signaling in PKC KO mice would lead (Abrams, et al 2010 
Paul 2003) to a greater degree of negative selection. However, transitional B cells 
emerging from the bone marrow further develop in the spleen where BCR signaling 
strength is required for the generation of B cell subsets. Here, strong BCR signals lead 
to the development of follicular B cells, weak BCR signals lead to the development of 
MZ and B-1 B cells (that are derived from bone marrow progenitors) and cells in which 
BCR signaling is absent would undergo apoptosis due to neglect (Cariappa, et al 2001, 
Maas and Hendriks 2001). In this environment the absence of PKC would lead to 
favoured development of follicular B cells. Generation of B-1 B cells in PKC KO mice 
could also be affected at an earlier stage in their development. Although it is known that 
B-1 cells mainly derive on the foetal liver during embryogenesis, the processes involved 
have not been studied (Kantor, et al 1992, Montecino-Rodriguez and Dorshkind 2012).  
This model where PKC affects Btk activity agrees with a "strength of signal" 
model proposed by Cariappa et al (Cariappa, et al 2001) (illustrated in Figure 6-1). 
Within this model, transitional B cells in the spleen respond to relatively strong or 
"triggered" signals delivered via the BCR with commitment to follicular B cell 
differentiation. Transitional B cells receiving weaker or "tickled" signals from the BCR 
differentiate into MZ B cells. Thus, the strength of BCR signaling is inversely related to 
the generation and survival of MZ B cells (Cariappa, et al 2001). The data I provide in 
Chapter 5 support this model. Overexpression of PKCII should weaken BCR signaling 
in Transitional B cells, and lead to the preferred development of MZ B cells in the 
spleen. This is exactly what I observe and is shown in Figures 5.4.2 and 5.4.4. Thus, in 
the EPKCII tg mice I observe a reduction in the proportion of follicular B cells and an 
increase in the proportion of MZ B cells. This expansion of MZ B cells is not only 
observed using flow cytometry, but is also apparent in H&E stains indicating an enlarged 
MZ (See Section 5.3.1) within the structure of the spleen, and in IgM stains showing that 
this expanded MZ consists mainly of IgM+ cells (see section 5.3.1).  
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I also observe in splenic tissue of EPKCII tg mice an expanded population of 
B-1 cells. Moreover, whereas in the control mice there was an equal distribution of B-1b 
and B-1a cells, in the EPKCII tg mice there was a preference for B-1a cells. 
Importantly, I observed that the proportion of B-1 cells in the spleen expands as the 
mouse ages (Figure 5.4.11). It is unclear why B-1a cells are resident in the splenic 
tissue of EPKCII tg mice in greater numbers than is observed in wild type mice. The 
development of the B-1 cell lineage occurs mainly within foetal tissues such as the yolk 
sac and then liver. However, B-1 cells can derive from bone marrow progenitors, but are 
produced at much lower numbers (Montecino-Rodriguez and Dorshkind 2012). Also, it 
has been recently suggested that B-1 cells can arise from sIgM+CD93+CD23+/- 
transitional B cells that are predominantly in the spleen of neonatal mice (Montecino-
Rodriguez and Dorshkind 2011). Here, this population of B-1 cells dramatically 
decreases in favour of the B-2 (follicular) population as the mouse ages due to unknown 
reasons. In EµPKCβII tg mice the overexpressed PKCII may maintain this neonatal B-1 
cell population, and later expand it as the mouse ages. 
Expansion of the B-1 cell population was particularly apparent in the peritoneum 
of Eµ-PKCβII tg mice. Typically, the peritoneum is the area of the body which is rich in 
B-1 cells, with these cells probably resulting from foetal progenitors. The expanded B-1 
cell population I observe in this compartment of the Eµ-PKCβII tg mice may result from 
favoured production and survival of foetal cell-derived B-1 cells, but may also result from 
additional favoured production and survival of B-1 cells derived from bone marrow 
progenitors. The evidence for the latter proposal comes from my observation that there 
is an apparent expansion of CD5+ B cells in bone marrow of Eµ-PKCβII tg mice 
compared to wild type mice, and, as discussed above, there is an expansion of B-1a 
cells in the spleen.  
In peripheral blood I observed expansion of a IgM+/IgDdim B cell population and 
concomitant reduction of IgM+/IgD+ mature B cells in the Eµ-PKCβII tg mice. The 
IgM+/IgDdim B cells could be transitional B cells that will eventually further differentiate in 
the spleen to MZ and B-1 cells. A proportion of these IgM+/IgDdim B cells could also be 
B-1 cells because B-1 cells are typically IgM+/IgD-/dim (Hua Gu 2004). Support for this 
197 
 
assertion comes from a single experiment where I analyzed IgM+ peripheral blood B 
cells for CD5 expression. I found that B cells that were IgM+CD5+ were much better 
represented in the EµPKCβII tg mice I analyzed (see section 5.4.3).  
 Taken together, my use of flow cytometry and immunohistochemistry to 
characterize the phenotype of EµPKCβII tg mice demonstrate favoured development of 
IgM+ B cells, and, in particular MZ and B-1 B cells. Thus, I conclude that my hypothesis 
is true. What remains is to discuss potential functional changes in the B cells of these 
mice resulting from the overexpression of PKCII.  
First, overexpressed PKCII may affect survival of specific B cell populations 
through its role in activation of the NFB pathway in BCR-stimulated cells. Here, PKC 
operates to phosphorylate CARMA1 leading to the assembly of a complex consisting 
additionally of Bcl10, the ubiquitin E3-ligase MALT1 and the MAP3K TAK1. NFB 
pathway activation occurs when the CARMA1-Bcl10-MALT1 complex recruits IKK 
where the ensuing ubiquitination of this latter protein stimulates TAK1-mediated 
phosphorylation and activation of IKK. This, in turn, catalyzes the downstream 
phosphorylation and degradation of IB leading to the translocation of RelA to the 
nucleus where it is able to stimulate gene transcription (Shinohara, et al 2005). 
Theoretically, I should observe enhanced NFB pathway activation in the B cells of 
EµPKCβII tg mice, and this may contribute to the phenotype I observe because 
maintenance of NFB pathway signaling is important for B cell development, particularly 






Figure 6-1. Schematic describing possible explanations for the phenotype observed in 
Eµ-PKCβII tg mice. 
 
Overexpressed PKCII could additionally play an important role in maintaining 
calcium homeostasis in B cells (Abrams, et al 2007). Obviously, down-regulation of Btk 
function would limit BCR-induced calcium release from internal stores in B cells. 
However, PKCII is also demonstrated to regulate the function of a calcium channel 
during BCR engagement (Numaga, et al 2010), and overexpressed PKCII may lead to 
increased intracellular calcium levels in the B cells of EµPKCβII tg mice. My results 
suggest that B cells isolated from splenic tissue of EµPKCβII tg mice have higher basal 
intracellular calcium levels than do B cells from wild type mice, and further 
characterization is necessary to confirm this observation. Nevertheless, higher levels of 
calcium would potentially result in constitutive NF-AT activity, and possibly support B-1 
cell development as is suggested in one study showing that B-1 cells in mice have 
constitutive activation of NF-AT (Wong, et al 2002). Further work characterizing this 
phenomenon in EµPKCβII tg mice is now necessary. 
The EµPKCβII tg mice also potentially reveals a specific role for PKCII in B cells. 
The gene for PKC is transcribed as two splice variants, PKCI and PKCII. These 
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variants differ from one another in the C-terminus of the protein, particularly in the last 
50 amino acids (Ono, et al 1986). So far a clear role for either PKCI or PKCII in 
phosphorylation of Btk or CARMA1 has not been demonstrated. An early study of mast 
cells suggested that PKCI could down-regulate Btk function (Kawakami, et al 2000). A 
recent second paper examining B cells of mice bearing a mis-sense mutation in prckb 
that results in down-regulated expression of PKCI has shown this to result in a 
decreased B-1a cell population in the peritoneum (Teh, et al 2013) (Teh, et al 2013). 
These results are at odds with the findings I present in this thesis showing that 
overexpression of PKCII leads to expansion of the B-1a cell population. One 
explanation could be that PKCII can substitute for PKCI function where the former is 
overexpressed. However, further work will be needed, possibly crossing the EµPKCβII 
tg mice with PKC KO mice in order to remove endogenous expression of PKCI and 
PKCII in order to more clearly define the role of PKCII. 
Although I did not observe development of CLL-like disease in the EµPKCβII tg 
mice I generated, the model I have created still deserves comment with respect to 
mouse models of CLL. There is now stronger evidence suggesting that human CLL 
develops from a B-1 lineage, with this evidence coming from genetic array analysis 
comparison of human CLL cells with a human equivalent of B-1 cells (Seifert, et al 
2012). Moreover, in virtually all of the existing mouse models of CLL the malignant cells 
derive from an expansion of B-1 B cells. However, in an earlier review Chiorazzi and 
Farrarini suggested that the normal counterpart of CLL in humans could derive from MZ 
B cells because these cells display many key features of mutated and un-mutated CLL 
cells (Chiorazzi and Ferrarini 2011). In EµPKCβII tg mice both the MZ and B-1 B cell 
populations are expanded, possibly facilitating the development of CLL if crossed with 
either the Tcl1tg or MDR-KO mouse models. Support for this notion is supplied by my 
observation that PKCII is overexpressed in splenic tissue derived from MDR-KO mice.  
In conclusion, this thesis relates the generation of a mouse that overexpresses 
PKCII specifically within the B cell compartment. The phenotype that is generated 
shows expanded populations of IgM+ B cells and a reduction of follicular (mature B 
cells). Within the IgM+ B cells, there appears to be favoured development of MZ and B-1 
200 
 
B cells in the spleen, and B-1 B cells in the peritoneum, peripheral blood and bone 
marrow. This mouse may be useful for the study of human CLL because of the potential 
to accelerate disease development, and would therefore serve as a useful model for 












Appendix B: Plasmids 
 
i. pBSVE6BK: pBSVE6BK (pEμ) plasmid was provided by Dr. Raif Geha (Harvard Medical 
School, Boston MA, USA). This plasmid is based on a pBluescript-IISK Phagemid 
backbone that has been modified to include the mouse IgH Promoter and IgH-Eμ 
enhancer elements, as well as the poly (A) site of Human β-globin gene.  
ii. pCR2.1 (Invitrogen): a cloning plasmid that is designed to receive PCR products. It uses 
a commercial cloning strategy designated as a TA cloning® Kit. 
iii.  pCEP4 (Invitrogen): a mammalian expression vector that exploits the CMV promoter to 
drive over-expression of genes. It carries a gene for ampicillin resistance for cloning 
purposes, and for Hygromycin resistance for generating stable cell lines expressing the 
gene of interest. 
iv. pmCherry (Clontech): a prokaryotic expression vector containing the mCherry gene. 
mCherry is a fluorescent protein derived from DsRed (a natural fluorescent protein from 
Tetrameric diacosoma). The excitation and emission maxima of mCherry are 587 nm and 
610 nm, respectively. 
v.   pIRESpuro3: this plasmid contains an internal ribosome entry site sequence (IRES) of 
the encephalomycarditis virus (ECMV). The IRES sequence allows the translation of two 
open-reading frames from a single messenger RNA. 
vi.  Phagemid vector pBK-CMV- N-EGFP (pPKCβ-EGFP): This plasmid encodes a fusion 
protein, consisting of PKCβII and enhanced green fluorescent (EGFP).EGFP is a red-
shifted, human codon-optimized variant of GFP that has been optimised for brighter 
fluorescence and higher expression in mammalian cells. PPKCβ-EGFP is expressed 
under the constitutive human CMV immediate-early promoter. Also, the plasmid has a 
neomycin-resistance cassette (Neo) containing the SV40 early promoter, the Tn5 
neomycin/Kanamycin resistance gene and this allows Kanamycin selection in E.coli and 
neomycin selection in eukaryotic cells. 
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